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Summary of the Thesis 
Background 
Antipsychotic medications are widely prescribed for schizophrenia and other 
related psychiatric conditions, but can have serious financial costs and adverse 
effects. The evidence base concerning the efficacy; effectiveness; and adverse 
effects of antipsychotic medications is extensive but variable in quality and 
applicability, and controversy continues to exist as to whether the newer 
medications are superior to the older antipsychotics. Locally derived data on the 
use and effectiveness of these medications can inform their future use, and 
complement the national and international studies. 
 
Aims & objectives 
To review the pertinent literature regarding antipsychotic medication, and to 
examine the use and clinical effectiveness of antipsychotic medication in a local 
context. Also to develop a valid but pragmatic scale to monitor the adverse side 
effects of antipsychotic medications. 
 
Methods 
A pre-existing case register was analysed to describe the contemporary patterns of 
antipsychotic usage. For the original data containing studies, one prospective and 
two retrospective attributions of clinical global impression (CGI) scores, as well as 
continuation and hospitalization rates were examined. The side effect scale 
(GASS) was devised after literature review and patient consultation, and tested on 
consenting patients in comparison to a well established existing scale (LUNSERS) 
and on healthy individuals.  
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Results 
Data from the Glasgow city case register shows antipsychotics are widely and 
appropriately prescribed there but polypharmacy is common. In the prospective 6 
month study, olanzapine and risperidone produced significant improvements in 
CGI but lack of power precluded similar conclusions with amisulpride, clozapine, 
and quetiapine. In the retrospective studies, clozapine was clinically superior to 
other oral antipsychotics but there was no significant clinical difference between 
the main 3 depot or long acting antipsychotics studied. The new side-effect scale – 
the GASS - was found to be easy to use and as discriminating as the LUNSERS.  
 
Discussion 
There can be difficulties generalizing data from short term RCTs to routine clinical 
practice. However this thesis demonstrates that simple but robust measures such 
as the CGI or GASS can be used to structure and inform everyday clinical practice. 
Consistent with the evolving debate on the relative merits of individual medications, 
this thesis showed there was little difference in clinical effectiveness between 
various oral antipsychotics, with the exception of clozapine. The lack of a 
significant difference between the old and newer long acting injectable 
antipsychotics is a new finding, and this area merits further study. 
 
Conclusions 
Structured routine monitoring of outcomes is possible in the NHS with regard to 
antipsychotic medication. Oral and LAI (or depot) antipsychotic medications 
continue to differentiated more by their adverse side effect profile rather than their 
relative effectiveness, with the exception of clozapine  A new short, inclusive, and 
valid side-effect monitoring scale – the GASS - is introduced. 
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CHAPTER 1 
 
INTRODUCTION 
 
Before undertaking an in-depth analysis of the use and comparative effectiveness 
of antipsychotic medications, it is worthwhile summarising the main clinical 
disorder associated with their use, namely schizophrenia. This is important as it 
places a clinical context around the later discussion of antipsychotic medication.  
 
Antipsychotic medications are commonly employed in the treatment of various 
psychotic conditions such as schizo-affective disorder; acute polymorphic or brief 
reactive psychosis; and bipolar disorder, the majority of the scientific research data 
on antipsychotic medication focuses on schizophrenia rather than these other 
forms of psychosis which explains why the reviews in this thesis focus solely on 
schizophrenia. However, in clinical practice the initial diagnosis is not always clear 
or straightforward and diagnostic shift between the various psychoses can occur 
over time. For this reason it was considered pragmatic and reflective of everyday 
clinical practice to include cases of psychosis rather be constrained to narrow 
schizophrenia in the original research studies reported here. Furthermore, the 
original studies described in this thesis are designed to be inclusive and naturalistic 
rather than have multiple exclusion criteria. 
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Schizophrenia – an overview 
Schizophrenia is a heterogeneous syndrome that presents in adolescence or early 
adulthood and has a fluctuating course. According to studies by the World Health 
Organization (WHO), schizophrenia represents one of the top ten causes of 
worldwide disability, with a point prevalence of 0.2–0.7%, as suggested by large 
community surveys. Epidemiological studies suggest that there are approximately 
two new cases of schizophrenia according to the International Classification of 
Diseases (ICD) definition and about one new case of schizophrenia according to 
the Diagnostic and Statistical Manual of Mental Disorders (DSM) definition per 
10,000 of the population every year. Over the decades, definitions of schizophrenia 
according to ICD and DSM criteria have changed but even so, schizophrenia 
remains a relatively common mental disorder, with a lifetime risk approaching one 
per cent. The disorder is slightly more common in men (Lawrie and Johnstone, 
2011).  
 
In terms of the historical descriptions of schizophrenia, one of the important early 
figures was John Haslam, who in 1809 noted an encroaching apathy after puberty 
with progressive deterioration in cases of youthful insanity. No review of 
schizophrenia is complete without mention of Emil Kraepelin, who in 1919 
dichotomised the insanity of early adult life into a cyclical manic depressive 
psychosis and an unremitting ‘dementia praecox’, or youthful dementia, which led 
in turn to a misconceived pessimistic prognosis for schizophrenia. Eugen Bleuler, 
working in Switzlerland throughout the 1930s coined the term ‘schizophrenia’ to 
represent a schism or disconnection between the functions of the mind. 
Unfortunately this term also led to unhelpful caricatures of schizophrenia as a 
Jekyll-and-Hyde-type split personality. 
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Bleuler attempted to characterise youthful insanity by proposing that the following 
were primary symptoms of schizophrenia (later known as the ‘four As’): 
       –    Abnormal associations (of thought) 
       –    Ambivalence (in decision making) 
– Abnormal affect or emotional tone 
– Autistic thought or behaviour 
 
Kurt Schneider went on in a further attempt to clarify the diagnosis of 
schizophrenia by suggesting they were pathognomonic symptoms of ‘first rank’ 
importance – the so-called ‘first rank symptoms’. Although this was unsuccessful, 
the first rank symptoms remain influential and comprise of: 
– Thought insertion, withdrawal or broadcasting. Alien thoughts are inserted or 
one’s own thoughts are taken out of one’s head or feel as though they are 
broadcast to others. Similar to the complaint of having one’s mind read. 
– Delusions of external control (passivity experiences). Here the sufferer feels his 
or her thoughts, actions or feelings are controlled by an external agency. These 
thoughts actions or feelings are sometimes referred to as ‘made’. 
– Delusional percept. This is a rare phenomenon which is a primary delusion 
arising fully formed from an unrelated normal perception. 
– Thought echo (echo de la penseé). An auditory hallucination, with a voice 
repeating the individual’s thoughts at the same time or immediately after they have 
happened. 
– Third-person auditory hallucinations or running commentary. The hallucination 
refers to the patient as ‘he’ or ‘she’, or gives a running commentary on their 
actions. 
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Schizophrenia – presentation and course 
Schizophrenia typically manifests in young people in their twenties, is usually 
lifelong and is characterised by “positive symptoms” such as auditory 
hallucinations, bizarre delusions, and disrupted speech (‘thought disorder’), and by 
“negative symptoms” such as social withdrawal, de-motivation, self neglect, and 
the appearance of flat emotional tone or affect. Subtle intellectual dysfunction, 
particularly in terms of impaired frontal lobe function such as executive function; 
planning; and verbal skills is also frequently evident clinically (Lawrie and 
Johnstone, 2011). 
 
The ICD 10 (WHO, 1992) diagnostic criteria for schizophrenia are given below, but 
a requirement for diagnosis is that one clear symptom, or two if less clear-cut, 
should be present for most of a one-month period or more. 
 
 Thought echo and social withdrawal or thought broadcasting. 
 Delusions of passivity, external control, referring to the body, or specific 
thoughts actions or sensations and delusional perception. 
 Running commentary style hallucinations. 
 Persistent inappropriate delusions. These are abnormal delusional beliefs 
that are culturally inappropriate and completely impossible in reality. These 
constitute ‘first rank’ symptoms of schizophrenia – see above. 
 Persistent hallucinations of any other sort when accompanied by fleeting 
delusions or over-valued ideas. 
 Thought disorder, including breaks or interpolations in thought, leading to 
incoherent or irrelevant speech or neologisms. 
 Catatonia, including mutism, posturing, stupor and excitement. 
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 Negative symptoms, such as marked apathy, poverty of speech and 
blunting or incongruous emotional tone. 
 
The developmental pathways that may result in schizophrenia are highly complex 
and poorly understood. They include family history of schizophrenia (St Clair et al, 
1990); obstetric complications (Eagles et al, 1990) and developmental difficulties 
(Miller et al, 2002); abuse (Janssen et al, 2004); major life events (Miller et al, 
2001); and parental loss (Morgan et al, 2007). Rates of schizophrenia are also 
increased in urban, poor, immigrant and ethnic minority populations (Allardyce et 
al, 2006). Nearer to the time of disease onset, social factors such as cannabis use 
(Semple et al, 2005) and acute life events (Miller et al, 2001) appear aetiologically 
relevant. 
 
Although many people do achieve remission of symptoms, the associated 
difficulties can be persistent and/or the individual diagnosed with schizophrenia 
can experience repeated episodes in between periods of remission. It is 
increasingly recognised that recovery from schizophrenia is more that the 
reduction or remission of symptoms per se (Yeomans et al, 2010). The Scottish 
Recovery Network has defined recovery as “… being able to live a meaningful and 
satisfying life, as defined by each person, in the presence or absence of 
symptoms”. 
 
About three quarters of people who meet diagnostic criteria for schizophrenia will 
experience a relapse at some point later in life. Unplanned disengagement from 
treatment is a significant risk for relapse (Robinson et al, 1999) and poorer social 
integration predicts a lesser recovery following a first or second episode of 
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psychosis (Drake et al, 2000). Relapse is linked to increasing disability via loss of 
important relationships and work and educational opportunities. A poor outcome is 
more likely in men, individuals who misuse drugs, people with low IQ and where 
there is long duration of untreated psychosis. Low levels of academic and social 
functioning prior to the onset of schizophrenia and more severe symptoms at 
presentation also predicts poor outcome as does having more prominent negative 
symptoms and a poor response to antipsychotic medication (Marshall et al, 2005) – 
all these factors are more thoroughly reviewed in the next chapter. 
 
The interpersonal context is a crucial aspect of recovery.  Individuals who live in 
supportive home environments and have more friends are more likely to 
experience a fuller recovery from an acute episode of schizophrenia. However, 
many individuals lose their friends and families’ support and may become subject 
to poverty, stigma and isolation and may end up facing discrimination and violence. 
About one half will have substance misuse problems (Cantwell R, 2003) and an 
overlapping half will have anxiety states and/or depression (Karatzias T et al, 
2007).  
 
People diagnosed with schizophrenia have life expectancy around 10-20 years 
shorter than the general population, with most patients smoking cigarettes, often 
heavily, many drinking alcohol to excess, and a poor diet and sedentary lifestyle 
being typical (eg Hamer M et al, 2008). 
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Risks associated with schizophrenia 
There is much stigma surrounding the diagnosis of schizophrenia. Stereotypes of 
people diagnosed with schizophrenia as violent individuals populate the 
imagination of the media and general public. Although violence committed by 
people with schizophrenia is rare and the proportion of violence in society 
attributable to schizophrenia is very small, there is a marginally increased risk of 
committing violence for someone with schizophrenia, compared to a member of 
the general public (Fahy T, 2002).  
 
More common and worrying is that individuals diagnosed with schizophrenia are 
more likely to hurt themselves. Five per cent of people with schizophrenia will 
commit suicide, and well recognised risk factors including male sex, illness severity 
and comorbidity, whilst the only consistent protective factor being delivery of, and 
adherence to, effective treatment (Hor and Taylor, 2010). This is one of the 
reasons that an independent review of the pharmacological treatment for 
schizophrenia, ie antipsychotic medication, is considered important. Incidence of 
attempted suicide following a first episode psychosis amongst adolescents is 32% 
(Falcone et al, 2007). Crucially linked to suicide are the feelings of depression and 
hopelessness that arise from perceptions of schizophrenia as a chronic, disabling, 
stigmatising diagnosis. 
 
Costs and care of schizophrenia 
There is significant expenditure in relation to the care of individuals diagnosed with 
schizophrenia and their families. In England this was estimated as £6.7 billion in 
2004/05. The direct cost of treatment was about £2 billion. Indirect costs to society 
amounted to nearly £4.7 billion, of which £3.4 billion was attributed to lost 
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productivity due to unemployment, absence from work and premature mortality. 
The cost of informal care and private expenditures borne by families was £615 
million, and that of lost productivity of carers was estimated to be £32 million. 
About £570 million was paid out in benefits and the cost of administering this was 
around £14 million (Mangalore R and Knapp M, 2006). Provided below (see Figure 
1) are some details of the direct costs of antipsychotic medication in Scotland, and 
although these figures are impressively high, they are dwarfed by the larger costs 
(both direct and the harder to measure indirect costs) of refractory or undertreated 
schizophrenia and its consequences.  
 
Nearly half of all mental hospital beds in Europe are occupied by people with a 
primary diagnosis of schizophrenia. Individuals with schizophrenia remain poorly 
serviced: the National Institute of Mental Health Epidemiologic Catchment Area 
survey from the USA reported that 40 per cent receive no care whatsoever in any 
given year. People with schizophrenia constitute roughly one-third of the homeless 
population in both Europe and the USA. The advent of community care has 
dramatically reduced the numbers of patients who live their lives in hospital, and 
has not resulted in an increase in the homeless hostel population (Geddes et al, 
1994). Many patients are now treated solely by their general practitioner without 
input from specialist services (Lang et al, 1997). The care needs of older patients 
with schizophrenia are also often neglected (McNulty et al, 2003).  
 
Antipsychotic use in Scotland 
Antipsychotic medication is the cornerstone of treatment for schizophrenia. 
Traditionally these medications have been licensed only for the treatment of 
schizophrenia. Over the last two decades or more however, antipsychotics have 
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been increasingly used off license in other mental disorders and over the last 
decade have received official license in the UK and elsewhere for the treatment of 
bipolar disorder. The widespread use of antipsychotic medication in mental 
healthcare is documented in chapter 3 of this thesis, and is evident from the 
following Scottish Government statistics (Figures 1, 2, and 3), reproduced with 
permission from Prescribing Information System (Ross MacLean), Information 
Services Division Scotland.  
 
Regarding nomenclature, later in this thesis the term ‘typical antipsychotics’ as 
mentioned below, will be substituted by ‘first generation antipsychotics’ or ‘FGAs’; 
and atypical antipsychotics’ will be termed ‘second generation antipsychotics’ or 
‘SGAs’. 
 
Figure 1   
Direct antipsychotic medication costs to NHS Scotland, over time. 
 
 
The increasing use of atypical or SGA medications over time has significant cost 
implications for NHS Scotland, as demonstrated in Figure 1. For example, the 
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direct acquisition costs of atypicals or SGAs rose in 2006 from nearly £22 million to 
nearly £32 million only five years later. 
 
Figure 2. 
Number of prescriptions for typical and atypical antipsychotics in Scotland over 
time. 
 
 
Figure 2 indicates that for 2011 over 600,000 separate items or prescriptions for all 
antipsychotic medications were written across Scotland. Also evident is that from 
2006 to 2011, there has been a dramatic 59% increase in the use of the more 
expensive atypical or SGA medications pari passu with a 22% reduction in the use 
of the older and cheaper typical or FGA medications. 
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Figure 3. 
Trends over time for the five most commonly prescribed antipsychotic medications. 
 
 
 
 
Figure 3 indicates that quetiapine has greatly increased its market share over the 
last 5 years, whilst chlorpromazine use has continued to fall over a similar period. 
Based on personal clinical experience and anecdotal evidence it is conjectured 
that this is due to a switch in the choice of off-label (ie unlicensed) use of a non-
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to come off patent. Thus it is anticipated that direct acquisition costs for the most 
frequently prescribed antipsychotic medications will actually fall in the next few 
years. 
 
From the above brief overview of the use of antipsychotic medication in Scotland, it 
can be seen that a more in-depth analysis of the use and comparative 
effectiveness of the most commonly prescribed antipsychotics would not only be of 
clinical value but also of interest to pharmacy budget holders. 
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CHAPTER 2 
 
 
OUTCOMES IN SCHIZOPHRENIA; AND EFFECTIVENESS VERSUS EFFICACY 
OF ANTIPSYCHOTIC MEDICATION 
 
 
The pre-medication era 
 
Early reports of psychosis (e.g. Joan of Arc) exist, but it was the Renaissance-
inspired physicians such as Haslam, Esquirol and Morel who provided the first 
descriptions of a progressive insanity affecting the young. The work of Kraepelin 
(1919) at the beginning of the 20th century remains highly influential, as it was his 
careful documentation that led to the differentiation of the two major patterns of 
youthful insanity: manic depressive (bipolar) psychosis and dementia praecox 
(premature dementia – now called schizophrenia). Kraepelin emphasized the early 
onset of dementia praecox and established a trend towards therapeutic pessimism, 
as he believed that dementia praecox would inevitably deteriorate, whilst the 
course in bipolar psychosis was viewed as fluctuating but benign. Today, most 
clinicians appreciate that there is a wide variation in disease course and outcome; 
indeed, Kraepelin’s own series of hospital-based cases revealed spontaneous, 
complete recovery in approximately 15% of patients.  
 
In an important meta-analysis of 22 early (1895–1925) studies, Hegarty et al 
(1994) found that 25–30% of patients with dementia praecox had a good social 
outcome after 5 years. In the Iowa 500 study (Tsuang MT et al, 1979), only 26% of 
patients (n = 200) with narrowly defined schizophrenia assessed between 1895 
and 1925 could be discharged into the community following their first 
hospitalization. Of those individuals who did not fully recover (approximately 74%), 
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Fuller (1930) suggests that 25% died, 35% were discharged over a 15-year period, 
and 39% remained chronically hospitalized throughout the study. 
 
The antipsychotic era 
 
McGlashan’s ‘Chestnut Lodge’ study (1984) found that, compared with patients 
with chronic affective disorder, patients with chronic schizophrenia were less likely 
to be working at long-term follow-up, and were more likely to be rehospitalized, 
exhibit more severe symptoms and show a higher level of disability. Also, a 
considerably higher proportion of patients with schizophrenia were viewed as 
continuously incapacitated than those with chronic affective disorder. Combining 
data from the Chestnut Lodge and Iowa 500 studies reveals that 28% of patients 
were chronically disabled, 55% lived in sheltered accommodation, and 30% were 
employed.  
 
Shepherd et al (1989) defined remission as full clinical recovery and relapse as re-
admission; 22% of patients in their study group remained relapse-free 5 years after 
a first episode of schizophrenia, while 35% had relapsed. By contrast, Crow et al 
(1986) defined relapse as either the development of psychotic features or a 
worsening mental state and using these criteria, 45% of patients in the Northwick 
Park sample group remained relapse-free 2 years after a first episode. 
 
In a study examining social disability in 349 patients over 15 years from first 
presentation, Wiersma et al (2000) concluded that only 17% of patients had no 
disability, whereas 24% experienced severe disability at long-term follow-up. 
Gender, age at onset, duration of untreated psychosis (DUP), type of psychosis, 
and remission during the first 2 years did not predict long-term disability. However, 
  
28 
 
severity of disability at earlier assessments contributed significantly to variance at 
15-year follow-up. Examining mortality, and 15- and 25-year illness trajectories, 
Harrison et al (2001) found that approximately 50% of surviving cases had 
favourable outcomes, although they noted marked geographical variations. Using 
regression modelling, they determined that the course of illness during the first 2 
years was the strongest predictor of outcomes at 15 years. Interestingly, 16% of 
early unremitting cases achieved late-phase recovery. The authors concluded that 
socio-cultural conditions appear to modify long-term course and that early 
intervention programmes may produce long-term gains. 
 
The greatest variability in disease course is observed in the initial stages of 
schizophrenia. In an evaluation of first-admission studies from the 1970s and 
1980s over a mean follow-up time of 17.4 years, 54% of patients exhibited social 
recovery despite 32% showing poor clinical outcomes (data adapted from Ram et 
al. 1992). Thus, while clinical and social morbidity can go hand in hand, a 
significant proportion of patients – often women – will demonstrate social recovery 
despite ongoing symptoms. 
 
It is generally agreed (Saha et al, 2007) that the life expectancy of individuals with 
schizophrenia is shortened and that death from all causes, particularly 
cardiovascular disease, occurs at a younger age than in the general population. A 
study by Tsuang et al (1980) estimated that life expectancy is reduced by about 10 
years among men and by about 9 years among women with schizophrenia and 
affective disorders.. Also of concern is that at least 5% of patients with 
schizophrenia commit suicide, with young men in the early stages of their illness 
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being most at risk (Hor and Taylor, 2010). Of those who commit suicide, two-thirds 
do so within the first 5 years of illness onset (Wiersma et al, 1998). 
 
Specific factors linked to outcome 
Factors associated with patient outcomes are shown in Table 1 (adapted with 
permission from Lewis and Buchanan, 2003). It should be recognized however that 
these factors account for only around 20% of the variance shown in long-term 
studies. 
 
Table 1.  Predictors of outcome (adapted with permission from Lewis and 
Buchanan, 2003) 
 
Factor Good outcome Poor outcome 
Demographic Female 
Married 
Male 
Single 
Genetic Family history of affective 
disorder 
Family history of schizophrenia 
 
Onset Good pre-morbid adjustment 
Acute onset 
Life event at onset 
Poor pre-morbid function 
Early onset 
Insidious onset 
Long duration of untreated psychosis 
Symptoms Affective symptoms Negative symptoms 
Neurological soft signs 
Psychosocial Family/peer support 
Living in developed country 
High expressed emotion in the family 
Social isolation 
Substance misuse 
Treatment Early treatment 
Good initial response 
Adherence 
Non-adherence 
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Adherence to medication 
The typical rates of non-adherence to medication of 40% for oral antipsychotics 
and 25–40% for depot antipsychotics are similar to those associated with drugs 
used to treat other chronic medical specialities (Pinikahana et al, 2002). Factors 
most consistently associated with non-adherence include poor insight, negative 
attitude, previous non-adherence, substance abuse, shorter illness duration, 
inadequate discharge planning, and poor therapeutic alliance. A small number of 
non-industry-sponsored studies have indicated that adherence to medication and 
patient satisfaction are enhanced by the use of SGAs as opposed to older drugs 
(Dolder et al, 2002). Interestingly, Robinson et al (2002) found that individuals with 
poor premorbid cognitive function were more likely to stop taking antipsychotic 
medications during the first year of treatment; those with Parkinsonian side effects 
also had a greater chance of discontinuing medication. 
 
Gender 
The degree of social impairment of men with schizophrenia is twice that of women 
with schizophrenia and men are less likely than women to experience complete 
remission, particularly when first-episode or recent-onset cases are studied (van 
Os et al, 1997). The reasons for these gender differences are not entirely clear, 
although there would appear to be an interaction with pre-morbid state, age at 
onset and substance misuse. Women are also more likely than men to manifest 
affective symptoms. 
 
Symptom profile 
Prominent early negative symptoms are associated with poor long-term outcomes 
(Fenton et al, 1991a), although it can be difficult to distinguish between negative 
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symptoms, poor pre-morbid functioning and over-treatment with antipsychotics. 
Conversely, paranoid and affective symptoms have been linked with better 
outcomes (Fenton et al 1991b).  
 
Cognitive function and IQ have been shown to deteriorate during the course of 
schizophrenia (Eberhard et al, 2003) which can have a substantial impact on 
insight and compliance, which can in turn lead to increased relapse rates (Rossell 
et al, 2003) In addition, there is some evidence to suggest that intelligence is an 
important variable in determining outcomes (Thompson 1985). 
 
Family history 
Few studies have examined whether a poor prognosis is related to family history or 
whether a positive family history of psychosis exacerbates disease course. The 
Copenhagen high-risk project (Jorgensen et al, 1987) and the McGuffin et al 
(1984) twin study provide some evidence for a link between a positive family 
history of schizophrenia and overall poor outcomes. 
 
Social factors 
A number of studies (eg McKenzie et al, 1995) have shown that lower social class 
correlates with poor long-term outcomes, treatment resistance and chronicity. It is 
not always clear whether this merely represents decreased accessibility to or 
uptake of healthcare services. 
 
An interesting study from Jamaica (Hickling et al, 2001) found that relapse rates 
after a first episode of schizophrenia were low and that good outcomes were 
related to high levels of gainful employment and the use of intramuscular 
antipsychotics. The authors noted that favourable short-term outcomes in 
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Jamaican patients were in contrast to the high relapse rates found in Afro-
Caribbean patients in the UK. Indeed, a generally more favourable outcome for 
schizophrenia has been shown (Leff J et al, 1992) for patients in the developing 
world in WHO-sponsored studies. 
 
In a meta-analysis of the effects of family interventions on illness course, Pitschel-
Walz et al (2001) concluded that relapse rates in schizophrenic patients could be 
reduced by approximately 20% if the families of those affected were included in 
treatment strategies. 
 
Duration of untreated psychosis 
An ‘expert briefing’ (2003) from the National Health Development Unit in England 
concluded that patients experiencing lengthy delays in treatment initiation were 
more likely to exhibit poor outcomes across a range of measures. However, the 
briefing also noted that further evidence was required to prove that shortening the 
DUP led to improved outcomes. Gumley (2003) re-analysed the 1998 Wiersma 
data and found that individuals with a longer DUP at relapse were almost twice as 
likely to have experienced both an insidious onset of schizophrenia and a delay in 
the initiation of antipsychotic treatments. 
 
Substance misuse and dual diagnosis 
Swofford et al (1996) noted that substance abusers with schizophrenia were twice 
as likely to be hospitalized and four times as likely to have a relapse as non-drug-
using individuals with schizophrenia during a 2-year follow-up study. Additionally, 
another study (McKenzie et al, 2001) showed that men with psychosis were two to 
three times more likely to abuse substances than women with psychosis; however, 
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there was no difference in the likelihood of patients abusing substances on the 
basis of ethnicity. Individuals with a ‘dual diagnosis’ of severe mental illness and 
drug misuse are generally hospitalized for longer periods than those who do not 
misuse substances (Menezes et al, 1996). In a 4-year community survival analysis 
(Hunt et al, 2002), patients with a dual diagnosis were more likely to be 
rehospitalized, regardless of whether they adhered to their treatment regimen. 
Non-adherent patients with a dual diagnosis accounted for 57% of all 
hospitalizations during the study. 
 
The nature of relapse 
Many studies use an arbitrary definition of relapse, such as a 40% decrement in 
score on rating scales, whereas more pragmatic studies tend to identify relapse by 
re-admission rate. In the real world, however, relapse is not usually measured by 
rating scales, nor does it inevitably lead to rehospitalization.  Relapse can be highly 
individualized and may often manifest itself as subtle changes in psychosocial 
functioning, disrupted sleep or apparent vagueness or confusion.  
 
Stressful life events and an increased emotional state can both trigger relapse, and 
it is not unknown for individuals experiencing early relapse or emotional distress to 
resort to alcohol or illicit drugs, which can further increase relapse rates (Hunt et al, 
2002). In addition, a lack of response or poor tolerability to medication can lead to 
non-adherence – one of the most common causes of relapse, although non-
adherence can also be an early manifestation of relapse. It is interesting to note 
that as many as 25–50% of patients do not respond fully to antipsychotics, thus 
increasing their likelihood of relapse. The risk of self-harm or injury to others is 
increased at times of relapse, and social disruption, increased stigmatization and 
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the secondary morbidity of low self-esteem are also indirect consequences of 
relapse.   
 
Csernansky et al (2002) found that the risk of relapse in patients with 
schizophrenia was approximately 42% per year. Predictors of more frequent 
relapse included poor adherence to medication, severe residual psychopathology, 
poor insight, substance abuse, and poor relationships with family and care 
providers. Robinson et al (1999) examined relapse rates 5 years after initial 
recovery from a first episode of schizophrenia or schizoaffective disorder and 
concluded that the cumulative first-relapse rate was 82%. Discontinuing 
antipsychotic therapy increased the risk of relapse nearly five-fold. Patients with 
poor pre-morbid adaptation to school and pre-morbid social withdrawal tended to 
relapse earlier, whereas other baseline measures, including DUP, baseline 
symptoms, effects during treatment and brain morphology, were not significantly 
related to time to relapse. Early pre-morbid adjustment was the only variable 
significantly related to first relapse independent of medication status. Early social 
isolation and poor adaptation to school were particular characteristics of this pre-
morbid state.  
 
Data from the Madras Longitudinal Study (Eaton et al, 1998) indicated that age at 
onset and DUP are variables associated with poor outcomes. It was also found that 
the use of antipsychotic medications diminished the time to remission after a first 
episode of schizophrenia, but not after the second episode, while withdrawal from, 
and non-adherence to, antipsychotic medication were predictive of relapse. 
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Using a first-episode patient cohort, Wiersma et al. (1998) found that 68% of 82 
individuals had one relapse during a 15-year follow-up study, while 58% of patients 
had two relapses, 49% had three relapses and 47% had four relapses. Thus, 
relapse is usual during the first 5 years following the initial episode. 
 
These observations on outcomes and relapse in schizophrenia confirm that it is a 
relapsing and remitting condition for the vast majority of individuals, and relapse 
itself can tend to exacerbate prognosis. Some of the factors mentioned above that 
are associated with poorer outcome are immutable, for example clinicians cannot 
alter the fact that a patient is male; single; and has a family history of 
schizophrenia. However, clinicians can hope to ameliorate psychosocial factors 
that are linked to relapse or poor outcome such as isolation or lack of employment, 
as well as comorbid substance misuse. Clinicians should also work with the patient 
to identify the best particular treatment for them, tacking account of both patient 
preference, previous response to medication, and of course the tolerability and 
efficacy of the proposed treatment. Similarly, once a response to effective 
treatment has occurred, it is the clinician’s responsibility to promote continuing 
adherence to that treatment. 
 
This thesis examines the relative effectiveness of the major antipsychotic 
medications available in Scotland at the time of study, where effectiveness is 
defined as a ‘real world’ combination of efficacy; tolerability; and adherence to that 
treatment. This is an important task as the major randomised controlled (licensing) 
studies for antipsychotic medications are not always generalisable to heterogenous 
clinical populations, such as those in the west of Scotland. 
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Effectiveness versus efficacy of antipsychotic medication 
Since the 1940’s randomized controlled trials (RCTs) have been the accepted 
method of establishing the efficacy of medical treatments due to high reliability and 
low intrinsic bias. Efficacy can be defined as ‘does an intervention produce a 
positive effect in the study variables under ideal conditions’.  In psychiatry, 
traditionally RCTs usually have a pre-agreed change in score on a relevant rating 
instrument such as the Positive and Negative Syndrome Scale or PANSS (von 
Knorring and Linstrom, 1995) as the primary outcome variable. However, many 
clinicians would have difficulty in equating an arbitrary 20% or 40% change in the 
PANSS to their everyday practice or deciding on whether a statistically significant 
change in mean score is clinically relevant.  Moreover, RCTs are generally 
undertaken by the pharmaceutical industry in order to meet regulatory 
requirements for drug licensing and positive results are generally associated with 
the study sponsor (Als-Nielsen et al, 2003) although this is not invariably the case 
(Fleishhacker et al, 2009) and meta analyses from Leucht et al (2009) and Davis et 
al (2008) did not detect a significant sponsor effect.. Lastly, RCT design (Heres et 
al, 2006) may also affect results and negative trial drug results may not be put into 
the public domain.  
 
RCTs measure efficacy but the controlled environment of a RCT affects the 
generalisability of the results in the ‘real world’, especially when high drop out 
rates, short trial duration, and the selection bias in patient recruitment are 
considered (Thornley and Adams, 1998; Hodgson et al, 2007)  The drop out rates 
of even relatively brief RCTs in medication trials in psychiatry can be up to 70% or 
even 80% confounding the applicability of the results. In addition, large multicentre 
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RCTs are expensive to conduct, which militates against undertaking long term or 
maintenance studies.  
 
In psychiatry the typical exclusion criteria of RCTs means that individuals with co-
morbid substance misuse or serious physical illness; or those who are suicidal or 
only intermittently cooperative will not be enrolled; nor importantly will any woman 
who cannot guarantee that she will not become pregnant. This problem of 
recruiting representative ‘real world’ clinical populations is depicted in Figure 4 
which contains hypothetical numbers for illustrative purposes only. Clearly this 
leads to a potentially unrepresentative RCT study population, which casts doubt on 
the generalisability of the RCT results.  
 
Figure 4 . Figurative illustration of the difficulties in recruiting into a randomised 
controlled trial (RCT) with strict inclusion and exclusion criteria.  
 
 
100 patients screened for 
a RCT   
10 included 
   
50 unwilling to 
participate in the trial    
  
40 excluded (substance 
misuse, risk of pregnancy, 
suicidal, physical illness, etc )   
  
50 willing to participate  
   
5 disappear or quit   
5 patients with results   
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These limitations of RCTs have resulted in renewed interest in observational 
studies. Observational studies assess effectiveness, namely whether a treatment 
or intervention works in the ‘real world’ of day-to-day clinical practice. It has been 
shown (Mallinkrote et al, 2003) that well constructed observational studies do not 
overestimate treatment effects, and statistical methodologies can reduce the 
impact of non-randomisation. Additionally, the lack of exclusion criteria can reduce 
selection bias (although this remains a concern) enhancing the utility of the results, 
particularly in large community based samples. Observational studies are also 
generally much cheaper than RCTs so can often be undertaken independent of 
any vested commercial interest.   
 
The concept of treatment effectiveness can be subdivided into the constituents of 
efficacy, tolerability, and adherence. Clearly, efficacy is a crucial constituent but an 
efficacious treatment only works if it is acceptable and used on a regular basis by 
the recipient or patient. Treatment acceptability is usually determined by whether 
the (subjective) beneficial effects are outweighed by the perception of intolerable 
treatment-related side effects, including any medically dangerous side effects.  
 
The World Health Organisation has recently suggested that lack of adherence or 
compliance with maintenance treatment is a key obstacle in the management of 
long term clinical conditions leading to, for example, initiatives to pay people to 
adhere to their anti-tuberculous antibiotic therapy in parts of the US. In the 
management of psychotic illness, the problem of medication adherence has long 
been known to be problematic, and the effectiveness of maintenance antipsychotic 
treatment is often undermined by poor medication adherence. Patel and David 
(2007) estimated an oral medication non-adherence rate in schizophrenia of 
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between 40-60%, with adherence to long acting injections of (or depot) 
antipsychotics being between 25-40%. 
 
Another major medication adherence problem that is commonly observed but 
poorly studied is the issue of partial adherence or compliance (Tacchi and Scott, 
2005), where intentional or inadvertent intermittent or erratic medication dosing 
occurs. In the management of psychosis, partial adherence may lead to poor 
symptom control irrespective of an increased risk of relapse. Partial adherence to 
medication is commonly encountered in clinical practice but not extensively 
studied. Some individuals who adhere poorly with tablets may be offered a long 
acting injection, but long acting injections are not a panacea for adherence 
problems nor are they the only strategy by which to improve adherence.  
 
 
Aren’t all antipsychotic medications the same? 
Debate over class and intra-class differences in effect between antipsychotic 
medications was highlighted initially by a controversial meta-analysis from Geddes 
et al (2000). This suggested the then newer (and more expensive) antipsychotic 
medications did not have superior efficacy to low dose haloperidol. Interestingly, 
this conclusion was not adopted by NICE guidelines (2002) which suggested 
atypical or second generation antipsychotics (SGAs) should be chosen in cases of 
first episode psychosis, after consultation with the patient, although the 2009 NICE 
guideline retracted from this position, simply advocating ‘an antipsychotic 
medication’ for schizophrenia without further specifying type. The debate moved 
forward after a further independent meta-analysis of the RCT PANSS outcome 
data, by Davis et al (2003), who used a larger data set than Geddes et al (2000) 
and found small but significant and clinically meaningful effect size differences (in 
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PANSS rated symptom reduction) between individual antipsychotics when 
compared with haloperidol. Here, clozapine, olanzapine, risperidone and 
amisulpride were superior to typical or first generation antipsychotics (FGAs) but 
quetiapine, aripiprazole, ziprasidone and sertindole were not. This study (Davis et 
al, 2003) also challenged the belief that any apparent atypical superiority over 
FGAs was merely a function of an excessively large haloperidol comparator trial 
dose. 
 
Leucht et al (2009) updated the 2003 Davis et al meta-analysis of antipsychotic 
efficacy, and also concluded there were small but important differences between 
individual antipsychotic medications. In particular, they found that amisulpride; 
clozapine; risperidone and olanzapine were more effective than low dose 
haloperidol in terms of global symptoms and negative symptoms.  
 
However, a smaller but more recent meta-analysis of FGAs versus SGAs in first 
episode psychosis (Crossley et al, 2010) added weight to the original conclusions 
of Geddes et al (2000)  finding that SGAs were no different to FGAs for either 
discontinuation rates (a proxy measure for effectiveness) or symptom efficacy. 
Crossley et al (2010) did show that the side effect profiles of the two groups were 
different, with FGAs being more likely to cause movement disorders, and SGAs 
more often associated with weight gain.  
 
Effectiveness studies of antipsychotic medications 
 
Here four of the larger recent effectiveness studies of antipsychotic medication are 
reviewed:   
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1) The NIMH funded landmark CATIE studies (Lieberman et al, 2005; Stroup et al, 
2006; McEvoy et al, 2006) introduced a paradigm shift in outcome measurement in 
the treatment of schizophrenia by utilizing medication discontinuation rate as a 
proxy for effectiveness, arguing that if either the clinician or patient initiated 
discontinuation then either the medication wasn’t working or it wasn’t being 
tolerated. After 18 months of randomized controlled study, olanzapine was found 
by Lieberman et al (2005) to be most effective oral antipsychotic despite inducing 
significant metabolic problems, although this phase of CATIE did not compare 
clozapine with olanzapine. A re-analysis of the CATIE data (Citrome et al, 2006) 
produced an impressively low “number needed to treat” (NNT) of between 5.5 and 
10 for olanzapine compared to perphenazine, quetiapine, and risperidone. The 
corresponding “number needed to harm” NNH for olanzapine ranged from -12.4 to 
-17.7 in terms of discontinuation from adverse metabolic effects. Clozapine (in 
phase 2 of CATIE) also had low NNT of 3 compared to risperidone and quetiapine, 
and 6.6 compared to olanzapine. 
 
2) The cost utility of the latest anti psychotic drugs in schizophrenia studies 
(CUtLASS) (Jones et al, 2006; Lewis et al, 2006) were sponsored by the UK 
National Health Services in an attempt to compare the effectiveness of the newer 
versus older anti psychotic medication.  Clinicians who entered patients into this 
study had to determine whether those individuals previously had a treatment 
resistant illness or whether a switch of antipsychotic medication was indicated for 
other clinical reasons. Furthermore these clinicians were free to opt for the 
individual antipsychotic of their choice from within 2 groups of medications.  Quality 
of life was chosen as the primary outcome measure in the CUtLASS studies, 
although traditional ratings such as PANSS were also undertaken. 
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CUtLASS was a one year open label randomised study and 227 people with 
schizophrenia were included.  After 1 year in this study 54 % of patients were still 
on the ‘typical’ antipsychotics and 63% were still taking an ‘atypical’ antipsychotic, 
although this difference was not statistically significant.  There were no other 
significant differences in other relevant outcomes including the primary outcome of 
quality of life.  However, included within the group of ‘typical’ or FGAs was sulpiride 
(although the related amisulpride was viewed as a SGA), and sulpiride was the 
antipsychotic medication most frequently chosen (49%) by the participating 
clinicians.  
 
Owens (2008) has observed that sulpiride was originally regarded as an ‘atypical’ 
anti psychotic when it was first marketed in the 1970s, and indeed Owens 
comments that the term “atypical” is no longer helpful in terms of understanding or 
dichotomising antipsychotic medication.  It is also worth observing that CUtLASS 
failed to meet its predefined recruitment target - this might have been due to 
clinician preference for SGAs over FGAs (a lack of clinical equipoise).  Lastly, as 
entrance to the CUtLASS study required the need for change in medication, a 
selection bias of patients who were either non or partial responders or intolerant to 
the previous medication may have been introduced. 
 
3) The EUFEST study (Kahn et al, 2008). This open pragmatic (the treating 
physicians were not blinded) study included 498 subjects from various centres 
across Europe (but not Britain), and randomised them to Haloperidol (at a low 
mean dose of 3mg), amisulpride, olanzapine, quetiapine and ziprasidone, with one 
year follow-up. Enrolled subjects were described as having a first episode of 
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psychosis, defined as being symptomatic for 2 years or less. The number of 
patients who discontinued treatment for any cause within 12 months was (in order 
of highest discontinuation rate) 63 (Kaplan-Meier estimate 72%) for haloperidol, 51 
(53%) for quetiapine, 31 (45%) for ziprasidone 32 (40%) for amisulpride and 30 
(33%) for olanzapine. Comparisons with haloperidol showed lower risks for any-
cause discontinuation with quetiapine (HR 0.52 [0.35-0.76]), ziprasidone (HR 0.51 
[0.32-0.81]). amisulpride (hazard ratio [HR] 0.37, [95% CI 0.24-0.57]), olanzapine 
(HR 0.28 [0.18-0.43]), However, symptom reductions were virtually the same in all 
the groups, at around 60%, according to PANSS, although minor but significant 
improvements on the CGI and GAF favoured amisulpride over haloperidol. 
Therefore this study indicated that risk for discontinuation was greatest with 
haloperidol, with incremental benefit for quetiapine, ziprasidone, amisulpride and 
olanzapine respectively, but that admission rates to hospital (often used as a proxy 
for relapse) were not significantly different between the five medications studied. 
EPSE were worst with haloperidol, whereas olanzapine (13.9 kg) and then 
quetiapine (10.5 kg) produced the most weight gain over the 12 month follow up 
period. EUFEST, which was described as independent but had sponsorship from 
three pharmaceutical companies, concluded that discontinuation rates were not the 
same as symptomatic improvement and hence they could not demonstrate any 
superior efficacy for SGAs over haloperidol. 
 
4). The Treatment of Early Onset Schizophrenia Spectrum Disorders  or TEOSS 
study was an RCT (Sikich et al, 2008; Findling et al, 2010) in children and 
adolescents in the USA aged between 8 and 19 years old. It was a randomised 
comparison of in 116 individuals of molindone, olanzapine, and risperidone for the 
treatment of early schizophrenia initially for 8 weeks with a 44 week maintenance 
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study phase for responders. The results after 8 weeks of treatment did not reveal 
any differences in symptomatic improvement between the three medications (only 
54 / 116 individuals responded in total - 50% to molindone; 46% to risperidone; 
and 34% to olanzapine) but adverse effects were “frequent” including pathological 
weight gain in all 3 groups (but particularly olanzapine) and movement disorders in 
the molindone group. Only 14 individuals were seen to clinically respond by the 
end of the study. 
 
The results of these studies are in some ways contradictory due in part to their 
differing designs; differing medications studied; and different study environments. 
CATIE; EUFEST and TEOSS demonstrate the sobering reality that the majority of 
individuals do not or cannot continue these medications long term, either due to 
lack of efficacy or intolerable adverse effects. However, both CATIE and EUFEST 
seem to indicate that discontinuation rates are lower for some (but not all) of the 
SGAs, which echoes the findings of the efficacy meta-analyses of Leucht et al, 
2009, and of Davis et al, 2003 (but not Geddes et al, 2000). Similarly, both CATIE 
and CUtLASS 2 suggest that switching to clozapine, when an adequate trial of an 
initial antipsychotic medication has failed to produce a reasonable response, 
confers a therapeutic advantage. Again this mirrors the meta-analytic comparative 
efficacy meta-analytic findings. However, there is enough confusion in the results 
described above to further stimulate recent debate (Kendall, 2011) over whether 
there really is a ‘class effect’ vis a vis typical or FGAs versus atypical or SGAs. 
This thesis examines the comparative effectiveness of the major antipsychotic 
medications in the west of Scotland populations, along with introducing a new 
scale for systematically monitoring the tolerability (or adverse effect) profile of 
antipsychotic medication.  
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Before original data on antipsychotic effectiveness is presented, there is a 
description and analysis of the use of medication for schizophrenia and bipolar 
disorder in secondary care in Greater Glasgow. This sets the scene, highlighting 
both the current prescribing practice in the ‘real world’ and the demographic 
characteristics of the individuals concerned.  
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CHAPTER 3 
 
DESCRIBING THE USE OF ANTIPSYCHOTIC MEDICATION IN GLASGOW 
USING A CITY WIDE CASE REGISTER 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MT was responsible for the design; concepts; data analysis and interpretation; and 
drafting of this chapter. John Park kindly extracted the requested data from the 
case register.   
 
 
 
Study conducted 2010 - 2011 
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The value of case registers in mental health has been reasserted (Perera et al, 
2009) and can not only aid research (Stewart et al, 2009) but also inform day-to-
day clinical practice and service provision by providing practice benchmarks and 
identifying need. The Psychosis Clinical Information System (PsyCIS) in Glasgow 
was developed (Park et al, 2008) as a clinically useful and accurate method of 
following up patients with psychotic illness in the Greater Glasgow area, using an 
electronic case record system. Greater Glasgow, in Scotland, is an urban area of 
approximately one million inhabitants, with the lowest life expectancy in the UK. 
The National Health Service (NHS Scotland) provides government funded 
healthcare for all individuals across primary, secondary, and tertiary care, and in 
Glasgow there is essentially no alternative care provider to the NHS for individuals 
suffering from serious mental illness.  PsyCIS commenced in 2002, with a back-
trawl of defined cases in each of the sixteen community mental health teams 
(general adult psychiatry for adults 16 – 65 years), and was later matched to local 
primary care (or family doctor) case lists of severe mental illness. Since 2002, all 
incident cases of psychosis presenting to community mental health services in 
Glasgow have been captured by PsyCIS, and senior psychiatrists in Glasgow 
complete standardised annual reviews on identified PsyCIS cases year on year.  
 
This chapter describes the socio-demographic characteristics of PsyCIS cohort, 
and reviews the main pharmacological treatments for selected diagnostic groups. 
This overview may allow comparison and benchmarking by mental health services 
elsewhere.  
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Aim 
To describe the socio-demographic profiles and pharmacotherapy employed in a 
systematically ascertained large cohort of individuals with psychotic illnesses. 
 
Method 
The PsyCIS case register has been fully described elsewhere (Park et al, 2008) It 
contains a record of all adult (16-65 years) patients with a consultant confirmed 
diagnosis of psychosis who are in contact with any of the 16 city-wide community 
mental health teams in Greater Glasgow . This chapter focuses on the following 
ICD 10 diagnoses: schizophrenia; schizoaffective; and delusional disorders (F20-
29); manic and bipolar affective disorders (F30-31); and depressive psychosis or 
severe depression with psychotic features (F32.3 and F33.3). Prior to inclusion on 
the register, where cases had not been assigned a diagnosis by a consultant 
psychiatrist or where there was uncertainty over the primary diagnostic coding, 
case notes were reviewed by the research team in consultation with the local 
consultant psychiatrist and a clinical consensus diagnostic coding applied. 
Thereafter, a standardised annual update records current social and legal status; 
risks including episodes of self harm and violence; and the precise treatments at 
that time. 
 
Socio-economic deprivation was assessed using Scottish Government originated 
quintiles (www.scotland.gov.uk/topics/statistics/SIMD), where category 1 
represents the highest, and category 5 the lowest socio-economic group. The 
category ‘working’ includes students registered part or full time. ‘Married’ status 
includes people cohabiting or in de facto marriages; ‘single’ marital status includes 
widows and widowers; and ‘divorced’ marital status includes those couples 
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separated but not divorced. ‘In care / support’ indicates that the individual is in long 
term staff assisted community residence, or long term hospital based 
accommodation. 
  
Age of onset is defined as first being diagnosed with psychotic symptoms by a 
psychiatrist, which is usually the first point of contact with mental health services. 
For the three main diagnostic groupings (schizophrenia; bipolar; and depressive 
psychosis) the use of medication is reported by early phase (3 years or less) and 
later (over 3 years illness duration) phase, to differentiate between those with first 
episode psychosis and those with chronic or refractory psychotic illness. High dose 
antipsychotic medication is defined as exceeding the BNF recommended 
maximum dose, either as a single drug or as a combination. First generation 
antipsychotics (FGA) is the preferred group name for ‘typical’ or older antipsychotic 
medications, and second generation antipsychotics (SGA) is the preferred label for 
‘atypical’ or newer antipsychotic medications. 
 
Simple descriptive statistics were used for analysis. All data contained on the 
PsyCIS system is kept confidential via secure protected electronic systems and 
anonymised prior to analysis. 
 
Results 
 
5073 individuals were included from the 2010 PsyCIS register, including all 
individuals diagnosed with schizophrenia; bipolar disorder; and depressive 
psychosis in secondary mental health care in Greater Glasgow. Specifically, there 
were a total of 2537 people with an ICD 10 F20 coding of schizophrenia; 986 
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people within the ICD 10 F21-29 diagnostic code range (diagnostic breakdown 
illustrated in table 2); 1242 individuals with a bipolar diagnosis (ICD 10, F30-31); 
and 308 people with a ICD 10, F32.3 diagnosis of depressive psychosis.  
 
Table 2. Diagnostic mix of the ICD 10 F21-F29 group in the PsyCIS case register 
 
           Diagnosis (ICD 10 code) Number of individuals and % of 
total (n=986) 
Schizotypal disorder F21           29;     3% 
Persistent delusional disorders 
F22 
         208;    21% 
Acute and transient psychotic 
disorders F23 
         175;    18% 
Schizoaffective disorders F25          301;     30% 
Other / Unspecified non-organic 
psychosis  
         273;     28% 
 
 
57% of the whole PsyCIS cohort is male. The median age of onset for the whole 
cohort was 31 years (range = 18-64 years).  
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Table 3. Socioeconomic group (SEG) status of the PsyCIS population expressed 
as a percentage of the whole (%). 
 
Quintile 1 is most affluent group, and quintile 5 is most deprived. 
SEG 
quintile 
Schizophrenia 
n=2537 
F21-29 
group 
n=986 
Bipolar 
n=1242 
Depressive psychosis, 
n=308 
1         6           8     13           8 
2        11          13     17          12 
3        19          16     20          18 
4        25          25     22          25 
5        39          38     28          37 
 
 
 
Table 4. Social characteristics of the PsyCIS population expressed as a 
percentage of the whole (%) 
 
 Schizophrenia 
n=2537 
F21-29 
n=986 
Bipolar 
N=1242 
Depressive 
psychosis, n=308 
Lives alone        53       43     49           45 
Lives with 
others 
       34       50     47           53 
In care / 
support 
       11        5     3           1 
Homeless        2        2     1           1 
     
Married        12        23      33           38 
Divorced         14        14      21           25 
Single        74        62      46           36 
Working        14        29      35           31 
Unemployed        86        71      65           69 
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Table 5. Regular pharmacotherapy within the PsyCIS population (%) in 2010 
  Schizophrenia 
n=2537 
F21-29 
N=986 
Bipolar 
N=1242 
Depressive 
psychosis, n=308 
Average number 
regular meds 
     1.6     1.6     2.1          2.1 
No medication (%)       2      12      5           4 
     
SGA antipsychotic 
(%) 
     67     74      39          66 
FGA antipsychotic 
(%) 
     14     11      15          15 
LAI antipsychotic 
(%) 
     31     13      7           4 
Antidepressant (%)      25     34      42          92 
Anti-convulsant (%)      5     11      44           5 
Lithium (%)      2      6      41           9 
 
SGA = second generation antipsychotic. FGA = first generation antipsychotic. LAI 
= long acting injectable (depot) antipsychotic medication. Anti-convulsant 
comprises of sodium valproate; valproic acid; carbamazepine; and lamotrigine. 
 
With regard to antipsychotic polypharmacy in the schizophrenia group, 2164 
individuals were regularly prescribed only one antipsychotic medication; 286 
people were on two regular antipsychotics; and 12 individuals were on three 
regular antipsychotics. Of the 4185 individuals in the whole cohort on regular 
antipsychotics; 112 people (3%) were on high dose medication; and of the 400 
individuals regularly prescribed 2 or more antipsychotics, 51 people (13%) were on 
high dose medication. The precise breakdown of combination antipsychotic 
medication within the cohort is listed in Table 6 below. 
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Table 6.  Antipsychotic combinations in the PsyCIS cohort, 2010. 
 Number of individuals 
Entire PsyCIS cohort 5073 
Total on regular 
antipsychotics 
4185 
2 or more antipsychotics 400 
FGA LAI + FGA oral 111 
SGA oral + FGA oral 98 
FGA LAI + SGA oral 66 
SGA oral + clozapine 56 
Two differing SGA 28 
FGA oral + clozapine 21 
SGA LAI + SGA oral 20 
 
SGA LAIs (ie risperidone consta) comprised 16% of total LAIs. The majority of 
individuals prescribed an LAI medication were voluntary patients, as depicted 
below in Table 7. 
 
Table 7. Use of the Mental Health (Scotland) Act, 2003 - ‘MHA’ - long term 
treatment orders, and current formulation of prescribed medication (in 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diagnosis LAI and subject 
to MHA (%) 
Oral medication and subject to 
MHA (%) 
Schizophrenia         15               8 
F21-29         22              11 
Bipolar         22               7 
Depressive 
psychosis 
        0               6 
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Where a medication was stopped in the previous year, it was overwhelmingly due 
to intolerable side effects rather than lack of efficacy for all four diagnostic 
groupings. 
 
Analysis of the most commonly prescribed medications, split according to early or 
mid-late phase of illness is depicted below, in table 8. 
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Table 8. Most frequently prescribed medications, by illness duration, within the 
PsyCIS cohort. Total percentages do not reach 100% due to other medications not 
shown. 
 
Schizophrenia Illness Length =<3 Years Schizophrenia Illness Length >3 Years 
Name 
Total no. 
patients     % total Name 
Total no. 
patients    % total 
Olanzapine 55 30 Clozapine 432 18 
Risperidone 33 18 Olanzapine 417 18 
Quetiapine 19 10 Flupentixol Depot 308 13 
Procyclidine 15 8 Risperidone 269 11 
Amisulpride 14 8 Procyclidine 236 10 
 
Bipolar Illness Length =<3 Years Bipolar Illness Length >3 Years 
Name 
Total no. 
patients    % total Name 
Total no. 
patients   % total 
Sodium Valproate 55 34 Lithium 451 42 
Lithium 37 23 Sodium Valproate 288 27 
Olanzapine 26 16 Olanzapine 192 18 
Diazepam 19 12 Carbamazepine 107 10 
Lamotrigine 17 11 Citalopram 97 9 
 
Depressive Psychosis, illness =<3 Years Depressive Psychosis, illness >3 Years 
Name 
Total no. 
patients % total Name 
Total no. 
patients   % total 
Olanzapine 32 29 Risperidone 43 22 
Citalopram 27 24 Olanzapine 40 20 
Risperidone 23 21 Venlafaxine 31 16 
Venlafaxine 23 21 Chlorpromazine 25 13 
Mirtazapine 13 12 Citalopram 24 12 
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Discussion 
Case registers like the PsyCIS register in Greater Glasgow can provide useful 
benchmarking data on the circumstances, diagnostic patterns, and treatment of 
individuals from a discrete geographic area. These data can inform public policy 
and service provision, and facilitate audit and research, although concerns around 
confidentiality and funding have been noted (Perera et al, 2009). PsyCIS regularly 
feeds back localised data compared to citywide medians to the clinicians who 
contribute, permitting reflective review of caseload and diagnostic and therapeutic 
practice. Our results represent a true picture of the status and treatment of people 
with psychotic illness living in Glasgow, as there is no privately funded care for 
these conditions available locally, and the match between the PsyCIS register and 
local primary care General Practitioner registers of those with serious mental 
illness (via the Quality Outcomes Framework) is known (personal communication, 
Dr Connolly) to be very high at 90%. Some individuals with psychosis however are 
probably unknown to both primary and secondary care, but the numbers are likely 
to be low given the serious impact on health and function of these illnesses. 
 
All people with psychosis on the PsyCIS register suffer more economic and social 
deprivation than the general population despite the presence of well developed 
local community mental health and social work services. Those diagnosed with 
schizophrenia are even less likely to be married, or working than those with bipolar 
disorder and depressive psychosis. This is a concern as it is likely that this social 
isolation and economic deprivation contribute to the premature mortality seen in 
schizophrenia (Bushe et al, 2010). Similar findings have been reported in other 
surveys of psychosis in urban areas (Jablensky et al, 2000), and emphasises the 
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need for targeted mental health care and social work input into the most deprived 
urban areas. 
  
Polypharmacy was frequently noted across all groups studied, particularly for 
bipolar disorder and depressive psychosis. This is not necessarily a bad thing as 
long as it’s rational and reviewed (Langan and Shajahan, 2010). A small minority of 
those with a psychotic illness were not on any regular medication (see Table 5). 
Interestingly, the majority of commonly prescribed medications identified in this 
study are generic, implying that direct medication costs are low for this population. 
Those with schizophrenia and related disorders followed up by PsyCIS are usually 
prescribed a second generation antipsychotic, and the use of a long acting 
injection of antipsychotic medication in 31% of those with schizophrenia reflects 
practice elsewhere in the UK (Barnes et al, 2009), reiterating the finding that these 
formulations are useful in reducing relapse (Tiihonen et al, 2011).  
 
Clozapine is the most commonly prescribed single medication for those with over 3 
years of schizophrenia, again consistent with good practice (Farooq and Taylor, 
2011). Nearly 10% of those on regular antipsychotic medication were routinely 
prescribed two or more regular concurrent antipsychotic medications, despite the 
lack of evidence (Barnes, 2011) supporting the practice of antipsychotic 
polypharmacy, and high dose medication was proportionately more common in this 
group leading to concerns over an increased side effect burden (Paton C et al, 
2008).  
 
Those with a bipolar disorder usually have a ‘mood stabiliser’ such as lithium or 
sodium valproate as their primary regular medication, concurrently with either an 
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antipsychotic or antidepressant. Geddes et al (2010) found combination therapy to 
be superior to monotherapy in prevention of bipolar relapse, and prescribers in 
Glasgow seem to agree. Individuals diagnosed with depressive psychosis usually 
receive an antipsychotic and antidepressant combination, and the pharmacological 
treatment of this condition seems poorly reported and researched.  
 
Most individuals in this PsyCIS cohort who are in receipt of regular medication are 
not detained on long term treatment orders under the Mental Health (Scotland) Act, 
2003, including those on long acting injections of antipsychotic medications. This 
implies that the majority of individuals with psychosis, including bipolar and 
depressive psychosis, are able to consent and willing to accept long term 
maintenance medication, although actual levels of medication adherence cannot 
be determined by this methodology. 
 
Strengths and limitations 
Strengths of this analysis include the large representative community based 
population studied in a prospective manner, allowing the results to be generalised 
to other urban areas with similar health and social care systems. Also, PsyCIS 
requires regular checks of data accuracy by the senior medical practitioners 
actually involved in the day-to-day case management, thus ensuring the validity of 
diagnosis and social state, as well as an up to date account of treatment provided. 
These local clinicians have a 2-way relationship with the PsyCIS team, which 
facilitates the return to consultants of clinically relevant information at individual 
caseload level. Limitations include the possibility of inaccurate data recording, 
either by the clinicians or when local returns are centrally uploaded. Clinical 
diagnosis, albeit by highly experienced psychiatrists, rather than a structured 
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diagnostic interview was used to establish diagnostic category. Also, PsyCIS 
excludes those under 16 and over 65 years old, as well as those whose psychotic 
illness is solely managed in primary care; addictions; old age psychiatry; or 
learning disability services, and hence this sample does not represent the gamut of 
psychotic illness. 
 
Implications 
Psychiatric case registers can permit accurate descriptions of the clinical 
populations surveyed, and inform service provision whilst being a tool for audit and 
research. The establishment and maintenance of clinical registers for long term 
conditions such as psychosis should also be politically desirable, as they can 
highlight areas of unmet need and facilitate quality assurance in the care pathway. 
Individual clinicians can also use registers like PsyCIS to compare their practice 
and caseload with similar neighbouring areas. 
 
Individuals with a psychotic illness in Glasgow, particularly those with 
schizophrenia, are not only disadvantaged by the direct signs and symptoms of 
their mental disorder but also by the attendant negative social and economic 
consequences of these disorders. This morbid concatenation of medical and social 
disadvantage has been associated with early death (Hamer et al, 2008), and 
requires targeted interventions by a combination of health and social services that 
are flexible enough to respond to challenges like comorbidity; homelessness; 
stigma; and variable help seeking behaviour. The vast majority of prescribing 
documented by PsyCIS appears rational, guideline-compliant and evidence based. 
SGA are used in over two thirds of patients with schizophrenia and the most 
frequently prescribed medications in long term patients were clozapine for 
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schizophrenia and lithium for bipolar disorder. These findings, plus the relatively 
low use of long term compulsory treatment orders, should be reassuring to the 
patients involved and their carers and advocates. 
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CHAPTER 4 
 
A SIX MONTH PROSPECTIVE STUDY OF THE EFFECTIVENESS OF FIVE 
ORAL ANTIPSYCHOTIC MEDICATIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MT conceived the study; analysed and interpreted the data, and drafted the 
manuscript. Drs Turner, Brown, and Watt contributed to the data interpretation and 
reviewed the manuscript. Ms Fraser and Ms Martin helped collect the data. 
 
Study conducted 2003 -2005 
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There are few long term head-to-head studies comparing the efficacy and safety of 
‘second generation’ antipsychotic (SGAs) medications, and fewer still that are 
independent of pharmaceutical industry support. Perhaps unsurprisingly 
commercially supported comparative studies (Conley and Mahmoud, 2001; Tran et 
al, 1997) tend to be outcome-neutral or favour the drug produced by the sponsor.  
 
Demonstrating efficacy in randomised controlled trials (RCTs) is not the same as 
showing effectiveness in routine clinical practice, where dual diagnosis or 
comorbidity, and lack of adherence are often the norm. Systematic all inclusive 
open label studies can complement RCTs, and a local demonstration of 
effectiveness can help inform local clinicians and formularies. A validated system 
with a scale based on the Clinical Global Impression (Guy, 1970) had previously 
been developed (Gilchrist et al, 2002) (see appendix 1) and the same methodology 
was used to compare symptom profiles and outcomes of individuals being newly 
prescribed five commonly used SGAs throughout the city of Glasgow, UK. 
 
 
Aims 
1. To demonstrate the feasibility of systematic outcome monitoring for 
antipsychotic medication in routine clinical practice. 
2. To compare the clinical outcomes after six months treatment of five differing 
antipsychotic medications. 
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Method 
Study design 
A naturalistic prospective assessment of the clinical response to medication in 
individuals who were newly started or newly switched to one of the following five 
antipsychotic medications: amisulpride; clozapine; olanzapine; quetiapine; and 
risperidone. Consultant psychiatrists in Glasgow were asked to complete a 
standardised rating (see appendix 1) based on the Clinical Global Impression scale 
when the new antipsychotic medication was commenced, and then undertake a 
similar structured standardised review after six months of treatment, or at the point 
of treatment discontinuation. These standardised clinical reviews were undertaken 
voluntarily by the consultants. 
 
In order to maximise enrolment by the treating consultant psychiatrist, no formal 
inclusion or exclusion criteria were stipulated for the patient enrolment. The study 
recruitment ran for one year, with a further six months for follow-up assessments of 
individuals enrolled towards the end of the one year study period. As this study 
was viewed as an extension of usual clinical practice by consultants who agreed to 
the protocol, ethical approval and informed consent were not sought from the 
patients enrolled. All personal data was anonymised prior to analysis. Participation 
in the trial did not affect treatment choice or delivery in any way. 
 
Patients 
All patients from secondary care adolescent, adult, and old age psychiatry in the 
Greater Glasgow urban area with a clinical diagnosis (from a consultant 
psychiatrist) of schizophrenia or schizophreniform disorder, and who were being 
newly prescribed either amisulpride, clozapine, olanzapine, quetiapine, or 
  
64 
 
risperidone were prospectively recruited into the study.  The patients included in 
this study were a combination of medication naïve individuals and those requiring a 
switch in antipsychotic medication as a consequence of lack of efficacy or 
tolerability, or both. 
 
Measures 
Demographic and clinical information (including one or more of five pre-specified 
reasons for initiating the anti-psychotic) was documented by the prescribing 
clinician.   A standardised assessment form with five linear analogue scales and 
referenced anchor points was also completed.  The scales comprised the Clinical 
Global Impression (CGI) scale (score range 0 to 7), as well as an assessment of 
the positive and the negative symptoms of schizophrenia, drug related adverse 
effects and impairment of quality of life (all with score range 0 to 4).  Both the CGI 
and the adapted CGI domain specific scales, along with the related anchor points, 
are detailed in Appendix 1. For all assessments the score increases with severity 
of symptoms. Where possible, the same clinicians re-assessed the patients still on 
their medication at six months. Previously ascertained (Gilchrist et al, 2002)  inter-
rater reliability weighted kappa scores for the five outcome scales were 0.60 for the 
CGI, 0.44 for positive symptoms, 0.39 for negative symptoms, 0.69 for drug-related 
side effects, and 0.75 for quality-of-life impairment. Kappa scores of 0.44 and 0.39 
represent only fair to moderate inter-rater reliability, according to conventional cut-
offs, whereas scores higher than this indicate good or excellent reliability. Although 
the low scores for the positive and negative symptom ratings are a limitation, they 
are representive of day-to-day clinical practice where both the physical and mental 
state examination have similar ratings (Mojtabai R et al, 1995). 
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Analysis 
Simple descriptive statistics are used for the numbers both started and dropping 
out of antipsychotic treatment, along with the prescribing clinician’s reason for the 
specific medication choice. Observer rated CGI and the four domain specific 
variable scores at baseline and six months are compared with the non-parametric 
Wilcoxon matched-pairs signed-ranks test, as the data were not assumed to be 
normally distributed, or that the variables under analysis would be independent. 
Significance level was set at the conventional 0.05. Median scores for the CGI at 
baseline are presented but subsequently the analysis focuses on mean CGI and 
specific domain scores for ease of comprehension.  
 
Improvement after six months treatment is presented as a percentage change from 
the mean baseline rating, along with standard deviations to indicate size of 
distribution. Change across the five treatment groups was analysed using the 
Kruskal-Wallis test. Data on patients who dropped out of the study early, ie were 
not on the specified medication at the six month review point, were not subject to a 
last observation carried forward analysis as there were only 2 data points, and 
relies on the assumption that the drop out was related to the treatment in question 
(discussed further below).  
 
 
 
Results 
Three hundred and seventy three patients (192 men, 181 women) were enrolled 
with a mean age of 45.9 years (range = 14 - 99). These were individuals being 
treated in National Health Service (NHS) in-patient and out-patient settings in the 
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Greater Glasgow urban area. This enrolment represented an uptake rate of 51% of 
all possible new medication prescriptions, according to pharmacy returns, by 
psychiatrists working in adolescent, adult, and old age specialities who were newly 
prescribing SGA medication within a one year period in Glasgow. This 51% 
enrolment of subjects was evenly distributed across geographic and specialty 
areas within Glasgow, and hence was felt to be representative of the whole 
population.  
 
There was a 64% completion rate of returns at the six month review point (n=157) 
or at discontinuation (n=81), with the remaining 135 subjects being lost to follow 
up.  
 
Criteria for patient selection as indicated by clinician (n=373):  The clinical 
indications for specific drug selection allowed were intolerable side effects 
(including extra-pyramidal symptoms or EPS) from previous antipsychotics 
(including first generation antipsychotics), minimisation of side effects (SE) from 
the outset of treatment as a priority, marked negative symptoms, refractory 
schizophrenia, being a first episode case, and other. Indicating more than one of 
these criteria was allowed, as denoted in Table 9. 
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Table 9. Reasons given by treating psychiatrist for patient / medication selection, at 
the time of switch / initiation. 
 
 Amisulpride 
    N=34 
Clozapine 
  N=25 
Olanzapine 
  N=161 
Quetiapine 
   N=38 
Risperidone 
  N=115 
Intolerable EPS         15          5        41        9        24 
Minimise side-effects from outset         17          3        70        16        45 
Marked negative symptoms          8          4        19        6        13 
Refractory psychosis         14         22        40       16        20 
First episode illness          0          0        16        5        12 
Other          4          1        32         7        28 
 
 
 
Baseline assessments (n=373).  The mean scores for all baseline ratings of 
impairment or disability are given in Table 10. Mean CGI scores ranged from 4.0 to 
5.3, with median scores clustering around 4 - 5 (moderate to markedly ill).  There 
was an anticipated difference in mean CGI based pathology scores between 
clozapine (the only drug licensed in the UK for treatment resistant schizophrenia) 
at a mean of 5.3, and the other four medications (4.0 - 4.4) although this was not 
statistically significant. 
 
 The other ratings were:  positive symptoms mean scores between 1.9 and 2.8 (2 = 
moderate and 3 = marked pathology); negative symptoms mean scores were 0.8 
to 1.7 (1 = mild to 2 = moderate severity); drug-induced side effects had mean 
scores between 1.0 and 2.0 (1= mild and 2= moderate disability); impairment in 
quality of life had mean scores from 2.9 to 3.6 (3 = moderate, 4 = severe). 
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Table 10. Mean rated levels of pathology at baseline assessment. 
  
 Amisulpride 
     n=34 
Clozapine 
    n=25 
Olanzapine 
     n=161 
Quetiapine 
     n=38 
Risperidone 
      n=115 
Clinical Global Impression  (0-7) 
Mean score 
        4.0      5.3       4.3        4.2        4.4 
Clinical Global Impression (0-7) 
Median score 
         4       5        4         4        4 
Positive symptoms  (0-4)         1.9      2.8       2.1         2.1             2.1 
Negative symptoms  (0-4)         1.3       1.7       1.1        1.1          0.8  
Side effect profile  (0-4)         1.9      1.8        1.3        1.7        1.1 
Impaired quality of life  (0-4)         2.9      3.6       2.9              3.0        2.9 
 
 
 
Dose.    The mean daily dose at six month review for amisulpride (n=16) was 487.5mg, for 
clozapine (n=12) was 429 mg, for olanzapine (n=65) was 13.7 mg, for quetiapine (n=8) 
was 350 mg, and for risperidone (n=56) was 3.4 mg. 
 
 
Comparison of baseline and follow-up assessments. 
After six months treatment there were 157 (66% of those not lost to follow up) 
individuals available for re-assessment who were still being prescribed the newly 
initiated SGA. Six month follow up individual ratings by the treating psychiatrist 
ranged from deterioration through unchanged to improvement, according to the 
Clinical Global Impression scores, as depicted in table 11. Mean ratings for each of 
the five treatment groups were improved at the six month review point, and the 
comparative mean improvement in the five rating scales for the five treatment 
groups are presented in Table 11, along with percentage change from baseline. 
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Table 11. Improvement after six months treatment – mean drop in ratings and 
percent change from baseline 
 
 Amisulpride 
     n=16 
Clozapine 
    N=12 
Olanzapine 
      n=65 
Quetiapine 
     n=8 
Risperidone 
      n=56 
CGI,          mean  (SD) 
                  percent change 
 0.85   (1.8) 
       19% 
 1.80   (1.7) 
     34%* 
1.18   (1.6) 
     33%** 
0.83   (1.3) 
     11% 
1.70 (2.1) 
     38%** 
Positive symps, mean  (SD) 
                  percent change 
0.55    (1.35) 
       30% 
1.50   (1.6) 
      54%* 
 0.9    (1.2) 
     51%** 
0.67   (1.75) 
      26% 
1.28 (1.4) 
      66%** 
Negative symps, mean  (SD) 
                  percent change       
0.40    (0.9) 
      24% 
0.40    (1.1) 
     20% 
0.26    (0.9) 
     11%* 
1.00   (1.55) 
     39% 
0.51 (1.0) 
      35%* 
Side effects,   mean  (SD) 
                   percent change  
0.87    (1.5) 
       54%* 
0.10    (1.6) 
     13% 
0.90   (1.6) 
     51%** 
1.50   (0.6) 
    53%  
0.74 (1.6) 
     47%* 
Quality of Life,  mean  (SD) 
                   percent change 
0.38   (2.0) 
     15% 
1.10   (1.7) 
     34% 
0.96   (1.5) 
     36%** 
1.17   (1.2) 
     31% 
1.23 (1.3) 
      40%** 
 
SD = standard deviation 
* denotes significance level, p<0.05, by Wilcoxon signed rank pairs 
** denotes significance level, p<0.005 by Wilcoxon signed rank pairs 
 
There was no significant difference (by Kruskal-Wallis) between the five groups of 
medication across the five different rating measures, after six months of treatment. 
For example, differential improvement in CGI between the five treatments, 
p=0.095.  
 
Dropouts. 81 patients were documented as discontinuing treatment within six 
months, constituting 36% of the total cohort available at six month follow-up. More 
than one reason for discontinuation could be specified by the treating psychiatrist, 
and the specified reasons for discontinuation are listed in Table 12. 
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Table 12. Reasons given by treating psychiatrist for discontinuation of medication 
 
 Amisulpride 
n=6 from 34 
Clozapine 
n=5 from 25 
Olanzapine 
n=32 from 161 
Quetiapine 
n=8 from 38 
Risperidone 
n=30 from 115 
Not effective         3          0            11            3            12 
Non adherence         2          2            13            4            7  
Side effects         3          3             8            3           19 
Other         0          1             8            1            4 
 
 
 
Discussion 
Principal Findings 
During a one year time frame over half (51%) of all newly initiated regular 
antipsychotic prescriptions across the city of Glasgow were followed up in 
systematic manner. The main reasons (45% of all choices) that one of the five 
specified antipsychotics were chosen was due to the perception of a favourable 
side effect profile, or to minimise side effects from the outset. This study was 
undertaken before there was a significant body of evidence available on the 
adverse metabolic side effect profile of a number of these SGA medications. 
Olanzapine and risperidone were the two most popular medication choices by 
prescribers during this study, and these two medications were the first two SGA 
medications to receive a license in the UK, in 1996 and 1993 respectively, implying 
that clinicians might have had sufficient experience in these medications to 
become confident in their use. 
 
Individuals prescribed clozapine had noticeably higher levels of psychopathology 
at baseline and less improvement in side effects after six months treatment 
compared to the four other groups, which is hardly surprising as by definition these 
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individuals were already treatment resistant before a switch to clozapine was 
contemplated. Patients being initiated on amisulpride, olanzapine, quetiapine, and 
risperidone had remarkably similar mean levels of observer rated psychopathology 
at baseline assessment. 
     
 The discontinuation rate (81/238 or 34%) for the antipsychotic medication noted in 
Table 12 is not dissimilar to dropout rates of 22% to 47% reported by Leucht et al 
(2003), but lower than the CATIE and TEOSS trials (Lieberman et al 2005 ; Findler 
R et al, 2010) The reasons for medication discontinuation in everyday practice are 
usually several and medication non compliance or adherence is not necessarily 
linked to experience of adverse side-effects, as illustrated in Table 12, but may be 
due to social factors; lack of efficacy; and forgetfulness.  
 
Some of the mean improvement scores at six month review did not achieve 
statistical significance, although for amisulpride, clozapine, and quetiapine this 
could be due to a lack of power secondary to the low numbers of patients still on 
these treatments at six month review. It is clear that all five antipsychotics studied 
produced clinically observable improvements in the five global ratings of pathology 
after six months therapy. These improvements in observer rated disease severity 
mainly occurred in patients switched to one of the five medications studied, as new 
prescriptions in a medication naïve individuals were less than 10% of the total, 
even though the evidence suggests switching between individual antipsychotics 
appears to confer little or no benefit (Rosenheck et al, 2009).  
 
The improvements in the clinical global impression (CGI) at six month review were 
mirrored by improvements in positive symptoms; side effects (except for clozapine) 
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and to a lesser extent quality of life. Negative symptoms of schizophrenia are 
arguably a challenging symptom domain for the clinician to detect in the out-patient 
clinic, as well as being notoriously difficult to treat. The quality of life assessment 
involved consideration of time utilisation and activities of daily living, and 
occupational or social role fulfilment.  
 
Differences, albeit trends, in outcome between the five treatments after six months 
are evident from table 11, but no statistically significant difference between the 
drugs for any of the five outcome measures studied was detected. This is most 
likely due to the relatively low numbers patients retained in the study at the six 
month point. It is also worth noting again that by definition, clozapine was being 
used in patients who were already treatment resistant and thus any therapeutic 
gains documented might have been harder to achieve. 
 
 
Strengths and limitations of the study 
A naturalistic ‘real world’ design was adopted for this effectiveness study.   Data 
were collected prospectively on a consecutively recruited sample of patients with a 
clinical diagnosis of schizophrenia or schizophreniform psychosis, and no 
exclusion criteria were applied as exemplified by the wide age range of subjects 
noted above.  Symptom severity was measured with a simple compound scale 
based on standardised psychiatric rating scales with proven reliability, and the 
scale used was considered pragmatic enough to be used by psychiatrists in 
Glasgow during their routine (busy) work. Levine et al111 have already 
demonstrated, perhaps surprisingly, that the Clinical Global Impression scale has a 
robust mathematical (and hence clinical) relationship with more in-depth scales 
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such as the Brief Psychiatric Rating Scale and the Positive and Negative 
Syndrome Scale, which reinforces the rationale for its choice as a rating scale in 
this study.  
 
Importantly, all patients with schizophrenia-type psychosis were included 
regardless of any additional diagnoses or problems, including those who were 
subject to the Mental Health Act; liable to pregnancy; or had co-morbidity such as 
substance misuse. Also, as this study of antipsychotic medication was undertaken 
without involvement from the pharmaceutical industry, it is less liable to 
sponsorship bias. 
 
Limitations of this study include the fact that standardised psychiatric interviews 
were not conducted in all subjects, and thus we cannot be sure that the subjects 
meet diagnostic criteria for schizophrenia, although the subjects are likely to be 
representative of patients given that clinical diagnosis by experienced psychiatrists.  
The improvements in ratings scores noted by the treating psychiatrists cannot 
automatically be assumed to be purely due to medication, even though the raters 
were explicitly guided to attempt to isolate the medication related impact on the 
patient. Also, it cannot be certain that the patients described in this study truly 
represent the gamut of patients with schizophrenia seen in secondary care in 
Glasgow, as only 51% of new antipsychotic prescriptions were captured during the 
one year enrolment study period. Further, the lack of power at six month follow up 
meant observations were sometimes not statistically significant, and this difficulty 
in retaining people with schizophrenia in follow up over a long period is mirrored in 
clinical practice. The analysis of missing data on patients (n=81) who ‘dropped out’ 
  
74 
 
before the six month review deserves further comment. On the one hand the 
exclusion of patients who dropped out might artificially inflate the apparent 
effectiveness of each medication to differing degrees. The technique of last 
observation carried forward (or LOCF) for the handling of ‘drop outs’ does have the 
advantages of minimising the number of the subjects who are eliminated from the 
analysis, and allowing examination of trends over time, rather than focusing simply 
on the endpoint. However LOCF does rely on the assumption that patients on the 
treatment will get better and that any change in state is related to the treatment in 
question, which cannot be guaranteed here. Also, LOCF is usually employed in 
studies with multiple data points over the study period, whereas here the design 
(and cost) necessitated only data acquistion at study entry and exit, so on balance 
a LOCF analysis of 'drop outs' was not undertaken. Nevertheless, a bias, 
particularly a selection bias, could have been introduced in the analysis here. 
 
It has previously been demonstrated (Gilchrist et al, 2002) that the scales we used 
had satisfactory inter-rater reliability at one point in time, but it does not necessarily 
follow that all the raters used in the study would all have agreed with each other to 
an acceptable extent.  However, our kappa values of 0.4 – 0.75 are similar to the 
typical values of 0.5 for most of the components of the physical examination in 
general medical practice (Sackett et al, 1991).    Indeed, in studies such as this 
one has to balance what is desirable with what is practical, and the use of 
potentially different raters for particular patients is analogous to clinical situations 
where one doctor has to assess the effect of a drug prescribed by another.  The 
use of some form of routine outcome rating is likely to provide more reliable 
information than a variable standard of case note documentation based on 
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components of a typical mental state examination, which may itself be even less 
reliable than a typical physical examination (Mojtabai and Nicholson, 1995). 
Nevertheless, observer bias cannot be excluded in this study. Finally a drop-out or 
medication discontinuation rate of 34% within a six month naturalistic study period 
is not unusual when compared to related studies (eg Lieberman et al, 2005), but 
does raise the possibility that improvements in global pathology documented at the 
six month review might not be representative of the whole population under review, 
and the results noted here may only be representative of patients who can 
continue their antipsychotic medication for at least six months. 
 
Conclusions 
 
In summary, this study demonstrates that is possible to work with busy 
psychiatrists to evaluate (relatively) new treatments in a systematic manner. At the 
time of the study, olanzapine and risperidone were the two most frequently 
prescribed antipsychotics, with prescribers usually stating that minimising the 
adverse side effect profile was the main goal of the prescription. Data presented 
here confirms that switching commonly prescribed antipsychotics may confer some 
clinical advantage to patients with schizophrenia, despite the dearth of positive 
data on the benefits of the commonly encountered practice of switching 
antipsychotics.  
 
 
 
 
 
  
76 
 
CHAPTER 5 
 
A TWO YEAR RETROSPECTIVE COMPARISON OF FIVE ORAL 
ANTIPSYCHOTIC MEDICATIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 
MT conceived and designed the study; participated in data collection and analysis; 
interpreted the data; and drafted the manuscript. Dr Shajahan designed the study; 
participated in data collection, interpretation, and analysis; and helped draft the 
manuscript. Professor Lawrie helped interpret the data and draft the manuscript. 
 
 
 
Study conducted 2006-2007. 
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Debate over the comparative benefits and risks of second generation 
antipsychotics (SGAs) has continued (eg Kendall, 2011). While the SGAs 
command widespread clinician confidence and have previously been 
recommended by influential guidelines, it is not clear that the SGAs are a 
homogenous group with a clear class effect (Owens 2008). Coupled with this 
apparent heterogeneity are the increasing licensed uses for some SGAs that have 
evolved in recent years from schizophrenia and related psychoses to specific 
phases of bipolar disorder. Deciding which SGA should be used in a particular 
circumstance is therefore often a matter of trial and error. 
 
Discontinuation rate of SGAs has been adopted as a measure of effectiveness in 
the landmark Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) 
studies (eg Lieberman et al, 2005), based on the understanding that people will 
stop taking medication if it is not beneficial or is producing intolerable side-effects. 
This study was designed to examine antipsychotic effectiveness using 
discontinuation rates, as well as describing the varying patterns of use of five of the 
most commonly used SGAs in a representative community based population. 
 
 
Aims 
1. To compare the clinical effectiveness of five antipsychotic medications. 
2. To describe the patterns of antipsychotic medication use in a large 
representative population. 
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Method  
Study design 
The county of Lanarkshire, Scotland, comprises approximately 550,000 people in 
mixed urban and rural settings, and is ethnically homogenous with comparatively 
low socio-economic status (www.scotpho.org.uk). Using an electronic patient 
record (EPR) system covering all mental health care contacts for a large area in 
Lanarkshire (approximately 400,000 people) the study aimed to describe and 
compare the patterns of use and discontinuation of SGAs, in all individuals 
prescribed these medications in a two year period. 
 
The EPR included all typed nursing and medical notes and correspondence for 
patients aged 16 to 65 from February 2002 to June 2005. The EPR system was 
searched for information on the most commonly used oral SGAs. Both generic and 
trade names of medications were used as keywords for the searches. The SGAs 
most commonly prescribed during the study period between 2002 and 2005 were 
amisulpride; clozapine; olanzapine; quetiapine; risperidone. Chlorpromazine and 
haloperidol were not chosen as comparators, as searches indicated these were 
only rarely used for maintenance treatment.  
  
Measures and Outcomes 
After initial identification from the EPR, every medical case record containing 
information on one or more of the five SGAs under study were manually 
scrutinised for demographic and clinical information, including all diagnoses; 
dosage of medication; and co-prescribed psychotropic medication. Cross checking 
between the EPR and 10% of individual case records was done to ensure 
accuracy of the EPR. All diagnostic groups were included. Diagnoses were always 
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made by experienced psychiatrists (with a minimum of 4 years postgraduate 
medical training) using clinical ICD 10 criteria.  
 
After the initial analysis of the total sample, only those cases with a diagnosis of 
schizophrenia or related psychoses (F2x category, ICD10) were selected for 
further analysis to allow valid comparisons between clinically comparable groups, 
Medical case records were only excluded from analysis if there was insufficient 
clinical or demographic information available.  
 
In this selected population, discontinuation rates for individual SGAs were 
calculated in cases where the SGA had been initiated after the EPR commenced 
(ie not including those on the medication prior to the introduction of the EPR) by 
dividing the number of individuals remaining on the specific medication during ther 
period of study provided there was definite discontinuation with evidence of a 
prescription being ceased. The mean number of days till discontinuation for each 
SGA was also calculated. Discontinuation rate was adjusted for length of exposure 
(ie length of record) but this did not affect the results. Reasons for the 
discontinuation noted in the EPR and medical case record were assigned to three 
groups: discontinuation due to intolerable side-effects; due to inefficacy; or due to 
other reasons (eg. patient choice).   
 
Hospital admission rates were also calculated for each SGA, but again only in 
those cases where the SGA was initiated after the EPR commenced.  
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In order to examine any relationship between mean dosage of SGA and 
discontinuation rate, the mean maximum dose of SGA used in both cases who 
continued and those who discontinued a particular SGA was calculated. 
 
Statistical analysis 
StatsDirect (issue1.8.9) was used for simple descriptive statistics. Statistical 
significance was set at two-tailed p<0.05; and 95% confidence intervals were 
calculated where appropriate. Paired t-test and chi square tests for comparisons 
between groups were used, where appropriate.  
 
 
Results 
Patient Characteristics 
A total of 11,250 case records were searched. 2013 individuals (18% of the total) 
were prescribed one or more of the five SGAs under scrutiny, but only 1464 
individuals (13% of total) had case records of sufficient quality (defined as having 
two or more independent documents mentioning the SGA in question) to allow 
thorough analysis. This relative proportion of case records available for analysis is 
illustrated in Table 13, along with the patterns of use of the five SGAs across broad 
diagnostic categories. 
 
Table 13. Diagnoses and use of SGA medication 
 Amisulpride Olanzapine Quetiapine Risperidone Clozapine 
 
Total number prescribed SGA      340       893      436      192      152 
Number available for analysis      251       632      309      136      136 
Schizophrenia / psychosis (%) 159   (63%)  323   51%)  121 (39%)  74    (54%)   132 (97%) 
Bipolar disorder (%)  28    (11%)  101  (16%)   65   21%)   7     (5%)    4   (3%) 
Depression / anxiety (%)  52    (21%)  153   24%) 106   34%)  42    (31%)    0 
Personality disorder (%)   4     (2%)  10     (2%)   11   (4%)   4     (3%)    0 
Other (%)   8     (3%)  45     (7%)    6    (2%)   8     (6%)    0 
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Diagnostic categories placed in the “other” group include post-traumatic stress 
disorder and dementia. Unsurprisingly, clozapine is used here almost exclusively 
for schizophrenia and related psychoses. Quetiapine, in contrast, was used in the 
majority of cases for mood disorder and anxiety, rather than schizophrenia. 
 
Table 14. Average dose of SGA (rounded to the nearest 0.5mg) 
 
 Amisulpride Olanzapine Quetiapine Risperidone Clozapine 
 
Number of cases      251       632       309     136      136 
Average 
dose 
mg. per day 
Schizophrenia      589      15.5       441      6      427 
Bipolar      396       14       375      2.5      350 
Other      356       10       240      2.5         - 
 
 
Table 14 reveals the average dosages of the five SGAs over the entire duration of 
treatment for all diagnostic categories, ie. schizophrenia and related psychoses; 
bipolar disorder; and “other” diagnostic categories which includes depression, 
anxiety, and personality disorder. Table 14 also shows that the average dose for all 
five medications studied is lower in bipolar disorder than schizophrenia [with 
average dose reduction between SGAs ranging from 16% (clozapine) to 59% 
(risperidone). 
 
For further analyses, only those individuals with a diagnosis of schizophrenia or 
related psychosis and who had commenced the relevant SGA after the start of the 
EPR were selected. The numbers of case records meeting these inclusion criteria 
are given in table 15, along with related demographic and clinical characteristics.  
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Table 15. Characteristics of individuals with schizophrenia newly started on a SGA 
 Amisulpride Olanzapine Quetiapine Risperidone Clozapine Significance 
 
 
Total number 
 
95 
 
148 
 
78 
 
39 
 
40 
 
 
Mean Age (years) 
[95% C.I.] 
 
41 [38-43] 
 
40 [39-42] 
 
41 [38-44] 
 
43 [39-47] 
 
37 [33-40] 
 
NS 
 
Percent male 
 
 
63% (n=60) 
 
64% (n=95) 
 
38% (n=30) 
 
62% (n=24) 
 
65%(n=26) 
 
p=0.0006a 
 
History of alcohol 
misuse* 
 
36% (n=34) 
 
34% (n=51) 
 
23% (n=18) 
 
28% (n=11) 
 
38% (n=15) 
 
NS 
 
History of illicit 
substance use** 
 
22% (n=21) 
 
23% (n=34) 
 
27% (n=21) 
 
10% (n=4) 
 
28% (n=11) 
 
NS 
 
Co-prescription 
(antidepressant) 
 
46% (n=44) 
 
55% (n=81) 
 
62% (n=48) 
 
46% (n=18) 
 
43% (n=17) 
 
NS 
 
Co-prescription 
(mood stabiliser) 
 
 
18% (n=17) 
 
8% (n=12) 
 
14% (n=11) 
 
15% (n=6) 
 
13% (n=5) 
 
NS 
 
Co-prescription 
(antipsychotic) 
 
37% (n=35) 
 
27% (n=40) 
 
26% (n=20) 
 
31% (n=12) 
 
8% (n=3) 
 
      NS 
 
NS = not significant  
aχ2=19.4, d.f.=4, p=0.0006 
* Any record of lifetime history of alcohol consumption greater than recommended safe limits (>21 
units or standard drinks per week for men, >14 units for women), or any diagnostic record of 
misuse or dependency. 
** Any record of lifetime history of regular illicit substance use. 
 
Table 15 indicates there were no significant differences in age between the five 
groups, with this being a middle aged population. Quetiapine was preferred in 
female patients (p=0.0006) but no other gender differences exist. The rate of drug 
and alcohol misuse for the entire population, as recorded in the patients’ clinical 
records, is relatively high, but no inter-group differences exist in substance co-
morbidity. The most common drug of misuse was cannabis.  
 
A high rate of psychotropic co-prescription is also documented in Table 15, with 
co-prescribed anti-depressants and perhaps surprisingly a second anti-psychotic 
medication being common. Clozapine is the SGA least likely to be combined with 
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another antipsychotic, (χ2=5.9, d.f.=1, p=0.015), No significant differences 
between the rate of co-prescription of antipsychotics among the other SGAs were 
observed. 
 
 
 
Table 16. Discontinuation and hospital admission rates, as well as duration of 
treatment.  
 
 
 Amisulpride Olanzapine Quetiapine Risperidone Clozapine Significance 
 
 
Total number  
 
      95 
 
      148 
 
      78 
 
      39 
 
     40 
 
 
Mean duration of record, 
days [95% CI] =A 
 
     716 
  [655-778] 
 
      644 
 [594-694] 
 
     670 
 [608-733] 
 
     530 
  [430-629] 
 
     705 
 [613-797] 
 
p=0.016a 
 
Discontinuation rate (%) =B 
 
51% (n=48) 
 
41%(n=60) 
 
36%(n=28) 
 
28% (n=11) 
 
18% (n=7) 
 
p=0.02b 
 
Discontinuation 
reasons 
 
Side 
effects 
 
35% (n=17) 
 
32%(n=19) 
 
46%(n=13) 
 
     0% 
 
14% (n=1) 
 
p=0.03 c 
 
Inefficacy 
 
33% (n=16) 
 
28%(n=17) 
 
36%(n=10) 
 
73% (n=8) 
 
    0% 
 
 
 
Other 
 
32% (n=15)  
 
40%(n=24)  
 
18% (n=4)  
 
27% (n=3)  
 
86% (n=6)  
 
NS 
 
Mean number days to 
discontinuation [95% CI] 
 
    232 
[165-299] 
 
   256 
[194-318] 
 
    191 
[113-231] 
 
   152 
[74-231] 
 
   427 
[108-746] 
 
NS 
 
Hospital admission during 
time of record 
 
 
24% (n=23) 
 
25%(n=37) 
 
29%(n=23) 
 
13% (n=5) 
 
35%(n=14) 
 
NS 
 
NS=Not significant  
a -F(4,399)=3.1, p=0.016 
b - χ2=4.3, d.f.=1, p=0.02 (Clozapine versus other 4 SGAs), but no significant difference between 
the 4 SGAs excluding clozapine. 
c - χ2=10.8, d.f.=4, p=0.03 
 
 
There were significant differences in the length of case record available in this 
selected population, as illustrated in Table 16, with the longest mean duration of 
record being for amisulpride (approximately 2 years) and the shortest mean 
duration being for risperidone (approximately 17 months). Overall medication 
discontinuation rate was significantly lower for clozapine than the other four SGAs 
studied, and this remained the case after adjusting for the length of psychiatric 
case record available. Removing clozapine from the analysis revealed that there 
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was no significant difference in medication discontinuation rate between 
amisulpride, olanzapine, quetiapine, and risperidone.  
 
Table 16 indicates that discontinuation due to side effects was lower for 
risperidone and clozapine compared to the other three SGAs although the 
numbers are low. Discontinuation with clozapine was associated with non-
adherence rather than lack of efficacy, and a weak trend (p=0.12) towards a higher 
mean number of days to discontinuation was also observed with clozapine.  
”Other” reasons for discontinuation were firstly non-adherence with medication, 
followed by improvement in clinical state, followed by unidentified reasons. Further 
analysis showed that those who continued treatment with risperidone were on 
significantly higher maximum dose (5.4 mg versus 3.2 mg [t=1.9, df=36, p=0.03]) 
than those discontinuing treatment. There was no significant relationship between 
mean dosage and discontinuation as opposed to continuation of treatment for the 
other four SGAs under examination. 
 
No significant differences in hospital admission rates between the five SGAs were 
evident, with lowest hospitalization rate being evident for risperidone (13%), 
although this was only five subjects, and the highest rate of hospitalization being 
seen in those on clozapine (35%).  
 
 
 
 
 
 
  
85 
 
Discussion 
Principal findings 
Here the comparative patterns of use and discontinuation of five of the most 
commonly used oral antipsychotic medications in a large representative community 
based population are reported. Rate of medication discontinuation was adopted as 
the primary outcome measure in this large independent observational study.  The 
study period ranged between 530 and 716 days, and as such this study represents 
one of the longer comparative analyses of antipsychotic medications.  
 
Approximately 18% of all individuals in contact with mental health services were 
prescribed SGAs. During the study period olanzapine was the most commonly 
prescribed antipsychotic, followed by quetiapine. Across Scotland according to 
government figures, 0.84% of the adult population are in receipt of daily 
antipsychotic prescriptions and by volume olanzapine, quetiapine, and risperidone 
are most frequently used nationally along with chlorpromazine (which is mostly 
used by general practitioners or on an ‘as required’ basis) – see chapter one. 
 
Clozapine had a significantly lower discontinuation rate than amisulpride, 
olanzapine, quetiapine, and risperidone in this study, and a (non-significant) lower 
age of initiation. The superior effectiveness of clozapine has been noted elsewhere 
(eg Farooq and Taylor, 2011) and a large industry sponsored observational study 
(Haro et al, 2006) found both clozapine and olanzapine to have lower 
discontinuation rates than the other three SGAs we studied. Clozapine was also 
significantly less likely to be combined with another antipsychotic medication, 
which is arguably a measure of individual medication effectiveness. It is worth 
noting that clozapine requires regular contact with health professionals due to 
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blood monitoring and is licensed only for treatment resistant schizophrenia due to 
its adverse side-effect profile. As such, prescribers may be less willing to 
discontinue or switch away from clozapine, as it may be felt to represent the ‘last 
best hope’ for the patient. 
 
In this study there was no association between our measures of effectiveness and 
average dose as a proportion of the maximum recommended dose in any of the 
antipsychotics studied, suggesting that effectiveness was not confounded by sub-
optimal dosing, although the dose - response relationship with antipsychotics is 
complex (Davis and Chen, 2004). 
 
Once clozapine was excluded from analysis, no significant difference in 
discontinuation rate between amisulpride, quetiapine, olanzapine, and risperidone 
was observed. This is in contrast to some data discussed elsewhere in this thesis, 
although others (eg. Crossley et al, 2010) have put forward analyses suggesting 
SGAs may be differentiated only by side-effect profile and not efficacy. One of the 
major if somewhat surprising findings to some observers of the CATIE studies was 
the high antipsychotic discontinuation rate (Lieberman et al, 2005). The 
discontinuation rates here are lower and possibly more representative of normal 
clinical practice although our lower discontinuation rates could also be attributable 
to differences in community based health care delivery between the UK and US, as 
well as differences arising from the demands of conducting RCTs, such as CATIE, 
in this population. This reinforces the value of routinely collected observational 
data. Additionally, the reasons given here for discontinuation need to taken 
cautiously in view of the low numbers involved.             
.  
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The patterns of use of SGAs described here for the period 2002-2005 demonstrate 
that off–license prescribing and polypharmacy were common. One survey (Lowe-
Ponsford and Baldwin, 2000) found that 65% of UK psychiatrists ‘admitted’ to 
prescribing off-license in the preceding month.  This study found that quetiapine 
(especially for women) and then olanzapine were the preferred choices for mood 
disorder, with quetiapine being used as an antipsychotic only in a minority of 
cases. This reflects other evidence suggesting these medications are useful in 
bipolar disorder (Taylor et al, 2009). The dose range of all five medications studied 
was lower in bipolar disorder than in schizophrenia, and this may be a 
consequence of antipsychotic medication in bipolar disorder often being employed 
as an adjunct to a mood stabiliser such as lithium or valproate as opposed to 
antipsychotic monotherapy in schizophrenia. 
 
For individuals with schizophrenia or related psychosis prescribed an SGA after 
the electronic record commenced, quetiapine was used significantly more 
frequently in women than the other four SGAs (which were used in men usually). 
Also the relatively high documented rates (up to 38%) of alcohol and drug misuse 
in this population reflects the ‘real world’ nature of the study. Psychotropic co-
prescription was common and except for clozapine, over a quarter of the patients 
studied were also prescribed a second antipsychotic medication. A survey (Paton 
et al, 2003) of over 4000 psychiatry inpatients in the UK found nearly a half were 
prescribed two or more antipsychotics, whilst other authors (Centorrino et al, 2004) 
have highlighted an association between antipsychotic polypharmacy and 
increased mortality or adverse events. On the other hand, Tiihonen et al (2006) 
demonstrated an increase in mortality in those individuals not using any 
antipsychotic medication after an initial hospitalisation.  
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Strengths and limitations of the study 
Mention must be made of the particular strengths and limitations of this study. This 
was essentially a retrospective case note review, with all the limitations that come 
with unstructured assessment and recording but it was a large, comprehensive, 
and inclusive electronic survey covering a representative community sample of all 
secondary mental health care contacts. It is possible that human error occurred 
during the manual counting of the various clinical measures, although it is highly 
unlikely that this could have occurred in a systematic manner. The use of a 
representative naturalistic population, should have reduced the possibility of 
selection bias and enhanced the generalizability of the findings, and sponsorship 
bias for this particular study has also been avoided. 
. 
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CHAPTER 6 
 
A RETROSPECTIVE LONG TERM FOLLOW UP OF THE 
EFFECTIVENESS OF LONG ACTING (DEPOT) INJECTIONS OF 
ANTIPSYCHOTIC MEDICATION 
 
 
 
 
 
 
 
 
 
 
 
 
 
MT conceived and designed the study; helped analyse and interpret the data, and 
drafted the manuscript. Dr Shajahan designed the study; collected, analysed, and 
interpreted the data; and drafted the manuscript. Drs Spence and Daniel collected 
the data; and contributed to the manuscript. Professor Pelosi designed the study; 
and helped draft the manuscript. 
 
 
Study conducted 2007-2008 
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Adherence to antipsychotic medication has been shown to be the single most 
important determinant of relapse in schizophrenia (Robinson et al, 2002). 
Compared with oral antipsychotics, long acting injections are associated with better 
global outcome, reduced risk of hospitalisation and longer times to discontinuation 
(eg Tiihonen et al, 2011). Risperidone long-acting injection was the first of the 
second generation antipsychotics to be available in depot or long-acting 
formulation and has been used in routine UK clinical practice since 2002.There is 
little research to inform prescribing decisions in the clinic between the various long-
acting injections. Meta-analytic review of first-generation depots found little 
difference between individual medications (Adams et al, 2001; Haddad et al, 
2009). No direct comparisons of risperidone long-acting injection with the first-
generation depots are available except for one open, 6-month randomised study 
that showed favourable outcome for risperidone long-acting injection compared 
with zuclopenthixol decanoate for individuals with comorbid substance misuse 
(Rubio et al, 2006).  
 
Due to the growing trend towards the use of second-generation antipsychotics in 
general, including risperidone long-acting injection, despite the lack of head-to-
head evidence noted above, we aimed to retrospectively identify and measure the 
outcome of patients started on: risperidone long-acting injection, zuclopenthixol 
decanoate, flupentixol decanoate, fluphenazine decanoate, pipothiazine palmitate 
and haloperidol decanoate. To assess effectiveness we applied the Clinical Global 
Impression (CGI) scale (Guy, 1970) and measured discontinuation rates and time 
to hospitalisation after the long-acting injection was started. 
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Aims 
1. To describe the patterns of use of long acting (depot) injections of 
antipsychotic medication in a large representative population. 
2. To compare the clinical effectiveness of the most commonly 
prescribed long acting antipsychotic injections. 
 
 
 
Method  
The electronic patient records covering all secondary care contacts for psychiatry 
in a discrete geographic area (the county of Lanarkshire, Scotland, population 
550,000) were examined up until the end of 2008. The electronic records were 
phased into NHS Lanarkshire’s mental health service over the period 2002 to 2005 
into general, rehabilitation, liaison, addiction and forensic psychiatry services. 
 
There are no private or independent secondary mental health care facilities in 
Lanarkshire, and no intensive home based alternatives to hospitalisation existed 
during this period. All individuals in mental health care follow up have a patient 
record. A total of ~35,000 individual records were available, and these were 
electronically searched using the data management system (Genesys) for the 
keywords relating to the generic and UK trade names of the following depot 
antipsychotic injections: 
 
 flupentixol decanoate 
 fluphenazine decanoate 
 haloperidol decanoate 
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 pipothiazine palmitate 
 risperidone long acting injection (risperidone consta), and 
 zuclopenthixol decanoate 
 
Inclusion criteria: Patient records were included if they contained the following 
ICD-10 diagnoses included in this study were schizophrenia (F20), persistent 
delusional disorders (F22), and schizoaffective disorders (F25). Exclusion criteria: 
All other ICD-10 diagnoses were excluded, Patient records resulting from this 
search which were considered inadequate for analysis, i.e. those where the drug 
was started before the electronic record became available, or those with only a 
single mental health contact were excluded. No other exclusion criteria were 
applied in order to maximise the ‘real world’ applicability of the findings. 
 
To assess effectiveness, the Clinical Global Impression (CGI) scale was applied 
(see appendix one) and discontinuation rates and time to hospitalisation measured 
after commencement of the depot. 
 
Demographic and clinical variables  
These were extracted from the records. These included age and gender; duration 
of contact with mental health services; compulsory treatment; lifetime history of 
drug or alcohol misuse; ICD 10 diagnosis; previous antipsychotic and reason for 
discontinuation; maximum doses of medication used; concurrent antipsychotic, 
antidepressant and mood stabilising medication; previous or subsequent clozapine 
treatment or consideration thereof. Additional concurrent antipsychotics were 
defined as being another regular (not ‘as required’) antipsychotic drug prescribed 
at least 50% of the time that patients were on the depots. This was quantified by 
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converting doses to percentage of British National Formulary (BNF, 2011) defined 
maximum dosage. For example, 100 mg per day of chlorpromazine = 10% of 
maximum BNF daily dose. This measure is important in clinical practice where 
BNF defined maximum dosages are linked to high dose antipsychotic protocols. 
 
Clinical Global Impression – see appendix one 
The clinical status of subjects was assessed using the Clinical Global Impression 
(CGI) Severity (S) and Improvement (I) scales. The proportion who improved as 
defined by CGI I scores 1-4 (very much improved through to minimally improved) 
was the primary outcome measure. The rationale for this broad definition was that 
in clinical practice, any degree of improvement is of potential value as opposed to 
clinical trials where more stringent criteria tend to be employed. The CGI scores 
were based on the details in the patient records and assigned retrospectively. 
Severity rating was assigned at the start of treatment, at approximately 3-5 months 
after onset of treatment and, at the end of treatment if the drug was discontinued, 
or at the end of the medical record. The reason for examining severity at 3-5 
months post depot initiation was that there were anecdotal reports of risperidone 
long acting injection (RLAI – otherwise known as risperidone consta) taking a 
longer time to show clinical benefit compared with other depots, and requiring 
longer oral antipsychotic supplementation during initiation compared to other 
depots. Improvement scores were assigned due to the perceived effects of the 
commenced medication and therefore took into account baseline severity of 
illness. Such retrospective CGI assignment has been used elsewhere for 
examining clinical response to antipsychotics (Shajahan et al, 2009).   
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Discontinuation and hospitalisation 
Time to discontinuation was examined for any cause and sub-categorised into time 
to discontinuation due to inefficacy or adverse effects. When investigators noted 
more than one reason for discontinuation, we used the clinically most important 
reason identified after reviewing the record, for the statistical analyses. Time to 
admission to hospital (mental health admission unit) was recorded as a further 
measure of effectiveness and can be considered a marker of antipsychotic 
treatment failure (Essock et al, 1996). 
 
Statistical analysis 
StatsDirect (issue 1.8.9) was used to perform for the analyses. Continuous data 
were reported as means with 95% confidence intervals and compared using 
analysis of variance and t-tests. Categorical and non-parametric data were 
analysed using χ2 tests and were log-transformed as appropriate. Significance 
levels required two-tailed p values <0.05. Kaplan-Meier survival curves were used 
to illustrate the probability of treatment discontinuation or hospitalisation over time. 
Hazard ratios [HR] were calculated for survival analyses, and survival curves were 
compared using nonparametric methods with no assumptions about the 
distributions of survival estimates. As prior or subsequent treatment with clozapine 
(a marker of treatment resistance) and affective symptoms were viewed as having 
an effect on proportional CGI improvement (less improvement with clozapine, 
more with schizoaffective disorder), analyses were performed on all subjects and 
separately after excluding patients with treatment resistance and schizoaffective 
disorder. The null hypothesis was that the risk of medication discontinuation or 
hospitalisation was the same for all depots.  
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Results 
Figure 6: Study profile for retrospective analysis of depot medication 
 
 
Search through electronic document management system for generic and trade names of following depot 
antipsychotic preparations, from all adult secondary mental health services in Lanarkshire, Scotland.  
Identify all individuals aged 16-65 who have ever been on the following depot preparations 
 
           
Risperidone 
LAI  
N=234 
 
Zuclopenthixol 
decanoate 
n=126 
 
Flupentixol 
decanoate 
n=288 
 
Fluphenazine 
decanoate 
n=86 
 Pipothiazine 
palmitate 
n=39 
 Haloperidol 
decanoate 
n=38 
           
 
Identify individuals newly commenced on the depot preparations after the electronic document management 
system was established (2002 onwards) 
 
           
Risperidone 
LAI  
n=141 
percentage 
new starts = 
60% 
 
Zuclopenthixol 
Decanoate 
 n=36 
percentage 
new starts = 
29% 
 
Flupentixol 
decanoate 
n=59 
percentage 
new starts = 
20% 
 
Fluphenazine 
decanoate 
n=13 
percentage 
new starts = 
15% 
 Pipothiazine 
palmitate 
n=7 
percentage 
new starts = 
18% 
 Haloperidol 
decanoate  
n=3  
percentage 
new starts = 
8% 
           
 
Identify those individuals where the depot was started for schizophrenia, schizoaffective  
or other psychotic disorders 
           
Risperidone 
LAI n=122 
(86%)a 
 
Zuclopenthixol 
decanoate 
n=31 
(86%)b 
 
Flupentixol 
decanoate 
n=43 
(73%)c 
 
Fluphenazine 
decanoate 
n=11 
(77%)d 
 Pipothiazine 
palmitate 
n=7 
(100%) 
 
Haloperidol 
decanoate n=3 
(100%) 
           
 
Extract demographic and clinical data and assign retrospective CGI ratings 
 
  
  
96 
 
a(bipolar affective disorder n=14, emotionally unstable personality disorder borderline type n=4, 
depressive disorder n=1) 
b(bipolar affective disorder n=3, emotionally unstable personality disorder borderline type n=2) 
c(bipolar affective disorder n=4, emotionally unstable personality disorder borderline type n=9, depressive 
disorder n=3) 
d(emotionally unstable personality disorder borderline type n=2) 
 
Figure 6 shows the study profile. 811 individuals were identified as having records 
mentioning that they had ever been on the depots being studied. Of these 811 
patients, 259 had been commenced on depots after the electronic document 
management system had become available. Of the 259 patients commenced on 
the six depot antipsychotics, 84% (n=217) had a diagnosis of schizophrenia, 
schizoaffective disorder or related psychosis (see Table 17 for further details of 
diagnosis).  
 
The proportion of patients commenced on RLAI exceeded the cumulative total of 
those started on the other depots, illustrating its prescriber preference over FGA 
depot antipsychotics during 2002 to 2008. As the numbers of patients commenced 
on fluphenazine decanoate, pipothiazine palmitate and haloperidol decanoate 
were small they were not included in further analyses.  
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Table 17.  Clinical profile of patients started on depot antipsychotics 
 
aRisperidone 
long acting 
injection n=122 
bZuclopenthixol 
decanoate 
n=31 
cFlupentixol 
decanoate 
n=43 
 
p value 
(a v  b 
v c) 
 
 
Mean Age (Years) 
[95% C.I.] 
 
39.0 
[36.9-41.0] 
39.0 
[34.3-43.6] 
40.1 
[37.1-44.5] 
 
NS 
Duration contact 
with mental health 
services prior to 
depot 
0-1 yr 5 4 1  
NS 1-3 yrs 8 3 2 
>3 yrs 109 (89%) 24 (77%) 40 (93%) 
 
Percent male 
 
62%  
 
52%  
 
58% 
 
NS 
 
Compulsory treatment 
 
23% (n=28) 
 
32% (n=10) 
 
14% (n=6) 
 
NS 
 
History of alcohol misuse 
 
47% (n=57) 
 
42% (n=13) 
 
44% (n=19) 
 
NS 
 
History of substance misuse 
 
34% (n=41) 
 
39% (n=12) 
 
30% (n=13) 
 
NS 
 
Diagnosis of schizoaffective 
disorder 
 
19% (n=23) 
 
26% (n=8) 
 
16% (n=7) 
 
NS 
 
Previously on oral or 
intramuscular antipsychotics 
(i.e.‘switching’ medications) 
92% (n=112) 81% (n=25) 86% (n=37) 
 
NS 
 
Previously on another depot 
antipsychotic 
23% (n=28)1 19% (n=6) 26% (n=11) 
 
NS 
 inefficacy 39% (n=48) 61% (n=19) 49% (n=21) 
 
 
Reason for 
discontinuing 
previous 
antipsychotic  
side-
effects 
11% (n=14) 6% (n=2) 9% (n=4)   NS 
 
Non-
adherence  
39% (n=48) 16% (n=5) 21% (n=9) 
 
 
  
aRisperidone 
 
bZuclopenthixol 
 
cFlupentixol 
 
p value 
(a v  b 
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long acting 
injection n=122 
decanoate 
n=31 
decanoate 
n=43 
v c) 
 
 
Regular additional oral 
antipsychotic 
 
25% (n=30)  
 
29% (n=9)  
 
40% (n=17)  
 
NS 
 
Co-prescription, 
antidepressant 38% (n=46) 42%(n=13) 51% (n=22) 
 
NS 
 
Co-prescription, mood 
stabiliser 11% (n=14) 16% (n=5) 7% (n=3) 
 
NS 
 
Clozapine considered or tried 
(before/after depot) 25% (n=30) 10% (n=3) 19% (n=8) 
 
NS 
 
Total patient years of depot 
treatment 166.4 44.2 48.8 
 
 
 
Median duration of electronic 
record before depot started, 
months [range] 
12.8 [0-58.6] 15.4 [0.5-55.9] 12.3 [0-51.7] NS 
 
 
BNF = British National Formulary 
1(flupentixol dec n=17, zuclopenthixol dec n=8, fluphenazine dec n=1, pipothiazine palmitate n=1, 
haloperidol dec n=1),  
 
 
Table 17 shows the inclusive nature of the study population with significant 
proportion of the whole sample being women (38%), requiring compulsory 
treatment (24%), having a lifetime history of alcohol or substance misuse (29-
47%), concomitant antidepressant and mood stabilising medications (9-42%), 
antipsychotic polypharmacy (defined as above - 30%) and treatment resistance – 
as defined by prior clozapine use or consideration of clozapine use (23%). The 
majority of patients (89%) were switching from another antipsychotic. There was 
trend for zuclopenthixol to be commenced after the previous antipsychotic was 
discontinued due to inefficacy.  There was a mean period of 15.6-18.5 months 
before the 3 main depot antipsychotic were introduced, reflecting the duration of 
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history and contacts prior to the depot being started, as noted in the e-record. The 
proportion of patients per treating psychiatrist, ie rate of prescription, varied 
between RLAI (4.1), zuclopenthixol decanoate (2.1) and flupentixol decanoate 
(1.7), as reflected in the ‘popularity’ of prescribing choice noted above. There were 
also differences in the mean total duration of record between the three main 
depots studied with zuclopenthixol decanoate records being around 8 months less 
than RLAI or flupentixol decanoate records. In total, the study incorporated 283 
patient years of depot antipsychotic experience. 
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Table 18.  Proportion of patients in depot medication study who improved 
according to CGI-I (<5)   
 
Risperidone long 
acting injection 
Zuclopenthixol 
decanoate 
Flupentixol 
decanoate 
 
p value 
 
 
All patients 
 
74% (n=90/122) 
 
74% (n=23/31) 
 
72% (n=31/43) 
 
NS 
Age less than 30  71% (n=21/31) 75% (n=6/8) 67% (n=6/9) NS 
Age greater than 30 76% (n=69/91) 74% (n=17/23) 74% (n=25/34) NS 
Male 72% (n=55/76) 81% (n=13/16) 72% (n=18/25) NS 
Female 76% (n=35/46) 67% (n=10/15) 72% (n=13/18) NS 
Service contact less 
than 3 years  
62% (n=8/13) 71% (n=5/7) 67% (n=2/3) NS 
Service contact over 3 
years 
74% (n=81/109) 75% (n=18/24) 73% (n=29/40) NS 
Schizoaffective disorder 86% (n=19/22) 50% (n=4/8) 57% (n=4/7) 0.08a 
Schizophrenia /other 
psychoses 
71% (n=71/100) 83% (n=19/23) 75% (n=27/36) NS 
*Treatment resistance  53% (n=16/30) 67% (n=2/3) 38% (n=3/8) 0.07b 
No treatment resistance  80% (n=74/92) 75% (n=21/28) 80% (n=28/35) NS 
Switching from another 
depot 
64% (n=18/28) 67% (n=4/6) 64% (n=7/11) NS 
Not switching from 
another depot 
77% (n=72/94) 76% (n=19/25) 75% (n=24/32) NS 
 25mg 73% 100-
350mg 
73% 20-
50mg 
75% 
Equivalent fortnightly 
dose 
37.5mg 75% 400-
600mg 
77% 60-
120mg 
67% 
 50mg 69% 800-
1200mg 
67% 150-
250mg 
100% 
 
*clozapine considered or prescribed before or after depot was commenced 
aχ2 =5.0, d.f.=2, p=0.08; bχ2 =3.2, d.f.=1, p=0.07 
 
 
Table 18 shows CGI severity and improvement scores. Adjusted results after 
excluding schizoaffective and treatment resistant patients showed similar patterns 
with statistical significance remaining. Flupentixol decanoate was started on 
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patients with a lower severity of illness score compared with zuclopenthixol 
decanoate (p=0.003) or RLAI (p=0.018). After 3 to 5 months CGI severity scores 
were lower with flupentixol compared to RLAI (p=0.038). Around 80% of patients 
made some degree of clinical improvement following the commencement of RLAI, 
zuclopenthixol decanoate or flupentixol decanoate. Within the CGI improvement 
categories (1-8) fewer patients had ‘very much improved or ‘much improved’ (CGI 
I=1 or 2) after commencing zuclopenthixol decanoate compared with RLAI or 
flupentixol decanoate (p=0.0007). 
 
 
 
Figure 7. Survival curves in depot medication study - Time to treatment discontinuation 
due to all causes (A), inefficacy (B), and side-effects (C) and time to hospitalisation (D). 
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Figure 7 depicts survival curves illustrating time to discontinuation for any cause, 
inefficacy, side effects and time to hospital admission. Survival curves after 
excluding treatment resistant and schizoaffective patients showed similar results.  
 
Any cause discontinuation differed significantly between zuclopenthixol decanoate 
and RLAI, (HR 0.46 [95% CI=0.27-0.77]) and flupentixol decanoate (HR 0.41 
[0.22-0.78]). Discontinuation due to inefficacy differed between zuclopenthixol 
decanoate and RLAI, (HR 0.12 [0.05-0.27]) and flupentixol decanoate (HR 0.14 
[0.05-0.39]). The likelihood of hospitalisation differed between zuclopenthixol 
decanoate and RLAI, (HR 0.32 [0.17-0.59]) and flupentixol decanoate (HR 0.34 
[0.16-0.71]).  Despite the trends evident in these results, none were statistically 
significant. 
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Table 19: Clinical Global Impression scores and duration of treatment 
(unadjusted) 
 
 Risperidone 
long acting 
injection 
n=122 
Zuclopenthixol 
decanoate  
n=31 
Flupentixol 
decanoate 
n=43 
 
p value 
 
 
 
CGI-S (severity) at onset of treatment, 
mean [95% C.I.] 
 
4.5 
[4.3-4.7] 
 
4.8 
[4.5-5.0] 
 
4.1 
[3.8-4.4] 
0.0026 a 
 
CGI-S (severity) at 3-5 months after 
starting depot, mean [95% C.I.] 
 
3.3 
[3.0-3.5] 
 
3.1 
[2.9-3.4] 
 
2.6 
[2.1-3.1] 
0.038b 
 
CGI-S (severity) percentage 
improvement after 3-5 months of 
treatment, mean [95% C.I.] 
 
24.7 
[19.7-29.8] 
 
32.6 
[25.6-39.5] 
 
36.4 
[26.6-46.3] 
NS 
 
CGI-S (severity) at end of treatment or 
record, mean [95% C.I.] 
 
3.3 
[3.1-3.5] 
 
3.1 
[2.8-3.4] 
 
2.9 
[2.6-3.3] 
NS 
 
CGI-S (severity) percentage 
improvement from onset of treatment, 
mean [95% C.I.] 
 
24.7 
[19.7-29.8] 
 
33.0 
[25.3-40.6] 
 
27.8 
[19.9-35.8] 
NS 
 
CGI-I (improvement),  
mean [95% C.I.] 
 
3.5 
[3.2-3.7] 
 
3.4 
[3.0-3.8] 
 
3.3 
[2.9-3.7] 
NS 
 
Percent improved  
[CGI–I <5] -all patients 
74% (n=90) 74% (n=23) 72% (n=31) NS 
CGI-I, 
Improvement 
category, 
percentage of 
patients 
1. Very much 
improved 
11% (n=13) 0% (n=0) 7% (n=3)  
2. Much improved 18% (n=22) 16% (n=5) 30% (n=13)  
3. Moderately 
improved 
21% (n=26) 55% (n=17) 21% (n=9)  
4. Minimally improved 24% (n=29) 3% (n=1) 14% (n=6)  
5. No change 20% (n=24) 26% (n=8) 23% (n=10)  
6. Minimally worse 4% (n=5) 0% (n=0) 5% (n=2)  
7. Moderately worse 2% (n=3) 0% (n=0) 0% (n=0)  
8. Much worse 0% (n=0) 0% (n=0) 0% (n=0)  
Duration of treatment with depot,  
mean months [95% CI] 
 
16.4 
[13.9-18.9] 
17.1 
[12.5-21.7] 
13.6 
[9.8-17.5] 
NS 
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aF(2,195) =9.2, p=0.0026 (difference between zuclopenthixol dec v flupentixol (p=0.003) and RLAI v 
flupentixol dec (p=0.018); no difference between RLAI v zuclopenthixol dec) 
bF(2,145) =3.3, p=0.038 (difference between RLAI v flupentixol dec) 
 
 
 
Discussion 
Principal findings 
Over the period 2002-2008, a trend towards the increasing use of long-acting 
risperidone over first-generation long-acting antipsychotic injections was observed 
here. This is consistent with the trend seen in the increasing use of SGA 
antipsychotics generally in Scotland (see Figure 1). Most (76%) of the sample on 
long-acting injections were not detained and hence were receiving the injections on 
a voluntary basis. Co-prescription of antidepressants occurred in up to 51% of this 
group of people with chronic schizophrenia and additional oral antipsychotics were 
required in up to 40%. In terms of percentage of individuals showing any degree of 
CGI improvement, there was no difference between the three main depots (72-
74% improved) although there were fewer people in the ‘very much improved’ or ‘ 
much improved’ groups with zuclopenthixol decanoate compared with risperidone 
long-acting injection and flupentixol decanoate. Those started on risperidone long-
acting injection who achieved ‘very much improved’ on the CGI had a higher initial 
illness severity to start with (two-tailed t-test P<0.001) and were less likely to have 
been tried on clozapine. Time to discontinuation as a result of inefficacy and time 
to hospitalisation (non-significantly) favoured zuclopenthixol decanoate over 
risperidone long-acting injection and flupentixol decanoate. Time to discontinuation 
as a result of side-effects did not differ between the three depots. Second-
generation antipsychotics were marketed on their superior side-effect profile and 
although we were unable to examine side-effects during treatment, discontinuation 
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because of side-effects did not differ significantly with risperidone long-acting 
injection compared with zuclopenthixol decanoate or flupentixol decanoate.  
 
Methodological issues 
All typed correspondence from clinicians was uploaded into the electronic 
document management system in NHS Lanarkshire mental health services and the 
record is considered an effective duplication of the correspondence section of 
paper-based case records. As individuals on depot medication are usually within 
secondary care services and have repeated, usually multidisciplinary contacts, 
confidence can be expressed that the electronic records (which include medical, 
nursing and occupational therapy documents) captured a comprehensive and 
accurate picture of clinical contacts for all patients on the depot antipsychotics 
studied.  
The possibility that the treatment practice or recommendations of a minority of 
psychiatrists, or the different lengths of the electronic records may be responsible 
for the results seen also requires consideration. Records for zuclopenthixol 
decanoate were shorter in duration than for risperidone long-acting injection or 
flupentixol by approximately 8 months on average. Theoretically, this allows less 
time for discontinuation events; however, using Kaplan-Meier derived survival 
curves and mean times to discontinuation or hospitalisation takes this into account. 
In addition, the mean duration of treatment was similar for the three main depots 
studied. Therefore, it is unlikely that different duration of records explains the 
different discontinuation rates seen.  
The lower discontinuation rates for zuclopenthixol decanoate may have reflected 
its use in more individuals with treatment resistant illness, similar to the situation 
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with clozapine where clinicians feel they are limited by subsequent choices after 
treatment failure and are reluctant to discontinue. There was some evidence to 
support this in that more individuals were started on zuclopenthixol decanoate as a 
result of inefficacy (61%) compared with risperidone long-acting injection (39%) or 
flupentixol decanoate (49%), although this just failed to achieve statistical 
significance. Similarly, a greater proportion of people started on zuclopenthixol 
decanoate were treated compulsorily, although again, this was not statistically 
significant. However, there was evidence to refute that zuclopenthixol decanoate 
was reserved for more treatment-resistant individuals in that these patients were 
less likely to have been tried on clozapine and there was no difference in the 
duration of contact with psychiatric services. Overall, these data do not support 
that zuclopenthixol was being used as a ‘last resort’ medication that clinicians were 
reluctant to discontinue.  
 
Strengths and limitations of the study 
The electronic record system allowed study of all patients who were started on the 
most commonly prescribed depot antipsychotics in secondary care mental health 
services in a discrete geographical region within a defined period. This meant that 
individuals with co-prescription of other psychotropic agents, with comorbid 
conditions such as alcohol and substance misuse, and those who would be unable 
to consent to clinical trials (e.g. high illness severity and detained patients) were all 
included, representing routine clinical practice. Such inclusiveness also permits 
follow-up of individuals over a relatively long period (in some cases over 5 years) 
thereby offering outcome information beyond the acute illness phase. This study is 
thus generalisable everyday clinical practice, in keeping with the views of Adams et 
  
108 
 
al (2001) that study populations of long acting injections of antipsychotics need to 
be as representative and long term as possible. The downside of this inclusiveness 
is that the ‘noise’ generated by many confounding variables (which would lead to 
exclusion from some clinical trials) may mask the efficacy signal from one 
particular compound. The selection of patients was not from strict a priori criteria 
but a reflection of clinician and patient choice in the decision to start a depot during 
a particular psychotic illness episode. The study population is predominantly white 
and middle-aged and so may not be necessarily generalisable to other specific 
populations, for example, young adults with first-episode psychosis.  
 
The effectiveness measure employed (proportion improved according to CGI) is a 
clinically relevant one, reflecting everyday clinical review of patients and their 
response to treatment. The CGI scale was originally designed to be used 
prospectively and is undoubtedly a less sophisticated instrument than specific 
symptom rating scales, but has been used elsewhere (eg Shajahan et al, 2009)  to 
identify clinical response retrospectively.  
 
Time to discontinuation has been increasingly used as a primary outcome measure 
in antipsychotic effectiveness research (Lieberman et al, 2005, Kahn et al, 2008). It 
is a relatively unbiased measure and usually, although not always, signals 
treatment failure because of inefficacy, adverse effects, non-adherence or 
combinations of these. Both time to and rate of hospitalisation (Hodgson et al, 
2007; Kahn et al, 2008) may also be considered as markers of treatment failure. 
However, experience of clinical practice informs that the reasons for hospitalisation 
are varied and usually include risks of self-harm, risk of harm to others and 
  
109 
 
adverse social circumstances. During this study, non-hospital options (e.g. home 
treatment teams) were not available during the study period.  
 
Conclusions 
When considering the study outcomes that were less subject to potential bias (i.e. 
time to discontinuation and hospitalisation) there was a trend for zuclopenthixol 
decanoate to be superior to risperidone long-acting injection and flupentixol. These 
findings are consistent with the meta-analytic review by Adams et al (2001) that 
showed an modest advantage for zuclopenthixol decanoate over other first-
generation depots in terms of discontinuation. However, when considering the CGI, 
which was arguably more prone to potential bias, zuclopenthixol was associated 
with fewer individuals in the ‘very much improved’ and ‘much improved’ categories 
compared with risperidone long-acting injection and flupentixol. Of interest was the 
use of zuclopenthixol decanoate in people with probably greater illness severity, 
suggesting clinician preference in its use when individuals were more severely 
unwell.  
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CHAPTER 7 
 
DEVELOPING AND VALIDATING A NEW SIDE-EFFECT SCALE FOR 
ANTIPSYCHOTIC MEDICATION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MT conceived and designed the study; collected, analysed, and interpreted the 
data, and helped draft the manuscript. Dr Waddell obtained ethical approval for the 
study; collected, analysed, and interpreted the data; and drafted the manuscript. 
 
 
Study conducted 2006-2008. 
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Lack of or partial adherence with antipsychotic medication is perhaps the main 
determinant of relapse in schizophrenia (Tacchi and Scott, 2005). The tolerability 
or experience of side effects of a particular antipsychotic medication has been 
regarded as one of the key factors predicting continued adherence (Lambert et al, 
2004) and crucially the experience of adverse antipsychotic side effects is 
commonly stated by patients as an important reason for non adherence.  This 
highlights the importance of an open and systematic discussion regarding 
medication related side effects. An open acknowledgement of the risks and 
benefits of a particular treatment helps establish a collaborative approach between 
clinicians and patients, and can contribute to a therapeutic rapport.  
 
Antipsychotic side effect rating scales have been used in research studies since at 
least 1970. They include traditional observer rated side effect scales such as the 
Simpson-Angus (1970) and the Barnes Akathisia scale (1989). These more often 
were found in research settings than routine clinical practice, and arguably side 
effect scales focusing only on movement disorder or extra-pyramidal symptoms 
have now become less relevant as the widely used second generation 
antipsychotics (SGAs) have a lower incidence of extra-pyramidal side-effects (eg 
Crossley et al, 2010).  
 
Additionally, although observer rated scales may avoid over-reporting bias they 
can be more time consuming than self report scales, and less likely to identify 
potentially embarrassing concerns such as sexual dysfunction. The Liverpool 
University Neuroleptic Side Effect Rating Scale (LUNSERS) (Day et al, 1995) is a 
commonly used self report scale which concentrates on one word symptoms but 
again is over a decade old. The LUNSERS also takes time to complete as it is 
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three pages long, and an audit (Negi, 2007; only presented in abstract form) found 
that use of the LUNSERS did not improve case record documentation of side 
effects. Lastly experience with the LUNSERS found that patients commonly have 
to ask for help in understanding terms such as “chilblains”, emphasising that the 
use of simple plain English is vital in self report scales.  
 
In view of this, it was felt that an easy to understand self-report side-effect scale 
that was brief, valid, practical and informative would be clinically useful. It was 
envisaged that a short self-report scale could facilitate further discussion in the 
clinic regarding the tolerability of antipsychotic medication.   
 
 
Aims 
1. To develop a new pragmatic scale for monitoring antipsychotic medication 
adverse side-effects. 
2. To test the validity and reliability of the new scale against the existing ‘gold-
standard’ scale, in individuals taking antipsychotic medication and healthy 
comparison subjects. 
 
 
Method 
Ethical approval for the study was granted by the local Greater Glasgow Primary 
Care Division Research and Ethics Committee (chair – Dr Paul Fleming) – see 
appendix two. 
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Constructing the scale 
A literature review was undertaken using Medline and other internet search 
engines with various keywords including neuroleptic; adverse effects; side effects; 
antipsychotic; rating scale; and schizophrenia. Also, medical, pharmacy, and 
nursing staff were questioned about their experience of identifying antipsychotic 
side-effects. All nine currently widely available antipsychotic side-effect rating 
scales were identified and reviewed to identify their strengths and weaknesses 
(see Table 20). 
 
Table 20. Existing side-effect rating scales 
 
Scale Number 
questions 
Rating Advantages Disadvantages 
Simpson Angus Scale (SAS) 
(Simpson & Angus, 1970) 
10 Clinician 
rated 
Objective rating of EPSE, 
quick & easy to perform 
Focus on extrapyramidal 
side effects (EPSE) only  
Abnormal Involuntary 
Movement Scale (AIMS) 
(Guy, 1976) 
12 Clinician 
rated 
Objectively records 
presence & severity of 
involuntary movements; 
quick to perform 
Focus on abnormal 
movements only  
Extrapyramidal Side Effect 
Rating Scale (ESRS) 
(Chouinard et al, 1980) 
12 Clinician 
rated 
Quick to perform, 
objective documenting of 
EPSE. 
EPSE only. No 
differentiation between 
dyskinesia & dystonia. 
Drug Attitude Inventory 
(Hogan et al, 1983) 
30 Self rated Simple to understand 
questions & true / false 
answers. Assesses 
attitude 
Not specifically aimed at 
detecting antipsychotic 
side-effects 
Side Effects Rating Scale for 
the Registration of Unwanted 
Effects of Psychotropics  
(Lingjaerde et al, 1987) 
47 Clinician 
rated 
Covers an extensive 
range of side effects from 
antipsychotic medication 
Requires a lengthy semi 
structured interview and 
clinical observation 
Barnes Akathisia Rating 
Scale  (Barnes, 1989) 
4 Clinician & 
self rated  
Both subjective & 
objective rating of 
akathisia; quick  
Focuses on akathisia 
only 
Hillside Akathisia Scale 
(HAS) 
(Fleischhaker et al, 1989) 
5 Clinician & 
self rated   
Both subjective & 
objective rating of 
akathisia; quick  
Focuses on akathisia 
only 
Liverpool University 
Neuroleptic Side Effect 
Rating Scale (LUNSERS) 
(Day et al, 1995) 
51 Self rated Assesses wide range of 
side effects; red herring 
questions for over-
reporting of side-effects 
One word symptoms that 
can be difficult to 
understand. 
Antipsychotic Non-
Neurological Side Effect 
Rating Scale (ANNSERS) 
(Yusufi et al, 2005) 
35 Clinician & 
self rated  
Covers wide range of side 
effects for 1st & 2nd 
generation antipsychotics 
Lengthy & time 
consuming.  
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After referring to existing scales, important antipsychotic side effects were listed 
using information from the British National Formulary and the pharmaceutical 
industry. Consistent with NICE guidelines (2010) these side effects were then 
ranked in importance by the author in terms of the gravity of the medical 
consequences. In addition, a focus group of patients already taking antipsychotic 
medication ranked the list of side effects in terms of acceptability. This focus group 
comprised six individuals on antipsychotic medication who were recruited on a 
voluntary basis from one community mental health team in north Glasgow, thought 
(by the author) to be representative of patients with psychotic illness on 
maintenance antipsychotic medication. Twenty two questions were arrived at 
which summarised the prioritised side effects with priority given to long term 
adverse medical consequences. These were then grouped into classical medical 
systems such as cardiovascular; and central nervous system (see ‘staff 
information’ section in Table 21).  
 
The majority of side effects addressed by the new scale are already contained in 
LUNSERS but the twenty two questions were converted into unambiguous plain 
English by consulting with non-health care staff.  The new scale, termed the 
Glasgow Antipsychotic Side-effect Scale or GASS was scored 0, 1, 2, and 3 for 
questions one to twenty, with higher scores reflecting more frequent experience of 
side-effects. Questions twenty one and twenty two scored 0 for “no” and 3 for 
“yes”. Total GASS scores were arbitrarily divided into suggested ranges for 
categorical severity, i.e. 0-12 = absent / mild side effects; 13- 26 = moderate side-
effects; and 27-63 = severe side effects. A separate (un-scored) column was 
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added to allow people completing the GASS to note if the side effect experienced 
was distressing. 
 
 
Participants 
 
Fifty outpatients aged 18 to 65 who were currently prescribed and taking a second 
generation antipsychotic (regardless of diagnosis or other medication prescribed) 
consented to participate. These individuals were recruited from outpatient and 
clozapine clinics in the three North Glasgow resource centres, covering an area of 
significant socio-economic deprivation (see related information in chapter three). 
Adherence with prescribed medication by the outpatients was confirmed at clinical 
interview with the author. Fifty comparison subjects within the same age range also 
agreed to participate after excluding individuals on prescribed medication and 
those working in mental health care. These individuals were recruited by directly 
approaching consecutive members of the public encountered on the streets of 
central Glasgow, after explaining the nature and purpose of the study and 
confirming that confidentiality was assured. Individuals unable to read English were 
also excluded.  
 
Assessment of the new scale 
Outpatients completed both the LUNSERS and the GASS at the same time, with 
the choice of which scale was completed first being randomly assigned via coin 
tossing. The out-patients were also asked to complete a copy of the GASS again a 
week later to assess test-retest reliability.  Comparison subjects completed the 
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GASS, to demonstrate that the GASS could differentiate between those taking and 
those not taking second generation antipsychotics.  
 
Statistical analyses were performed using MedCalc for Windows, version 9.2.0.1 
(MedCalc Software). Categorical differences were determined using the Mann 
Whitney test, with significance set at p< 0.05. Level of agreement between the 
scales was assessed using the weighted kappa and Spearman correlation 
coefficient.  No analysis of internal consistency or factor variance eg via principal 
components analysis, was undertaken.  
 
 
 
Results 
The GASS is illustrated below (see Table 21). Table 22 shows the mean ages and 
the mean GASS score for the two groups. 
 
There was no significant difference in age between the two groups (U=1410, 
p=0.27). The GASS scores for the two groups differed significantly (Mann Whitney 
U test, U= 2336, p<0.0001) with a mean of 14.3 for those on antipsychotic 
medication, and 3.6 for those not on medication. This confirms the construct 
validity of the GASS. 
 
Figure 8 shows the spread of the GASS scores within each of the proposed 
categorical cut off points, for both cases and normal comparisons. Cases 
prescribed polypharmacy or monotherapy are also shown separately. As expected 
all controls scored within the absent to mild category.  
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29 of the outpatient group were prescribed clozapine, 9 risperidone (7 oral, 2 
depot), 8 olanzapine, and 4 amisulpride. All doses were prescribed within BNF 
limits. 36 outpatients were prescribed only a second generation antipsychotics 
whilst the remaining 14 were on other regular medications (8 on antidepressants, 5 
on mood stabilisers, 1 procyclidine, 1 methadone and 1 oral hypoglycaemics). 
 
Repeating the analysis of GASS scores excluding the results of the 14 
polypharmacy outpatients still revealed that outpatients had a significantly higher 
mean GASS score of 11.5 (SD=7.9) and they differed significantly from the normal 
comparisons (U score 1681, p<0.0001). 
 
When the GASS was compared to the LUNSERS in the fifty outpatients, the kappa 
score = 0.73, with spearman rank correlation coefficient = 0.93 (sum of squared 
differences = 1548; ie 93% level agreement). This indicates a strong level of 
agreement between the GASS and LUNSERS, according to convention for the 
interpretation of kappa. 
 
Only 17 of the 50 outpatients returned (by post) the second GASS questionnaire 
adequately filled out a week later. Test- retest reliability was good, with kappa = 
0.72. The Mann Whitney U test failed to identify any significant difference in the 
GASS score of those that returned the second GASS questionnaire and those that 
did not (U=308, p=0.57) or their age (U=284, p=0.94). There were 10 males and 7 
females in the group that returned the second GASS, compared to 16 males and 
17 females in the group that did not.  
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Table 21.    Glasgow Antipsychotic Side-effect Scale (GASS) 
Name:                                                                          Age:                      Sex:  M  /  F 
Please list current medication and total daily doses below: 
 
 
This questionnaire is about how you have been recently. It is being used to determine if you are suffering from excessive 
side effects from your antipsychotic medication.   Please place a tick in the column which best indicates the degree to 
which you have experienced the following side effects. Tick the end box if you found that the side effect distressed you.      
                                                                                                                                             
Over the past week: Never 
 
Once A few                          
times 
Everyday
 
Tick this box if 
distressing 
1. I felt sleepy during the day 
 
     
2. I felt drugged or like a zombie 
 
     
3. I felt dizzy when I stood up and/or have fainted  
 
 
     
4. I have felt my heart beating irregularly or unusually fast 
 
     
5. My muscles have been tense or jerky       
6. My hands or arms have been shaky       
7. My legs have felt restless and/or I couldn’t sit still 
 
     
8. I have been drooling      
9. My movements or walking have been slower than usual  
 
     
10. I have had, or people have noticed  uncontrollable 
movements of my face or body 
 
     
11. My vision has been blurry  
 
     
12. My mouth has been dry  
 
     
13. I have had difficulty passing urine 
 
     
14. I have felt like I am going to be sick or have vomited      
15. I have wet the bed  
 
     
16. I have been very thirsty and/or passing urine frequently 
 
     
17. The areas around my nipples have been sore and swollen  
 
     
18. I have noticed fluid coming from my nipples  
 
     
19. I have had problems enjoying sex  
 
     
20. Men only: I have had problems getting an erection 
 
     
 
Tick yes or no for the following questions about the last three months No                                      Yes                               Tick this box if 
distressing 
21. Women only: I have noticed a change in my periods    
22. Men and women: I have been gaining weight     
  
119 
 
Staff Information 
 
 
 
1. Allow the patient to fill in the questionnaire themselves. Questions 1-20 
relate to the previous week and questions 21-22 to the last three months. 
 
2. Scoring 
 
For questions 1-20 award 1 point for the answer “once”, 2 points for the 
answer “a few times” and 3 points for the answer “everyday”. 
Please note zero points are awarded for an answer of “never”.  
 
 
For questions 21 and 22 award 3 points for a “yes” answer and 0 points for 
a “no”. 
 
 
Total for all questions= 
 
 
3. For male and female patients a total score of:  
                  0-12 = absent/mild side effects 
    13-26 = moderate side effects  
  over 26 = severe side effects 
 
  
4. Side effects covered by questions 1-2 sedation and CNS side effects 
            3-4 cardiovascular side effects 
            5-10 extra-pyramidal side effects 
            11-13 anticholinergic side effects 
            14 gastro-intestinal side effects 
            15 genitourinary side effects  
            16 screening for diabetes mellitus 
            17-21 prolactinaemic side effects  
            22 weight gain 
 
 
The column relating to the distress experienced with a particular side effect is not 
scored, but is intended to inform the clinician of the service user’s views and 
condition. 
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Figure 8. Spread of GASS scores in patients and normal comparisons 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 22. Mean ages and GASS scores of participants 
 
Statistic Cases (n=50) Comparisons (n=50) 
Mean Age (years) [SD] 41.4   [9.1] 39.9   [14.1] 
Age Range (years) 24 to 65 19 to 65 
No. Males 26 21 
Mean GASS [SD] 14.3  [10.5] 3.6  [4.1] 
 
SD = standard deviation 
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Discussion 
A new self-report rating scale assessing SGA side effects that is easy to use was 
constructed. The GASS takes five minutes to complete and contains self 
explanatory questions in everyday plain English whilst providing a structured 
systematic method of reviewing antipsychotic side effects. In the waiting room of a 
busy community mental health team, or on the in-patient unit, the use of simple, 
jargon-free language will enhance understanding and accurate completion of a self 
report scale, particularly if that scale is seen as brief. Furthermore, recognising that 
the experience of a side-effect may not necessarily be adverse even if it is 
common or may not cause distress or functional impairment when present, a 
column to the GASS allowing the subject to rate whether the experienced side-
effect was in fact distressing (or not) was added. This was left as a simple global 
‘yes / no’ response in view of the complexity of this judgement. Thus the GASS 
allows a grading not only of the frequency of an experienced side-effect but also a 
subjective judgement of the distress associated with a particular side-effect. 
 
The widespread use of SGAs is in large part due to a perception of increased 
tolerability, although later independent studies (eg Lieberman et al, 2005) have 
confirmed SGAs have important adverse side-effects with associated long term 
health implications. Numerous studies have demonstrated that adherence with 
prescribed medication is a key determinant of relapse prevention (eg Robinson et 
al, 1999), and medication side-effects are commonly cited by patients as a main 
reason for non-adherence (Tacchi and Scott, 2005) perhaps because clinicians 
consistently underestimate the severity and frequency of side effects. The routine 
use of rating scales or systematised evaluation in psychiatry is not widespread, but 
arguably will increase and can be used to enhance the clinician-patient interaction. 
  
122 
 
Self-report scales generally are less onerous for the busy clinician and arguably 
permit a more complete and considered responses as well as minimising potential 
embarrassment on subjects such as sexual dysfunction.   
 
The older side effect rating scales (see Table 20) such as the AIMS; Simpson 
Angus; Barnes Akathisia all focussed exclusively on movement disorder and 
extrapyramidal symptoms and are usually observer rated. The more recent scales 
such as LUNSERS and ANNSERS are more comprehensive and suitable for 
SGAs but are lengthy and time-consuming. The LUNSERS is regularly used in the 
UK, despite its size, age, and occasionally confusing language, illustrating that a 
systematic appraisal of medication side effects is considered important. Both the 
weighted kappa score and Spearman’s rank correlation score demonstrated a very 
good level of agreement between the LUNSERS and the GASS in a representative 
psychiatric out-patient population. The test-retest results also indicate that the 
GASS is reliable and stable over time (test-retest time here was one week) 
although the fact that only 17 of the 50 patients asked to re-complete the GASS 
actually did so diminishes the validity of this finding. Ideally replication of these 
findings - the comparison with the LUNSERS; validation against non-medication 
using comparison subjects; and test-re-test reliability should occur in another 
centre.  
 
The results demonstrate that individuals taking SGAs had significantly higher 
GASS scores than matched normal comparison subjects, as hypothesised, and 
that this difference was not confounded by polypharmacy.    
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The use of medical and consumer opinion as well as the literature review may well 
have enhanced the face validity of the GASS, and as the GASS combines brevity 
with validity it is suitable for busy clinical environments and as part of routine 
clinical monitoring e.g. during ward round or out-patient review. The GASS can 
also be completed outside the actual clinical interview, and can thus open up 
discussion between clinician and service user on medication tolerability in a 
systematic and structured manner, rather than relying on an ad hoc approach.  
 
Given these results, the GASS is proposed as a valid reliable tool which could aid 
systematic clinical assessment, particularly in view of its brevity and user-friendly 
language.  
 
Strengths and limitations 
The GASS was only assessed in outpatients taking SGAs, so the results may not 
be applicable to those on typical or first generation antipsychotics or acute 
inpatients. It may not be possible to generalise the results of this study beyond a 
white middle aged population in view of the age range and ethnicity of the two 
study groups. Furthermore, only one patient in this study was rated as having 
‘severe’ side-effects using the suggested categorical cut-offs which could cast 
doubt on the validity of this category. Ideally this validation study should be 
repeated with a larger sample in a different setting. Although the GASS appears to 
be as discriminating as the LUNSERS in terms of identifying emergent medication 
related side-effects, this study does not necessarily definitively measure what it 
purports to measure, as there has not been any external validation with objective 
measures, eg weight gain. The subjective rating of distress caused by each side 
effect also requires further study. 
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CHAPTER 8 
 
DISCUSSION AND CONTEXT OF THE RESULTS 
 
This concluding chapter deals with the differences and similarities between the 
antipsychotics studied in chapters 3 to 6 with a view to informing prescribing 
choice. There will be specific comment on the commonly occurring polypharmacy 
as noted in chapters 3 and 5; with a subsequent specific focus on clozapine and 
depot or long acting injectable antipsychotics, in view of the findings in chapters 5 
and 6. This chapter will also attempt to highlight how routine monitoring of 
medication related outcomes, including the Glasgow Antipsychotic Side-effect 
Scale (GASS – see chapter 7), is informative for day-to-day clinical practice. 
 
Choice of antipsychotic medication 
 
A diverse range of factors influence a prescription choice  and include not only the 
scientific evidence base of randomised controlled trials (RCTs); meta-analyses; 
and clinical guidelines (evidence or consensus based); but also less rational 
factors such as personal experience; peer opinion; and marketing influence. This 
section will solely focus on the scientific evidence base when discussing the 
context of the results in chapters 3, 4, 5 and 6. 
 
The National Institute for Health and Clinical Excellence (NICE, 2010) guideline 
suggests that there is little to differentiate between any oral antipsychotic for the 
acute treatment of schizophrenia in terms of clinical efficacy, with the main 
differences relating to side effect profiles.  However, the meta-analysis by Leucht 
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and colleagues (2009) which compared SGAs with low dose haloperidol concluded 
that four of the SGAs, namely amisulpride, clozapine, olanzapine and risperidone 
were better than the other antipsychotics studied in terms of overall efficacy – with 
small to moderate effect sizes. The symptom reduction effect size (Hedges’ g) for 
clozapine was -0.52 compared to amisulpride (g=-0.31); olanzapine (g=-0.28); and 
risperidone (-0.13).  The results in Chapter 5 also highlight the superior 
effectiveness of clozapine, and this will be discussed further below. It is notable 
that other SGAs such as aripiprazole and quetiapine were not more efficacious 
than low dose haloperidol, even for negative symptoms, in the meta-analytic 
review of Leucht et al (2009).  The small to moderate efficacy differences noted 
above need to be balanced with the large differences in side effect profiles for 
individual patients. Furthermore, the large meta-analyses of the comparative 
efficacy and tolerability of antipsychotic drugs are largely based upon short-term 
(eg 12 weeks) RCTs of antipsychotic drugs for acute relapses of schizophrenia. 
This is in contrast to the six month prospective study (chapter 4) and 2 year 
retrospective study (chapter 5) noted here, which arguably makes generalisation of 
the findings difficult, and hence studies examining longer term relapse need to be 
reviewed. In particular, rates of relapse and psychiatric hospitalisation are directly 
relevant to the data in chapters 4 and 5.  
 
Early RCTs showed that individuals who are well stabilised on antipsychotic drugs 
have high rates of relapse when their medication is discontinued or switched to 
placebo (Kane, 1996).  Relapse risk is especially increased if medication is 
stopped abruptly, but about one-half will relapse within six months even if 
medication is withdrawn gradually. Continuing antipsychotic medication treatment 
over several years can reduce relapse rates by approximately two thirds (Leucht et 
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al, 2011) although various studies (eg Shepherd et al, 1989) suggest that about 
20% of patients will have a single episode implying that maintenance treatment is 
not required for all patients.  Another RCT (Marder et al, 2003) showed that active 
treatment relapse rates were one third of those on placebo, with relapse predictors 
also including persistent symptoms, poor adherence, lack of insight, and substance 
misuse.  The industry sponsored SOHO observational study (Haro et al, 2007) had 
a similar naturalistic design to the study described in chapter 4, and found a 
relatively constant relapse rate over the 3 years, with 25% relapsing in total. 
 
An early meta-analysis (Davis et al, 1993a) of 35 double-blind studies (not all of 
which were RCTs), comparing maintenance treatment with FGAs versus placebo 
in over 3,500 service users found that relapse was reported in 55% of those who 
received placebo, compared to 21% of those receiving active drugs. Davis et al, 
(1993b) suggested that the number of people who survive without relapse after 
discontinuing drug treatment declines exponentially by around 10% a month; but 
approximately 20-30% of patients will not relapse after their initial episode(s). 
Gilbert and colleagues (1995) reviewed 66 antipsychotic withdrawal studies, 
published between 1958 and 1993, involving over 4,000 patients, and found a 
mean cumulative rate of relapse in the medication withdrawal groups of 53% 
compared with 16% (follow-up of approximately 8 months on average) in the 
antipsychotic maintenance groups. Similarly, a meta-analysis by Leucht et al 
(2003) concluded that SGAs as a whole reduced relapse rate by 23% as compared 
to 15% for FGAs as a group, suggesting that antipsychotics perhaps do not all 
have comparable effectiveness 
.  
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Of relevance to the choice of antipsychotic treatment for adults in terms of 
effectiveness over the medium to longer term are the findings of three pragmatic 
trials of antipsychotic treatment (EUFEST, CATIE and CUtLASS1). In the EUFEST 
study (Kahn et al, 2008) 500 participants with first-episode schizophrenia or 
schizophreniform disorder were assigned to low-dose haloperidol or one of four 
SGAs. The main finding was that treatment discontinuation over 12 months was 
significantly more common in patients assigned to low-dose haloperidol than in 
those treated with the SGAs, and the lowest discontinuation occurred with 
olanzapine. There were however no significant differences in therapeutic efficacy 
between the different treatment groups in terms of symptom severity.  The CATIE 
studies (Lieberman et al, 2005; Stroup et al, 2006; McEvoy et al, 2006) also used 
all-cause discontinuation as the primary outcome measure, and of the 1493 
participants, antipsychotics were discontinued in 60–80% of cases within the 18-
month follow-up period. There was a significantly lower chance of discontinuation 
of olanzapine overall, compared to perphenazine, quetiapine, and risperidone but 
olanzapine was also associated with more discontinuation due to weight gain or 
metabolic effects. The Cost Utility of the Latest Antipsychotic Drugs in 
Schizophrenia Study (CUtLASS1 – Jones et al, 2006) was a smaller UK trial which 
compared allocation to an FGA or an SGA (excluding clozapine) in 227 
participants with established schizophrenia for whom a change in antipsychotic 
medication was considered by their psychiatrist to be clinically indicated due to 
inadequate clinical response or intolerance. For each participant in the study, the 
choice of individual drug within the assigned FGA or SGA group was the choice of 
the prescribing clinician. Over the 1-year follow-up, there was no apparent 
disadvantage in using FGAs compared to SGAs in terms of quality of life, 
symptoms or the associated costs of care. It is scientifically reasonable and 
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relevant to compare these pragmatic randomised effectiveness studies with the 
results in chapter 4 and particularly chapter 5, where little difference was found in 
the measures of antipsychotic effectiveness between amisulpride; olanzapine; 
quetiapine; and risperidone.    
 
In clinical practice, the choice of maintenance treatment for a particular patient is 
probably best made on the correct drug, dose and formulation for that individual, 
bearing in mind patient preferences, illness severity, likely adherence, known 
previous drug response(s), any substance misuse, levels of depression, cognitive 
function and adverse effect profile. Generally, patients with schizophrenia will 
benefit from reduced relapse rates if they remain on antipsychotic medication. No 
particular drug or class is conclusively better in terms of efficacy (leaving aside 
clozapine – see below), or at reducing relapse rates than any other, despite the 
findings of Leucht and colleagues (2003, 2009). The available RCTs tend to favour 
SGAs (especially amisulpride, risperidone and olanzapine) but numerous 
methodological factors (e.g. comparator drug and dose, drop out rates) could 
account for any such differences. This benefit of maintenance antipsychotic 
medication may also only apply to one-third to two-thirds of patients however and 
there is as yet no reliable method of predicting who will benefit compared to those 
who will relapse on an individual basis.  The factors which tend to be associated 
with an increased chance of relapse clinically – such as illness severity and 
substance misuse - are also those which predict poor adherence with medication.       
 
Tolerability of antipsychotic medication 
Most RCTs of SGAs and FGAs are of relatively short duration and not designed to 
prospectively examine side effects, so these trials provide little insight into the 
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longer-term adverse effects of treatment or whether there are clinically significant 
differences between antipsychotic drugs.  The overall drop out (leaving the study 
early) specifically due to adverse effects in these studies is approximately 5-10%, 
in the short term, with no apparent difference between drugs.  A clear advantage 
for SGAs was fewer episodes of tardive dyskinesia according to a review by Correll 
and Schenk (2008), which occurred with an annual incidence of 3.0% in SGAs vs. 
7.7% with FGAs. 
 
Adherence with anti-psychotic medication generally runs at approximately 50% in 
the medium to longer term (Patel et al, 2009), and results in chapter 5 demonstrate 
that a major reason for non-adherence is the experience of intolerable side-effects. 
This is why systematic review of antipsychotic side-effects using a valid instrument 
such as the GASS (as described in chapter 7) is so important, both in terms of 
good clinical practice and maintaining rapport through inclusive discussion. The 
three pragmatic trials of antipsychotic treatment (EUFEST, CATIE and CUtLASS1) 
described in detail above reached essentially the same conclusions in terms of 
medication discontinuation.  In the EUFEST study (Kahn et al, 2008), all cause 
treatment discontinuation over 12 months ranged from 33% to 72%. The CATIE 
studies (Lieberman et al, 2005; Stroup et al, 2006; McEvoy et al, 2006) funded by 
the National Institute of Mental Health, also used all-cause discontinuation as the 
primary outcome measure and found that antipsychotics were discontinued in 60–
80% of the 1493 participants within the 18-month follow-up period. Both studies 
favoured SGAs.  The Cost Utility of the Latest Antipsychotic Drugs in 
Schizophrenia Study (CUtLASS1, Jones et al, 2006) funded by the NHS Research 
and Development Health Technology Assessment Programme in England, found 
that more patients randomized to receive an SGA than an FGA remained in their 
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allocated treatment arm for the whole year, but this difference was not significant 
(65% [71/109] vs. 54% [64/118]). These rates are generally somewhat higher than 
the discontinuation rates observed retrospectively in Lanarkshire in chapter 5, but 
this may be explained by the demands of the trial rather than a naturalistic study 
population. 
 
In terms of EPS all SGAs are associated with much fewer adverse effects than 
haloperidol.  The data comparing SGAs with low potency FGAs such as 
chlorpromazine are less clear. Antipsychotic-associated weight gain, its metabolic 
consequences and the associated morbidity are a major concern.   All of the SGAs 
with the exception of aripiprazole and ziprasidone caused more weight gain than 
haloperidol (but not low-potency FGAs).  Clozapine, olanzapine, sertindole and 
zotepine caused the most weight gain.  In terms of sedation, clozapine, quetiapine 
and zotepine were more sedating than haloperidol, and aripiprazole was less 
sedating. Sexual dysfunction has been less well studied in these trials, but is 
usually thought to be related to prolactin elevation with risperidone and amisulpride 
are thought to be the worst culprits of the SGAs in this domain. The full range of 
potential side-effects should be captured in a systematic way by a single scale, 
and the GASS (described in chapter 7) has probes on EPS and other neurological 
problems; sedation; weight gain; incipient diabetes; and sexual and menstrual 
dysfunction. These are the factors that patients themselves (see chapter 7) and the 
literature reviewed here regard as the most common and serious side-effects 
associated with antipsychotic medication. 
 
In summary, antipsychotic medication appears to be acceptable to approximately 
one-half of patients in the long term, in that they will largely adhere to their 
  
131 
 
prescription. The SGAs appear to be better tolerated in the short term but as a 
whole have worrying longer term metabolic effects.  In routine clinical practice, 
treatment acceptability varies from drug to drug in different patients, and the 
incidence of emergent side-effects can be hard to predict on an individual basis. 
 
Optimal dose of antipsychotic medication 
The Cochrane review of chlorpromazine dose (Liu et al, 2009) found that on low 
dose (<=400mg/day), compared to medium dose (401-800 mg/day), more people 
left for inefficacy of treatment but all measured EPS tended to be lower. When low 
dose was compared with high dose (>800mg/day) global state outcomes tended to 
favour the high dose group, but more people in the high dose group left early due 
to disabling adverse effects. Significantly less dystonia and other unspecified EPS 
were reported in the low dose group  The Cochrane review (Li et al, 2009) of 
risperidone dose highlights 4-6mg daily as the optimal balance between drop-outs 
due to inefficacy (at <4mg) versus adverse effects (at >6mg).  The studies 
documented in this thesis did not use chlorpromazine as a comparator as it is not 
widely prescribed as a maintenance medication for schizophrenia in either 
Glasgow or Lanarkshire, but the mean dose of 3.4mg in the 115 individuals taking 
risperidone highlighted in chapter 4 and the mean dose of 6mg in the 74 patients 
with schizophrenia identified in chapter 5 are similar to the Cochrane derived 
‘optimal range’, suggesting clinicians in the west of Scotland are aware of this 
issue. 
 
Recently, Uchida et al (2011) compared the efficacy between standard dose 
[World Health Organization defined daily dose (DDD)] vs low dose (50-100% DDD) 
or very low dose (<50% DDD) for relapse prevention in schizophrenia in RCTs with 
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a follow-up duration of at least 24 weeks, in thirteen studies with 1395 subjects. 
Compared with the standard-dose treatment, the low-dose therapy did not show 
any statistically significant difference in overall treatment failure or hospitalization, 
while the standard dose showed a trend approaching significance for superiority in 
risk of relapse. The very low–dose group was inferior to the standard-dose group in 
all efficacy parameters. No significant difference was found in the rate of dropouts 
due to side effects between either standard dose versus low dose or very low 
dose.  
 
Optimal duration of antipsychotic treatment 
There are surprisingly few studies regarding ideal duration of antipsychotic 
treatment. In the Northwick park first episode study (Crow et al, 1986) 25 (46%) of 
60 patients randomised to antipsychotics (chlorpromazine, haloperidol, 
trifluoperazine, pimozide or flupentixol decanoate) had relapsed within 2 years as 
compared to 46 (61%) randomised to placebo. In the Cochrane review of 
chlorpromazine (Adams et al, 2007), the longer term data (6 months to 2 years) 
favoured the chlorpromazine group over placebo (n=512, 3 RCTs, RR 0.57 CI 0.5 
to 0.7, NNT 4 CI 3 to 5) for relapse prevention. The Cochrane review of haloperidol 
(Joy et al, 2006) found the relapse rate in people maintained on antipsychotic 
treatment approached that in those withdrawn from treatment over time, but was 
still consistently lower in those still on treatment at 2 years (RR 0.70, CI 0.57-0.87). 
Robinson et al (1999) examined relapse rates during the five years subsequent to 
initial recovery in a cohort of 104 individuals after their first episode of 
schizophrenia, and found a relapse rate of 82% after 5 years (CI 71%-93%). 
Discontinuing antipsychotic medication was the single biggest factor predicting 
relapse in this study, raising relapse risk nearly five-fold, with the only other 
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independent risk factor for relapse being a poor premorbid level of function. A more 
recent study by Chen and colleagues (2010) from Hong Kong studied 178 patients 
after they achieved remission on quetiapine following at least one year of treatment 
subsequent to their first episode of psychosis. Patients were randomised to either 
placebo or to remain on quetiapine at this point and then followed up for another 
year. 79% of the placebo group and interestingly 41% of the quetiapine group 
proceeded to relapse back into psychosis during the one year study period, with 
the authors noting that more discontinuations due to adverse events were seen in 
the quetiapine group. 
 
Overall, there is clear evidence to justify recommending that patients with 
schizophrenia should remain on antipsychotic medication for two and possibly up 
to five years after an acute episode. Some patients will however relapse despite 
continued treatment and some others will only have one psychotic episode with or 
without subsequent treatment. Unfortunately it is difficult to identify who will and 
who will not relapse at treatment outset. 
 
Antipsychotic polypharmacy 
Studies have reported variable rates of regular concurrent antipsychotic 
prescription depending on the population considered. An Australian study (Keks et 
al, 1999), examining people receiving out-patient treatment for schizophrenia, 
showed a 13% rate of multiple antipsychotic prescription use, whereas a Japanese 
study (Ito et al, 1999) indicated that the rate of antipsychotic polypharmacy there 
exceeded 90%. Results from Glasgow contained in chapter 3 indicate a regular 
antipsychotic polypharmacy rate of 12% in a population of people receiving 
maintenance treatment for long term psychotic illnesses. Similarly, the data from 
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Lanarkshire (in chapter 5) suggests regular antipsychotic polypharmacy commonly 
occurs, varying between 8%-37% depending on which combination is looked at. 
Further, regular co-prescription of mood stabilisers and antidepressants with an 
antipsychotic happens frequently in schizophrenia (as detailed in chapter 5) with 
rates of antidepressant prescription exceeding 60% of cases with those on 
quetiapine, for example.  Evidence elsewhere (Leucht et al, 2009) suggests that 
only clozapine and amisulpride of the SGAs studied have a beneficial effect on 
depression, as measured by the relevant items on the PANSS. 
 
A further complication when considering antipsychotic polypharmacy is that the 
combinations used by clinicians are highly varied, as noted in chapters 3 and 5. 
This makes direct comparison between polypharmacy groups and monotherapy 
groups difficult because often the number of individuals on the same combination 
regimens are small. An audit carried out by the Prescribing Observatory for Mental 
Health (Royal College of Psychiatrists, 2010) found that 74% of people prescribed 
more than one antipsychotic were prescribed an SGA in combination with a FGA 
drug. These findings point to the possibility that combination of antipsychotics may 
even be the preferred polypharmacy practice, although Table 5 in chapter 3 notes 
a wide variation within antipsychotic polypharmacy between FGAs; SGAs; long 
acting (depot) injections; and clozapine supplementation. The literature regarding 
the practice of polypharmacy has generally concluded that ‘except in cases where 
an individual has failed to respond to adequate trial of monotherapies including 
clozapine, antipsychotic polypharmacy has little support in the medical literature’  
(Taylor, 2010). NICE (2010) does recognise that there ‘are circumstances where 
patients and clinicians serendipitously hit upon effective combinations’. Thus, 
polypharmacy should only be considered after a failed period of monotherapy, 
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which should include a failed adequate trial of clozapine. Interestingly a study 
examining previous clozapine use in those on polypharmacy surprisingly found that 
only 4% had been given a trial of clozapine before being commenced on 
polypharmacy (Miller and Craig, 2002). This suggests that polypharmacy is being 
considered earlier in a patient’s management plan than expected and that it is not 
being reserved for truly treatment-resistant cases.  
 
Despite the frequent practice of antipsychotic polypharmacy, there are few 
scientific studies examining the issue. A large meta-analysis including a number of 
studies in the Chinese literature (Correll et al, 2009) found a slight therapeutic 
advantage for antipsychotic co-therapy, but noted clear publication bias in favour of 
positive studies. Other evidence suggests antipsychotic polypharmacy increases 
time in hospital (Centorrino et al, 2004)  and decreases cognitive performance (Elie 
et al, 2009). There is also worrying evidence that antipsychotic polypharmacy 
increases the risk of metabolic disturbances (Taylor et al, 2004).  
 
Legitimate concerns regarding the cost; safety (including the increased likelihood 
of side-effects); drug-drug interactions; and the possibility of reduced adherence to 
complex medication regimens exist with regard to long term polypharmacy. Also 
the risks of unanticipated high dosing need to be borne in mind with antipsychotic 
polypharmacy. Similarly, the longer term effects of antipsychotic polypharmacy 
have not yet been fully studied and so this too is an area of concern.  Waddington 
and colleagues (1998) found that ‘the greater the maximum number of 
antipsychotics given concurrently, the shorter was patient survival’. Subsequently, 
Joukamaa and colleagues (2006) in Finland added to Waddington’s findings by 
demonstrating ‘a graded relationship between the number of neuroleptics 
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prescribed and mortality of those with schizophrenia’ finding that ‘those prescribed 
three antipsychotics simultaneously were twice as likely to die as those who were 
prescribed only one’. Joukamaa et al (2006) also stated that this ‘could not be 
explained by coexistent somatic disease or other risk factors known for premature 
death’. These concerns exacerbate the problems of premature mortality known to 
exist in this population (Bushe et al, 2010). 
.  
Although the long-term effects of antipsychotic polypharmacy prescription are not 
well defined and there are worries about increasing liability to metabolic problems 
and premature mortality, as noted above, it is still relatively common in clinical 
practice as demonstrated in Chapters 3 and 5. Further long term comparisons of 
antipsychotic monotherapy and polypharmacy are required, particularly in terms of 
the risk / hazard balance of potential superior efficacy versus increased liability to 
side-effects.  
 
Clozapine 
Treatment resistant schizophrenia is a common clinical problem, leading to 
significant individual disability and costs to society. Clozapine remains the only 
medication licensed for treatment resistant schizophrenia, a form of chemotherapy 
for schizophrenia – the most effective but possibly the most toxic in class. Despite 
significant safety and side-effect issues noted below, clozapine continues to be 
widely used in clinical practice, as evidenced by the finding in chapter 3 of this 
thesis that 18% of all people with schizophrenia seen in secondary care in 
Glasgow during 2010 were on regular clozapine medication.  
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Prevalence estimates of treatment resistant schizophrenia vary depending upon 
the definition used, but up to a third of individuals with schizophrenia have a 
suboptimal response to adequate trials of antipsychotic medication. Studies based 
on prescription patterns in routine practice almost universally show a much lower 
proportion of individuals with schizophrenia are prescribed clozapine, which is 
exemplified in chapter 3 where a prescription rate of 18% in seen in a secondary 
care case register. The clozapine prescription rate in Italy of 1.5% has been 
reported (Tognoni, 2004), and in England data (Downs and Zinkler, 2007) from 41 
mental health trusts showed that only 30% of those eligible were actually receiving 
clozapine. Low rates of clozapine use would imply only the suicidal or most 
refractory cases are enrolled, which in turn would reflect on the outcomes in these 
populations. The common alternative to clozapine is antipsychotic polypharmacy, 
as noted above, and which may only serve to worsen treatment resistance and add 
to the side effect burden. 
 
In terms of efficacy, the previously mentioned review (Leucht et al, 2009) found 
clozapine to be the most efficacious antipsychotic compared to low dose 
haloperidol, and in a separate head to head comparison (Leucht et al, 2008) of 
SGAs including only double blind studies, clozapine proved superior to zotepine 
and to risperidone (in doses >400mg/day) but was non-superior to olanzapine and 
quetiapine, although this latter non-superiority was likely due to study designs that 
required an  upper dose limit for clozapine of 400 mg/day. 
 
The superior effectiveness for clozapine is supported by the previously reviewed 
CATIE and CUtLASS studies. In phase two of CATIE (McEvoy et al, 2006) patients 
were re-randomised to receive open-label clozapine or double blinded risperidone, 
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olanzapine, or quetiapine, mainly because of lack of therapeutic effect in phase 
one of CATIE. The time to all-cause medication discontinuation, the primary 
outcome measure, was significantly better for clozapine compared to all other 
drugs studied apart from olanzapine. The number needed to treat (NNT) for the all-
cause discontinuation for clozapine was 4 compared to risperidone, and 3 
compared to quetiapine. Clozapine was significantly superior to olanzapine; 
quetiapine; and risperidone in terms of time to discontinuation due to inadequate 
therapeutic effect. In CUtLASS2 (Lewis et al, 2006), 136 patients exhibiting a poor 
response to more than two antipsychotic agents were randomized to receive either 
clozapine or a non-clozapine SGA, and their quality of life was compared over one 
year. Clozapine was found to be significantly superior to non-clozapine SGAs with 
regard to symptoms, and exhibited a trend towards superiority regarding quality of 
life (p=0.08). Lastly, a large observational study (Tiihonen et al, 2006) from Finland 
also showed that following first hospitalisation for schizophrenia, individuals treated 
with clozapine had the lowest risk of treatment discontinuation, and of re-
hospitalisation of all the ‘initiated’ oral antipsychotics studied. 
 
Clozapine also seems to be a broad spectrum antipsychotic, with robust evidence 
of effectiveness in suicidality, aggression and substance misuse. In the US, 
clozapine is approved by the FDA for the management of suicidality in patients 
with schizophrenia or schizoaffective disorder. In addition, clozapine has been 
shown to have anti-aggressive properties. For example Krakowski et al (2006) 
undertook a randomized controlled trial of patients with schizophrenia who were 
not treatment resistant but had had confirmed episodes of assault and persistent 
aggression during one year of hospitalization. Clozapine was superior to both 
olanzapine and haloperidol in reducing the number and severity of assaults, and in 
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reducing overall aggression Krakowski et al (2006). Clozapine may also play a role 
in diminishing substance misuse. For example, Brunette and colleagues (2006) 
found after 10 years of follow up that clozapine was associated with reduced 
relapse of substance misuse, compared to other antipsychotics.  
 
Clozapine use is limited by a number of troublesome adverse effects such as 
hypersalivation, drowsiness and constipation. Recognition of this unique clozapine 
associated side effect profile led to a wish to modify the GASS described in 
chapter 7 to specifically probe for these side-effects, and hence the ‘GASS for 
clozapine’ was created after literature review and consultation with experts in the 
field. This new and un-tested scale, and would be suitable for future research, 
‘GASS for clozapine’ is illustrated in the appendix three.  Life threatening side 
effects like myocarditis; cardiomyopathy; agranulocytosis; a lowered seizure 
threshold and metabolic syndrome can also occur.  However, Tiihonen et al (2009) 
compared mortality in 66881 individuals versus the total population of Finland (5·2 
million) over 11 years, and found that people regularly taking clozapine had the 
lowest risk of premature mortality compared to both those on other antipsychotics, 
and those on no regular medication172. This protective effect will in part be due to 
the anti-suicidality mentioned above, but despite its well known metabolic side-
effects, death from ischaemic heart disease was no different for clozapine than any 
other medication studied. Recently, Kelly et al (2010) also found  in a retrospective 
cohort study that the risk of cardiovascular mortality did not differ significantly in 
patients started on clozapine (n=1084) compared to those initiated on risperidone 
(n=602) over 8-10 years follow up, despite the fact that clozapine is associated 
with more weight gain than risperidone. 
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The risk of clozapine-induced leucopenia or agranulocytosis decreases 
exponentially over time, and after one year of treatment the incidence of 
agranulocytosis is nearly equivalent to that observed in phenothiazines. Monitoring 
of clozapine-induced blood dyscrasias has helped minimise the incidence of this 
serious issue. Based on data from 30 studies, Merrill and colleagues (2005) 
concluded that clozapine is associated with a low (~0.1%) risk of potentially fatal 
myocarditis or cardiomyopathy. 
 
Clozapine can not be offered as first line therapy, partly in view of these 
troublesome side-effects and partly due to lack of evidence for efficacy in first 
episode psychosis. However, Agid et al (2007) were able to offer a trial of 
clozapine as early as 25 weeks, after patients failed to respond to two trials of 
SGAs following a standardised first episode psychosis programme. The treatment 
resistant patients, in this pragmatic study, who received clozapine did experience 
an improvement in symptoms (mean Brief Psychiatric Rating Scale - BPRS score 
decreased from 53.5 to 34.5). Those who were also treatment resistant but had 
refused clozapine exhibited a 2-point increase in mean BPRS score (from 53 to 55) 
with continued SGAs. Agid et al (2007) concluded, perhaps controversially, that 
clozapine had an important role in first episode patients who had failed to respond 
to SGAs in the first months of treatment.   
 
There are concerns (Farooq and Taylor, 2011) about the under-utilisation and 
delayed initiation of clozapine and this may be exacerbated by suboptimal dosing. 
Plasma level studies generally show that higher clozapine levels correlate with an 
excellent clinical response, whereas lower clozapine plasma levels were 
associated with a poor response, suggesting that many patients require doses 
  
141 
 
greater than 400 mg. This may be further complicated high prevalence of cigarette 
smoking in this population, which can adversely affect serum levels.  
 
Another less well studied issue is the attitude towards clozapine in staff and 
patients (Taylor et al, 2000). Neilsen et al (2009) surveyed patients on clozapine 
and found that 87% felt the advantages of clozapine outweighed any 
disadvantages. However, when Neilsen et al (2009) systematically questioned one 
hundred psychiatrists regarding attitudes to clozapine, they discovered that many 
were reluctant to use clozapine as they felt the patients would not like it, and said 
they would rather combine two other antipsychotics in treatment resistant cases, 
emphasising the points made earlier on both the lure and perils of antipsychotic 
polypharmacy. Farooq and Taylor (2011) suggested that these negative beliefs 
may be linked to limited experience and knowledge, particularly as clozapine is 
now a generic drug and less actively marketed. A self perpetuating cycle can then 
ensue, as trainees do not see the benefits of clozapine, and do not develop 
confidence in its use. However, results presented in Chapters 3 and 5 of this thesis 
demonstrate the continued use (and thus continued perceived value) of clozapine, 
and in Chapter 5 there is data consistent with results from both the CATIE and 
CUtLASS trials that confirms clozapine’s superior effectiveness compared to the 
most commonly employed SGAs.   
 
 
Long acting injections (LAIs) or depot antipsychotics 
Data from the Psycis case register (Chapter 3, and see Figure 9) reveals that the 
LAI usage rate in maintenance treatment in this large UK cohort is 33% for broad 
schizophrenia (one third of the total antipsychotic prescriptions), and 8% in bipolar 
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disorder (14% of the total antipsychotics prescribed). 23% of men and 18% of 
women receive LAI maintenance treatment in this cohort. Co-prescription of 
regular oral antipsychotic medication, in combination with a regular long-acting 
injection of antipsychotic medication occurs in a significant minority of cases, 
namely 24.5% of those individuals with schizophrenia, and 28% of those with 
bipolar disorder. Additionally, the Psycis sample described above which includes 
both community and hospital based patients, 15% of those individuals receiving 
regular LAI or depot antipsychotic were currently detained under long term 
treatment orders under the Mental Health Act, compared to 12% of the total 
sample, i.e. a negligible difference, suggesting that at the current time in Glasgow 
the use of LAIs is not necessarily linked to detention under the Mental Health 
(Scotland) Act, 2003.   
 
Figure 9. PsyCIS cases (n=5221) use of maintenance antipsychotic medication 
(%) by diagnosis 
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In view of the continuing frequent of use of LAIs, it is valuable to review efficacy 
and effectiveness of LAIs. The first LAI antipsychotic medication introduced was 
fluphenazine enanthate, in 1966, and the second, fluphenazine decanoate, arrived 
some 18 months later. Early evidence (Denham et al, 1971; Johnson and 
Freeman, 1973) of the effectiveness of long acting antipsychotic medications came 
from two mirror image studies, with both studies showing a decrease in the number 
of admissions to hospital and a reduction in morbidity. A Swedish mirror image 
study (Gottfied and Green, 1974) also showed reduced hospitalization rates for 
long acting injections of flupentixol compared to the previous treatment. These 
mirror image studies catalysed the use of FGA-LAIs in routine clinical practice, and 
are summarised in greater detail in Figure 11.   
 
Another early influential study (Hogarty et al, 1974) compared fluphenazine in oral 
and LAI forms, with and without social therapy.  Importantly the study duration was 
two years, and the authors found that a lower relapse rate (measured by 
hospitalization rate) on the LAI formulation was not apparent until after one year of 
treatment, although the result was not statistically significant (due to small sample 
size). Interestingly it was the interaction between social therapy and the LAI (rather 
than the LAI alone) that accounted for the reduced relapse rate in year 2 compared 
to the oral form. A later similar study (Schooler et al, 1980) over 2 years confirmed 
that intermittent or very low dose fluphenazine decanoate was worse in preventing 
relapse and rehospitalisation than continuous moderate dosing (12.5 – 50mg each 
fortnight) regardless of family therapy. 
 
Subsequently, the use of LAI antipsychotic maintenance treatment has become 
established in chronic schizophrenia, but has had a differential uptake around the 
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world.  The patterns of individual LAI usage in Scotland over a 5 year period are 
depicted in figure 10. It can be seen that the introduction of risperidone LAI in 
Scotland in 2003 was followed by increasing use of this drug accompanied by a 
decrease in prescription rate of FGA-LAIs, mostly notably flupentixol decanoate. 
The total rate of LAI use however has remained largely unchanged in that 5 year 
period. Despite the introduction and increasing use of SGA-LAIs it is clear that 
FGA-LAIs are still widely used in routine clinical practice, as demonstrated in both 
Chapters 3 and 6 of this thesis.  
 
Figure 10. Trends in individual LAI use over time, 2003-2007, in Scotland (data 
provided by the Information and Statistics Division (ISD) of the Scottish 
Government. 
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Comparing individual LAIs – Chapter 6 
Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses has 
been subject to a Cochrane review (da Silva Freire et al, 2009) which found 4 
studies allowing comparison of zuclopenthixol decanoate with other long acting 
(depot) formulations of antipsychotic medication, and concluded that 
zuclopenthixol decanoate prevented or postponed relapse when compared against 
other long acting injections of antipsychotic (NNT= 8, CI = 5-53). However they 
also showed that zuclopenthixol decanoate may induce more adverse effects than 
the other LAIs (NNH = 5, CI = 3-31) despite a decreased need for anticholinergic 
medication. In summary, the authors felt there was “a real difference” between 
zuclopenthixol decanoate and the other LAIs studied, despite the limited trial data. 
 
David et al (1999) studied flupentixol decanoate for schizophrenia or other similar 
psychotic disorders and noted there were no placebo trials and not many studies in 
total, but concluded there was “nothing to choose between flupentixol decanoate 
and other depots”. Furthermore, they observed that no clinical benefit accrued from 
dosing higher than a ‘standard’ dose of 40mg per fortnight. 
 
When Adams and colleagues (2001) reviewed the data comparing specific FGA-
LAIs, they reached the conclusion that “there were few convincing data that any 
real differences exist between depots”. Only the outcome of mental state relapse 
showed that zuclopenthixol decanoate was statistically superior to the control LAIs 
(largely fluphenazine – n=296, NNT = 8, CI= 5-53). However publication bias could 
not be excluded as an explanation for this finding. 
 
  
146 
 
The only RCT published at the time of writing that compares a FGA-LAI with a 
SGA-LAI is that by Rubio et al (2006) which compared risperidone long-acting 
injection (RLAI – also known as risperidone consta), to zuclopenthixol decanoate in  
patients with schizophrenia and co-morbid substance use (cannabis, cocaine, 
opiates and ecstasy). This study randomised patients who had been admitted to 
hospital with worsening psychosis. After stabilising their illness in hospital, 115 of 
183 patients interviewed agreed to participate and were alternately allocated to 
RLAI (n=57) or zuclopenthixol decanoate (n=58) and followed up for 6 months as 
out-patients. The clinical assessors were blind to the treatment. The primary 
outcome measure was number of positive urine drug tests during the 6 month. 
Secondary outcome measures were PANSS subscales and compliance with the 
weekly psychotherapeutic programme. In terms of the primary outcome measures 
there was a statistically significant advantage with RLAI for number of positive 
urine drug tests (8.7 for RLAI versus 10.3 for zuclopenthixol, p=0.005). However, 
relapse rate and survival time to first positive urine drug test did not differ. PANSS 
scores, particularly for negative symptoms, and measures of EPS showed an 
advantage for RLAI. The RLAI group also demonstrated better adherence to the 
psychotherapeutic programme.  This study by Rubio et al (2006) involved an 
important group of patients seen in routine psychiatric practice (and not just in 
addiction specialties) but caution should be exercised in generalising these results 
to all patients with schizophrenia as patients with co-morbid substance use may 
differ in terms of aetiology, clinical presentation and treatment response compared 
with those with no substance misuse disorder. 
 
Rosenheck and colleagues (2011) have published an influential randomised 
comparison of RLAI with oral SGAs (viewed perhaps wrongly as a homogenous 
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group), and did not find any statistical superiority to RLAI over the oral SGAs in 
terms of treatment discontinuation over the two year study. However, this may be 
due to lack of power as RLAI did lead to less subsequent re-hospitalisation (36% v 
43%) and less outpatient contact (122 v 136 total visits) compared to the oral 
SGAs. This study also failed to achieve its pre-agreed recruitment target. Lastly, 
clinical experience suggests that RLAI requires oral antipsychotic supplementation 
(ie dual oral and LAI therapy) over a period of many months possibly as a result of 
its novel delivery system. Performing a similar comparison with more recent SGA 
LAI formulations such as paliperidone palmitate will be important as these 
compounds may not appear to require such prolonged ‘dual’ oral supplementation. 
 
Prospective observational studies have compared a LAI to one or more oral 
antipsychotic cohorts, and they adopted various pragmatic outcome measures 
including risk of readmission and time to all-cause discontinuation of medication.  
The results were mixed; two studies found a better outcome for FGA-LAI 
compared to an FGA-oral (Tiihonen et al, 2006; Zhu et al, 2008). The 
Schizophrenia Health Outcomes Study (SOHO), funded by the manufacturers of 
olanzapine, found poorer outcomes for FGA-LAI than oral olanzapine (Haro et al, 
2007) and a fourth study (Conley et al, 2003) found oral antipsychotics to be 
superior to haloperidol decanoate but equivalent to fluphenazine decanoate.  
 
Tiihonen et al (2006) assessed the outcome of patients after their first admission 
with schizophrenia or schizoaffective disorder in relation to the antipsychotic they 
were taking on discharge. Initial use of perphenazine LAI was associated with a 
significantly lower adjusted risk for all-cause medication discontinuation than 
haloperidol and the second lowest discontinuation rate of the ten drugs studied.  
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An analysis of rehospitalisation rates, calculated according to the ongoing 
antipsychotic, showed that perphenazine LAI had the lowest risk of 
rehospitalisation (68% reduction in fully adjusted relative risk compared to 
haloperidol). Interestingly, perphenazine LAI performed better on both measures 
than oral perphenazine.  
 
This initial cohort study from Finland was followed up by a more recent separate 
study (Tiihonen et al, 2011) using the national data bases from 2000-2007, and 
contrasted oral and LAI formulations of the same individual antipsychotic agents. 
Oral risperidone was used as the baseline comparator compound rather than 
haloperidol in view of evolving clinical practice. The main findings from this large 
(n=2588 individuals consecutively hospitalised for the first time with schizophrenia) 
study were that 42% did not collect any further prescriptions in their first month 
after their hospital discharge, and secondly that use of LAI or depot medication 
reduced the risk of re-hospitalisation by 64% compared to the same molecule in 
oral form. Finally the use of any antipsychotic medication compared to no 
antipsychotic of any sort lowered overall mortality during the study period by 55%. 
 
The study by Zhu et al (2008) used data from the US-SCAP (Schizophrenia Care 
and Assessment Program) study to assess the time to all-cause medication 
discontinuation in the first year after initiation of a FGA-LAI or oral antipsychotic. 
The same two antipsychotics, haloperidol and fluphenazine, in oral or LAI form 
were assessed, being the only two FGA-LAIs available in the United States. The 
LAI-group had a significantly longer mean time to all-cause medication 
discontinuation and patients receiving a LAI were twice as likely to remain in 
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treatment compared to the oral group. The SOHO study (Haro et al, 2007) was a 3 
year observational study of patients with schizophrenia. The likelihood of not 
achieving remission, the risk of relapse and the all-cause discontinuation rate of 
medication were all higher for those treated with FGA-LAI compared to oral 
olanzapine. By 3 years the baseline medication had been discontinued by 36% of 
those who initiated treatment with olanzapine, 50% for those who initiated a FGA-
LAI (and 53% for those who initiated an FGA-oral drug).  Only the SOHO study 
presented tolerability data and this was limited to descriptive data without statistical 
analysis. The period-prevalence for EPS was 43% for the FGA-LAI cohort, 31% for 
FGA-oral cohort and for the various SGA-orals values ranged from 13% 
(quetiapine) to 32% (risperidone).  Assessment of both EPS and TD was based on 
clinical judgement and not objective rating scales. The proportion of patients who 
gained >7% weight from baseline to medication-discontinuation was higher for 
FGA-LAI than FGA-oral (22% versus 16%) as was mean weight gain (2.6 kg 
versus 1.5kg).  
 
Mirror image studies have been previously reviewed and analyzed in detail 
(Haddad et al, 2009). In each of the 11 mirror image studies, total inpatient days 
and number of admissions were lower on FGA-LAI than during the preceding 
treatment period, as indicated in Figure 11.  Furthermore where p-values were 
available, or could be calculated, the differences were statistically significant.  Ten 
(of the 11) studies provided the mean number of inpatient days for the LAI-
treatment period and preceding-treatment period.  Based on these 10 studies, the 
mean number of inpatient days per patient fell from 114.9 in the pre-FGA-LAI 
period to 28.6 during FGA-LAI treatment.  This confirmed the conclusions of an 
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earlier important review (Davis et al, 1994) regarding the utility of LAIs in 
maintenance treatment of schizophrenia. 
 
Figure 11. Summary of all mirror image studies examining time in hospital, 
comparing FGA-LAIs with oral antipsychotic medications (with permission, 
Haddad, Taylor, and Niaz). Distribution (%) of total inpatient stay between 
previous-treatment and FGA-LAI treatment periods for each mirror image study 
(n=11) with each horizontal bar totalling 100%. 
Key: each blue bar represents proportionate time in hospital prior to LAI / depot, 
with each purple bar depicting proportionate time in hospital after commencement 
of LAI / depot. 
 
Olfson et al (2007) used the California Medicaid database to analyse the use of 
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treatment. This study was not included in the ‘mirror image’ section above as 
patients who were admitted for 14 days or more were excluded. They found few 
clinical or demographic differences between the three treatment groups and recent 
oral non-adherence was frequently seen. Only a small minority of patients 
continued on the three long acting injections for the full 180 days post-initiation 
(5%, 10%, and 3% respectively), and the authors noted that California Medicaid 
patients were less likely than European patients to be given a LAI for maintenance 
treatment, and the ones that were frequently had comorbid problems. The most 
striking finding of the Olfson et al (2007) study from the US was the extremely low 
continuation rate of all three LAIs over six months, coupled with supplementary 
oral polypharmacy.  
 
Chapter 6 of this thesis highlighted data on people with schizophrenia, or related 
psychosis who were commenced on a long acting antipsychotic injection in a 
discreet Scottish population of ~500,000 within a defined period (2002 to 2008). An 
advantage of this study was that all new medication starts in the study period were 
included, so patients were likely to be representative of clinical populations 
requiring LAI treatment compared to those included into clinical trials. Risperidone 
long acting injection (RLAI) was the most popular choice of new start long acting 
injection outnumbering all the other conventional long acting injections. Compared 
with RLAI and flupentixol depot, patients on zuclopenthixol decanoate showed 
significantly better outcomes in terms of time to discontinuation (see Chapter 6) 
and hospitalization rates. However, fewer of those on zuclopenthixol decanoate 
were considered ‘much improved’ or ‘very much improved’ in terms of CGI 
compared with flupentixol decanoate or RLAI. These apparent contradictions may 
reflect the ‘real world’ nature of the data collection, although the data on treatment 
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discontinuation and re-hospitalisation are less prone to observer bias. This 
advantage of zuclopenthixol decanoate is consistent with the conclusion of Adams 
et al (2001) and the Cochrane review of zuclopenthixol decanoate which 
suggested it may have (a modest) superiority over other FGA-LAIs. The finding 
that zuclopenthixol decanoate was superior to RLAI is contrary to the findings of 
the Rubio et al (2006) study mentioned above, and the findings in Chapter 6 
represent the only other known direct head-to-head comparison of new versus old 
LAI or depot antipsychotics. However, the limitations of the retrospective non-
randomised design in Chapter 6 mean these findings need to be viewed 
cautiously.  
 
Further research is warranted especially given the cost differential of SGA-LAIs 
compared to FGA-LAIs, as more SGA-LAIs are being licensed in the UK. Future 
studies involving LAIs should be of adequate duration to assess relapse, for 
example 18 months or more, and outcome measures should include relapse, 
symptomatic improvement and  a range of adverse effects including EPS, TD, 
weight gain and metabolic parameters. Patient satisfaction and cost-effectiveness 
also need to be examined. To reduce the problem of selective recruitment such 
studies should be pragmatic and have minimal exclusion criteria.   
 
 
Conclusions and implications for clinical practice 
RCTs; meta-analyses; and observational studies have their individual  strengths 
and weaknesses and reviewing all these study designs together provides the most 
comprehensive context for the data contained in Chapters 3 to 6. 
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Several large randomized trials in schizophrenia, including the Clinical 
Antipsychotic Trial of Intervention Effectiveness (CATIE), have confirmed that 
although antipsychotics differ markedly in their side-effect profiles they are broadly 
similar in terms of efficacy in schizophrenia, and this is reflected in the data 
contained in Chapters 4 and 5, with the notable exception of clozapine. The debate 
over the false dichotomy between SGAs and FGAs, or atypical and typical 
antipsychotics has largely moved on (Kendall, 2011) with the conclusions of the 
most recent meta-analyses (Leucht et al, 2009; Crossley et al, 2010) confirming a 
lack of class homogeneity and small or modest differences in efficacy. These 
studies also demonstrate that the commonly prescribed antipsychotics are easily 
differentiated by side-effect profile, with the broad distinction being that the older 
FGAs more likely lead to EPS whereas the newer SGAs are more liable to cause 
adverse metabolic shifts. However, the differentiation (albeit modest) of three of 
the SGAs in terms of efficacy according to the strongest meta-analysis available 
(Leucht et al, 2009) – namely amisulpride; olanzapine; and risperidone – from the 
other SGAs and low dose haloperidol prompts the interesting proposition that in a 
long term condition such as schizophrenia perhaps even a modest efficacy 
difference is worth taking seriously, particularly as all these three compounds are 
now generic (ie cheap). These considerations on efficacy do need to be balanced 
by the much larger side-effect profile differentials between individual antipsychotics 
noted above. 
 
The exception to this debate is clozapine, which has superior efficacy and 
effectiveness (as demonstrated in Chapter 5) but is only licensed for treatment 
resistant schizophrenia. As observed above, the figures on clozapine usage in 
Chapter 3 are reassuring but the data elsewhere suggests that clozapine is used 
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too little or too late (see above). Furthermore, as it is a ‘difficult’ medication for both 
patient and clinician in terms of initiation and regular blood monitoring, this can act 
as a disincentive to clozapine use, and trainee psychiatrists are at risk of not 
obtaining adequate experience or confidence in the use of clozapine.  
 
There is no sign of an imminent major efficacy breakthrough in antipsychotic 
development. This means that ensuring the optimum benefit from current 
antipsychotics is important and for many patients this means improving medication 
adherence. Although poor adherence has long been seen as a problem in 
schizophrenia, many thought it would lessen following the introduction of the oral 
SGAs in the 1990s. This did not happen. Indeed a key finding of the CATIE and 
related studies was that even in a highly supported clinical trial, patient retention 
rates on a range of oral SGAs were disappointingly low. This problem of long term 
adherence to medication is emphasised by the findings of the observational 
studies which consistently demonstrate low levels of prescription pick up or high 
rates of discontinuation for antipsychotics. This is important not just in terms of 
relapse prevention but also in reducing associated morbidity and mortality.  From a 
managerial perspective, clinical strategies that reduce the need for recurrent 
hospitalisation are also important as up to 70% of the direct costs in mental 
healthcare are associated with in-patient psychiatric care. It is also worth pointing 
out that poor medication adherence is a major challenge not just in schizophrenia 
but in all long term medical disorders such as diabetes mellitus, chronic obstructive 
airways disease, and hypertension. 
 
LAIs provide one way, although not the only way, to improve adherence. The main 
advantages of LAIs are that they eliminate covert non-adherence, can improve 
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adherence, and can be a more convenient way of taking medication for some 
patients. LAIs do have disadvantages and some patients find it unacceptable to 
receive medication by injection. In addition adherence can be poor with an LAI just 
as it can with oral medication, but the key difference is that non-adherence with an 
LAI is overt. Good adherence with a LAI, as with any drug, requires the prescribing 
decision to be the result of shared decision-making by the patient and prescriber. 
Prescribing an LAI in isolation will do little to overcome adherence problems as a 
LAI does not remove the need to ensure that other elements of care are provided. 
As newer LAIs become available it will be important to understand their 
advantages and disadvantages compared with ‘treatment as usual’. At this time the 
extant data suggests comparable efficacy between LAIs with the only exception 
being some modest data in Chapter 6 and from Adams and colleagues (2001) 
suggesting that a moderate dose of zuclopenthixol decanoate may be more 
effective than some other LAIs. The evidence also suggests that a broader range 
of patients with psychosis could benefit from the LAI formulations of antipsychotics. 
For example, studies by Tiihonen et al (2006, 2009) concluded that LAIs can be of 
benefit early in the course of schizophrenia compared to oral antipsychotics, 
notwithstanding possible concerns over coercion and autonomy. However, 
clinicians can regard LAIs as a treatment of last resort (Waddell and Taylor, 2009) 
and only use them when the risk of relapse is perceived as high. 
  
Patient safety is an essential consideration at an individual and at a service level – 
“first do no harm”. This final Chapter has reviewed the literature on antipsychotic 
discontinuation and on the side-effect profiles associated with individual 
antipsychotics. Screening for adverse medication effects should cover the full 
range of potential adverse effects including weight gain and metabolic 
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abnormalities and ideally should occur in a systematic manner using a practical but 
valid scale. It is worth noting that since the GASS was developed, as described in 
Chapter 7, it has become widely adopted around the UK. This is in part due to 
GASS being cost-free to use and reproduce; being independent from the 
pharmaceutical industry; and because effort was made to make it accessible via 
use of plain English with it contained on only one side of A4 paper. The GASS is 
no more discriminating than LUNSERS but does contain probes on metabolic 
related symptoms, and is arguably more user friendly. GASS needs to be studied 
in other centres, and has not been subject to principal components analysis or an 
objective validation of individual items (eg whether self report weight gain or tremor 
correlates with objective assessment). 
 
The best outcome in most major psychiatric disorders requires an optimized 
pharmacological treatment to be put in place so that psychological and social 
treatments can be built around the patient’s individual needs for their recovery.  
Good clinical practice suggests that the decision to use a specific antipsychotic for 
a particular patient should be made at an individual level, reflecting the evidence 
base and being an informed decision jointly made by the clinician and patient.  
 
Directions for future research 
 
1. How can clinicians target their antipsychotic treatments more effectively? 
There seems to be little data to guide prescriber choice on which patient 
characteristics, either demographic; clinical; or genetic might inform 
potential therapeutic response to a specific medication. Currently, this is 
where the art of psychiatry meets the scientific evidence base, with some of 
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the data described above on relative efficacy and side-effects being useful 
but each prescription essentially representing an individualised experiment. 
 
2. How can clinicians measure response to treatment in busy routine practice? 
This thesis has demonstrated that a simple ‘severity index’ such as the 
Clinical Global Impression scale may be pragmatic but valid enough for use 
in busy day-to-day practice even though concerns regarding inter-rater 
reliability need to be addressed. A side-effect scale such as the GASS (see 
Chapter 7) can also facilitate systematic medication review. Elsewhere in 
medicine, recording of outcomes in routine clinical practice is more usual, 
and this should be encouraged in mental health care. 
 
3. Are newer long acting injections of antipsychotic medications superior to the 
older LAIs, or to oral antipsychotics? The evidence reviewed above, 
including the original data in Chapter 6, is not conclusive on this question so 
a pragmatic independent trial of sufficient duration would add value to the 
evidence base. In particular there is a notable dearth of new versus old LAI 
head-to-head scientific comparisons. 
   
4. Is antipsychotic polypharmacy helpful or harmful? As seen above, the 
practice of antipsychotic polypharmacy remains common in the UK and 
elsewhere despite the lack of supporting scientific data. Furthermore, 
concerns about the adverse health risks of antipsychotic polypharmacy 
have been noted, so a prospective study of the possible benefits and risks 
of this practice would be valuable. 
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Appendix 1 
 
Clinical Global Impression 
(adapted from Guy W, 1976) 
 
 
Name:                                                                   Date: 
 
CMHT: 
 
 
 
Considering your total clinical experience with this particular population, how 
mentally ill is the patient at this time? 
 
1 Normal, not at all ill 
2 Borderline mentally ill 
3 Mildly ill 
4 Moderately ill 
5 Markedly ill 
6 Severely ill 
7 Among the most extremely ill patients 
 
 
 
Considering your total clinical experience with this particular population, how 
mentally ill is the patient at this time? 
 
1 Normal, not at all ill 
2 Borderline mentally ill 
3 Mildly ill 
4 Moderately ill 
5 Markedly ill 
6 Severely ill 
7 Among the most extremely ill patients 
 
 
 
Rate total improvement, compared to the condition at admission, how much has 
he/she changed? 
 
3 Very much improved 
2 Much improved 
1 Minimally improved 
0 No change 
-1 Minimally worse 
-2 Much worse 
-3 Very much worse 
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Guidance notes: Completion of the Clinical Global Impression (CGI) should be self 
explanatory. Less experienced clinicians may wish to confer with senior colleagues before 
assigning a rating. 
 
2. Severity of positive symptoms. Positive symptoms can be conceived as being 
pathologically "added" to the patient's experiences and behaviour. They include 
hallucinations in all sensory modalities; and primary and secondary delusions, be they 
persecutory, religious, somatic, hypochondriacal, grandiose, or nihilistic. Conceptual 
disorganisation or thought disorder; and overarousal and hostility are included here.  The 
scale is a global summary assessment of these symptoms.  
 
    0 = none or absent  
    1 = mild. The symptom(s) are clearly established but not pronounced and interfere little 
with day-to-day functioning. 
    2 = moderate. The symptom(s) represents a serious problem, occurring only 
occasionally, or only intruding modestly on daily life. 
    3 = marked. Frequent and marked manifestations distinctly impacting on functioning, 
but not all consuming and usually can be contained at will. 
    4 = severe. Gross psychopathology, being frequent and highly disruptive and / or 
distressing. Often necessitating direct or close supervision by clinicians, carers, or family 
members. 
 
3. Severity of negative symptoms. Again, a global summary measure, this 
psychopathology can thought of in general terms as something that has been subtracted 
or taken away from the patient. Typically these include social and emotional withdrawal; 
decreased or absent volition and motivation; lack of spontaneity and flow of conversation; 
poor rapport; blunting of affective response; and difficulty in abstract thinking.  
 
     0 = normal, or absence of any the features above that can be classed as pathological.  
     1 = mild.  Little initiative, stilted conversation or facial expression. No pronounced effect 
on day-to-day function. 
     2 = moderate. Aloof or distant, with reduced expressiveness. Little spontaneous talk. 
Can be encouraged into activity. 
     3 = marked. Flat affect, may avoid eye-contact. Virtually no initiative or interest in 
environment. Concrete thinking, with one or two brief replies. 
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     4 = severe. Neglectful of personal needs. Indifferent to interviewer, very occasional 
replies. Profound apathy and isolation. 
 
4. Severity of drug-related side-effects.  Overall summary assessment, including extra-
pyramidal side-effects; dystonias; akathisia; tics; and choreoathetosis of the face, mouth 
and tongue, trunk, and limbs. Also included is weight gain; sedation; and sexual 
dysfunction entirely attributable to medication effects. 
     0 = absent or none.  
     1 = mild, or minimal. Could be extreme normal. 
     2 = moderate. Clearly observable, with minor subjective distress and impairment in 
functioning. Probably not continuously present. 
     3 = marked. Continuous and debilitating, but not overwhelmingly unpleasant. 
     4 = severe. Continuous with extreme subjective distress or discomfort. Viewed as a 
profound handicap. 
 
5. Impairment in quality of life.  A summary assessment entirely attributable to illness 
rather than social circumstance. Takes account of social and occupational roles including 
extent of relationships; time utilisation; and activities of daily living. Psychological 
fulfillment can be rated here, paying attention to sense of purpose; curiosity; empathy; and 
any anhedonia. 
      0 = none. Full and varied life, in work or at home. 
      1 = minimal. Minor concern over domestic or social situation. Able to live and work 
independently if opportunity exists. 
      2 = moderate. Difficulty living independently or performing work over long periods. 
Able to attend to personal and financial needs, and usually sociable. 
      3 = marked. Rarely able to live independently. May have legal trouble, or have been a 
victim of crime. Has difficulty socialising. Needs help with the more complex tasks of daily 
living eg. finances. 
     4  = severe. Completely dependent on others; seriously disabled; unaware of 
surroundings; and in a hopeless position. 
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Appendix 2 
Confirmatory letter of ethical approval from Greater Glasgow Primary Care Trust regarding 
GASS study (chapter 7) 
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Appendix 3 
GASS for Clozapine 
Name:       
Date:       
Caffeine intake:        ………….cups/day  
Smoker: Y / N           .…………cigarettes/day  
Current Medications:     
       
 
Has there been a recent change in your smoking habit?:  Increase/Decrease 
by…………………………cigarettes/day 
 
This questionnaire is being used to determine if you are suffering from excessive side effects from your medication.  
Please put a tick in the column which best indicates how often or how severely you have experienced the following 
side effects. 
 
Over the past week: Never Once A few 
times 
Everyday Tick if 
severe or 
distressing 
1 I felt sleepy during the day      
2 I felt drugged or like a zombie      
3 I felt dizzy when I stood up or have fainted      
4 I have felt my heart beating unusually fast or irregularly      
5 I have experienced jerking limbs or muscles      
6 I have been drooling      
7 My vision has been blurry      
8 My mouth has been dry      
9 I have felt sick (nauseous) or have vomited      
10 I have felt gastric reflux or heartburn      
11 I have had problems opening my bowels (constipation)      
12 I have wet the bed      
13 I have been passing urine more often      
14 I have been thirsty      
15 I have felt more hungry than usual      
16 I have been gaining weight      
17 I have felt breathless      
18 I have had chest pain      
 
 
I have also experienced:  
(please write down any other side effects that you may have experienced over the past week) 
16  
17  
18  
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Staff Information 
 
1. Allow the service user to fill in the side-effects scale themselves. All questions 
relate to the previous week. 
 
2. Scoring  
0 Points “Never” 
1 point “Once” 
2 points “A few times” 
3 points “Everyday” 
 
3. Results 
0-16 absent/mild side-effects 
17-32 moderate side-effects 
33-48 severe side-effects 
 
4. Side-effects covered include: 
1-2 Drowsiness and sedation 
3 Postural hypotension  
4 Tachycardia 
5 Myoclonus  
6 Hypersalivation  
7-8 Anticholinergic side-effects  
9-10 Gastrointestinal side-effects 
11 Constipation  
12 Nocturnal enuresis  
13-14 Screening for diabetes mellitus 
15-16 Weight gain 
 
5. The column relating to the severity/distress experienced with a particular side 
effect is not scored, but is intended to inform the clinician of the service user’s 
views and condition. 
 
 
